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Multiple Modes of Mdmx Regulation Affect p53 Activation 
Daniele M. Gilkes 
ABSTRACT 
 
MDMX has emerged as a negative regulator of p53 transcriptional activity 
following DNA damage, loss of ribosomal integrity, and aberrant mitogenic signaling. 
Disruption of rRNA biogenesis by ribosomal stress activates p53 by releasing ribosomal 
proteins from nucleoli which bind MDM2 and inhibit p53 degradation. We found that 
p53 activation by ribosomal stress requires degradation of MDMX by MDM2. This 
occurs by L11 binding to the acidic domain of MDM2 which promotes its E3 ligase 
function preferentially towards MDMX.  Further, unlike DNA damage which regulates 
MDMX stability through ATM-dependent phosphorylation events, ribosomal stress does 
not require MDMX phosphorylation suggesting p53 may be more sensitive to 
suppression by MDMX under these conditions. Indeed, we find that tumor cells 
overexpressing MDMX are less sensitive to ribosomal stress-induced growth arrest by 
the addition of actinomycin D due to formation of inactive p53–MDMX complexes that 
fail to transcriptionally activate downstream targets such as p21. Knockdown of MDMX 
increases sensitivity to actinomycin D, whereas MDMX overexpression abrogates p53 
activation. Furthermore, MDMX expression promotes resistance to the chemotherapeutic 
agent 5-fluorouracil (5-FU), which at low concentrations activates p53 by inducing 
ribosomal stress without significant DNA damage signaling. Knockdown of MDMX 
 xii 
abrogates HCT116 tumor xenograft formation in nude mice. MDMX overexpression 
does not accelerate tumor growth but increases resistance to 5-FU treatment in vivo.  
In addition to MDMX regulation at the protein level, we found that regulation of 
cellular MDMX levels, like MDM2, can occur at the transcriptional level by inducing the 
Ras/Raf/MEK/ERK pathway. We found MDMX levels in tumor cell lines closely 
correlate with promoter activity and mRNA level. Activated K-Ras and growth factor 
IGF-1 induce MDMX expression at the transcriptional level through mechanisms that 
involve the MAPK kinase and c-Ets-1 transcription factors. Pharmacological inhibition of 
MEK results in down-regulation of MDMX in tumor cell lines. MDMX overexpression is 
detected in ~50% of human colon tumors and showed strong correlation with increased 
Erk phosphorylation. Taken together, the data show that MDMX has multiple modes of 
regulation, which ultimately determine the overall extent of p53 activation. 
 
 1 
Chapter One 
Introduction 
 
 
Cancer 
Although ancient Egyptians and their successors had knowledge of cancer as early 
as 400 BC, its prevalence could not be appreciated until more recently when average life 
expectancies have reached as high as 78 years old. Major causes of death in the past 
included common childhood and infectious diseases which have been eradicated by 
improved public healthcare and awareness ensuring the majority of the population will 
live beyond the age of 55. This is important because 77% of all cancers are currently 
diagnosed in people over the age of 55 (American Cancer Society 2007).  The incidence 
of cancer rises dramatically with age, most likely due to risk accumulation over a life 
span accompanied by the tendency for cellular repair mechanisms to be less effective as a 
person grows older. Why some cancers occur in young children is still partially a 
mystery. Although it is now clear that some cancers occur in young children because of 
inherited predisposition.   
Cancer is a leading cause of death worldwide. From a total of 58 million deaths 
recorded worldwide in 2005, cancer accounts for 7.6 million (or 13%) of all deaths 
(American Cancer Society 2007). The main types of cancer leading to overall cancer 
mortality are: lung (1.3 million deaths/year); Stomach (almost 1 million deaths/year); 
Liver (662,000 deaths/year); Colon (655,000 deaths/year) and Breast (502,000 
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deaths/year). For Americans living in the United States this means men have a one in two 
lifetime risk of developing cancer; for women, the risk is one in three. These striking 
statistics exemplify the importance of researching the prevention and cure for cancer. 
Tumorigenesis 
Cancer is thought to arise from one single cell. The transformation from a normal 
cell into a tumor cell is now well accepted as a multistage process typically progressing 
from a pre-cancerous lesion to a malignant tumor. Tumor progression occurs via a 
sequence of sometimes-arbitrary events, which include both genetic and epigenetic DNA 
alterations. Based upon the observation that all cancers contain genetic alterations, it has 
been suggested that cancer cells are genetically unstable (Cahill, Kinzler et al. 1999).  
This instability may represent an early stage in cancer formation, suggesting that genetic 
instability results in a cascade of mutations to genes involved in cell growth, death, and 
differentiation. Successive accumulation of genetic abnormalities in a cell may be the 
overall driving force for tumor progression (Bishop 1987).  
Genetic instability refers to abnormally increased tendencies for DNA to undergo 
mutations. When DNA damage rates supersede the rate of DNA repair, permanent 
mutations can occur. DNA mutations at the single nucleotide level occur in the form of 
base substitutions or deletions or insertions of a few nucleotides. Alternatively it can 
occur at the chromosomal level (chromosomal instability) resulting in losses and gains of 
whole chromosomes or large portions of a chromosome by translocation or 
amplifications (Lengauer, Kinzler et al. 1998).  Epigenetic alterations can occur through 
DNA methylation, histone modifications or gene imprinting (Feinberg and Tycko 2004).    
Ultimately, DNA modifying events affecting genes responsible for cell growth, death, 
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and repair, such as the activation of oncogenes or inactivation of tumor suppressor genes 
lead to cancer progression. Furthermore, genetic changes have been linked to 
environmental factors such as: 
physical carcinogens - ultraviolet (UV) and ionizing radiation  
chemical carcinogens - asbestos and tobacco smoke  
biological carcinogens -  viral infections  (Hepatitis B or Human Papilloma Virus 
(HPV)),  bacteria (Helicobater pylori and gastric cancer) , contamination of food by 
mycotoxins such as aflatoxins   
The culmination of deregulated genes controlling cellular homeostasis can lead to self-
sufficiency in growth signals, insensitivity to antigrowth signals, evasion of apoptosis, 
limitless replicative potential, sustained angiogenesis, and metastasis – the hallmarks of 
cancer (Vogelstein and Kinzler 1993; Hanahan and Weinberg 2000).  Characterization of 
genes that promote or prevent cell proliferation is paramount to discovering treatments 
for cancer. 
Tumor Suppressor Genes and Knudson’s Two-Hit Hypothesis 
Tumor suppressor genes reduce the probability that a normal cell will become a 
tumor cell. Therefore, it follows that mutations or deletions of tumor suppressor genes 
increase the probability of tumor formation. Indeed, experiments involving somatic cell 
fusion and chromosome segregation  pointed to the existence of genes that could suppress 
tumorigenicity (Harris, Miller et al. 1969; Stanbridge 1976). Unlike oncogenes, tumor 
suppressor genes generally follow the 'Knudson’s two-hit hypothesis,' which implies that 
both alleles that code for a particular gene must be affected before an effect is manifested 
(Knudson 1971).  If one allele for the gene is damaged, the second can still produce the 
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correct protein.  In other words, tumor suppressors are usually not haploinsufficient 
(Comings 1973).   
From these initial observations three properties were derived which are used to 
characterize ‘classic tumor suppressors’.  First, they are recessive and undergo biallellic 
inactivation in tumors. Second, inheritance of a single mutant allele accelerates tumor 
susceptibility, and only one additional mutation is required for complete loss of gene 
function (termed loss of heterozygosity (LOH)). Thus a germline mutation can be the 
underlying cause of a familial cancer syndrome that exhibits an autosomally dominant 
pattern of inheritance. Third, the same gene is frequently inactivated in sporadic cancers. 
The classic features of tumor suppression were first exemplified in studies of 
retinoblastoma and Wilm's tumor (Knudson 1971). Shortly thereafter, one of the most 
famous tumor suppressors studied to date, p53 was beginning to be characterized. 
The Tumor Suppressor p53 
P53 is a tumor suppressor gene located on the short arm of human chromosome 17 
(17p13.1).  P53 performs a variety of tumor surveillance functions in order to prevent the 
formation of tumors. Consequently, p53 mutations are shared by a wide variety of cancer 
types. When the integrity of genomic DNA is threatened by DNA damage, oncogene 
activation, nucleotide deprivation, or hypoxia, indolent p53 becomes stable and active. 
Upon activation, p53 triggers a variety of responses depending upon the type, extent, and 
duration of the imposed stress. The responses include but are not limited to cell cycle 
arrest, initiation of apoptosis, differentiation, senescence, and DNA repair. Cell cycle 
arrest and apoptosis are the most well-characterized effects of p53 activation (Vousden 
and Lu 2002). 
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Knocking out p53 in mice has highlighted the role of p53 in cellular homeostasis 
and tumor protection. Although most p53 knockout mice develop normally, they exhibit a 
high incidence of spontaneous lymphomas and sarcomas at an early age (Donehower, 
Harvey et al. 1992).  Moreover, thymocytes (lymphocytes that derive from the thymus 
and are the precursor of a T cells) from p53 null mice are profoundly resistant to DNA-
damage induced apoptosis.  These observations indicate that a normal p53 gene is 
dispensable for embryonic development, but its absence predisposes the animal to 
neoplastic disease. 
p53 History 
Two independent groups identified p53 in 1979 as a cellular protein that bound to 
the simian virus (SV40) large T antigen and accumulated in the nuclei of cancer cells 
(Lane and Crawford 1979; Linzer and Levine 1979).  Oren and Levine (1983) cloned the 
gene encoding p53 (TP53) from neoplastic rodent and human cells, and characterized it 
as having weak oncogenic activity  (Lane and Crawford 1979; Oren and Levine 1983). 
This was further supported by the fact that p53 could cooperate with the activated Ha-Ras 
oncogene to transform normal embryonic cells (Eliyahu, Raz et al. 1984; Parada, Land et 
al. 1984). Other investigators found that the p53 gene was rearranged and inactivated in 
mouse erythroleukemia cells by insertion of the Friend murine leukemia virus into the 
gene locus (Mowat, Cheng et al. 1985). These changes were observed in vivo during the 
natural course of virus-induced disease, although the precise nature of the selective 
advantage conferred by p53 disruption remained unclear. Later, to further complicate 
earlier results, a murine p53 cDNA derived from F9 embryonal carcinoma cells failed to 
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form foci in the presence of activated Ras unless it was mutated (Hinds, Finlay et al. 
1987). 
It took several years for researchers to determine that the first form of p53 
discovered was actually a missense mutant of p53 and not the wild-type gene.  Moreover, 
the missense mutations found in the original TP53 cDNA clones proved to be the key to 
understanding the pathobiological activity of p53.  Mutant p53 can behave in a dominant-
negative fashion. For example, the allele-producing mutant p53 suppresses the activity of 
wild-type p53 by binding and forming inactive tetramers. In 1989, a landmark study 
showed that p53’s native function in a cell is actually as a suppressor of transformation 
(Finlay, Hinds et al. 1989).This was further exemplified in studies showing p53 was 
deleted in human colorectal cancers (Baker, Markowitz et al. 1990). Mutations of p53 
were soon documented in many other forms of sporadic cancer and were revealed to be a 
causative genetic factor in patients with the familial Li-Fraumeni cancer susceptibility 
syndrome (Malkin, Li et al. 1990). Oncogenic human DNA viruses have also evolved a 
mechanism to inactivate p53 functions. Several viral oncoproteins including human 
papilloma virus (HPV) E6 and the adenovirus E1B 55K protein can bind to p53 and 
enhance its ubiquitin-dependent proteolysis (Zantema, Fransen et al. 1985; Werness, 
Levine et al. 1990). By the 1990s, p53 was widely recognized as a tumor suppressor 
gene, mutated or lost in ~50% of all human cancer cases worldwide making it a molecule 
worthy of intensive biomedical research studies in years to come. 
Structure and Function of p53 
Human p53 contains 393 amino acids with four functional domains including:  
amino-terminal transactivation domain (TAD), core DNA-binding domain (DBD), 
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carboxy-terminal oligomerization domain (OD) and a regulatory domain (RD).  The first 
42 amino acids of p53 encodes its transactivation function. This region is relatively acidic 
and has been shown to interact with components of the transcriptional machinery such as 
TATA-binding protein (TBP) (Lu and Levine 1995). The MDM2 oncoprotein has been 
shown to bind p53 in the N-terminal region where it negatively regulates p53’s 
transactivation function (Lin, Chen et al. 1994). The proline-rich domain of p53 between 
residues 60 and 90 contains five copies of the sequence PXXP and is thought to play a 
role in p53-mediated suppression of cell growth and apoptosis (Sakamuro, Sabbatini et al. 
1997; Venot, Maratrat et al. 1998).  
The core DNA-binding domain allows p53 to bind to DNA in a sequence-specific 
manner. The consensus DNA binding sequence consists of two repeats of the 10 bp motif 
5’-PuPuPuC(A/T)(A/T)GPyPyPy-3’ separated by 0-13 bp (el-Deiry, Kern et al. 1992). 
The C-terminal region  of p53(26 amino acids) is relatively basic in charge and regulates 
the ability of p53 to bind to specific DNA sequences at its core domain (Wang and Prives 
1995; Wang, Vermeulen et al. 1996). Upon stabilization of p53, a discrete region within 
the C-terminal domain regulates oligomerization of p53. Deletion, phosphorylation, or 
binding of antibody to the C-terminal domain activates site-specific DNA binding by the 
central domain. The nuclear localization signals (NLS) are located within the c-terminal 
domain of p53 (Dang and Lee 1989). 
Functions of p53 
P53 functions by both transcriptionally-dependent and independent mechanisms.  It 
plays a role in a wide variety of cell signaling mechanisms, which lead to cell-cycle 
arrest, DNA repair, cellular senescence, differentiation and apoptosis (Figure 1). 
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Ultimately, p53 can facilitate the repair and survival of damaged cells or eliminate 
severely damaged cells as a protection mechanism. When transactivated, p53 binds to 
DNA as a tetramer and stimulates expression of downstream genes that negatively 
regulate growth and invasion or mediate apoptosis (Vogelstein, Lane et al. 2000).   
Alternately,  p53 acts as a transcriptional repressor. Transrepression by p53 relies on its 
ability to interact with basal transcriptional machinery, co-repressors or other DNA 
binding proteins. 
 
Figure 1. P53 Signaling.  P53 plays a role in a wide variety of cell signaling mechanisms 
(Bullock and Fersht 2001). 
  
Cell Cycle Arrest 
The cell cycle is an ordered set of events, culminating in cell growth and division 
into two daughter cells. Cyclins, cyclin dependent kinases (CDK), and CDK inhibitors 
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are the major proteins, which control cell cycle progression. There are several cell cycle 
checkpoints which are key to preventing the proliferation of cells with flawed 
DNA(Kopnin 2000). P53 can transactivate proteins, which are responsible for monitoring 
both the G1/S and G2/M phases of the cell cycle. Perhaps the most well studied gene 
transduced by p53 is the cell cycle inhibitor p21WAF1.   Basal levels of p21WAF1 are 
required for cyclin/cdk complexes to assemble and be active; however, high levels block 
cdk activity thereby inhibiting cell cycle progression (Kastan, Onyekwere et al. 1991; 
Agarwal, Agarwal et al. 1995). The inhibitory effects of p21WAF1 are dominant, since 
induction or over-expression of p21WAF1 inhibits the activity of cdks, especially cyclin 
E/cdk2 complexes (Xiong, Hannon et al. 1993). Induction of p21WAF1 by p53 requires the 
transcription factor Sp1 and an intact p53 binding site localized far (> 1.9 kb) upstream of 
the coding sequence (el-Deiry, Harper et al. 1994; Macleod, Sherry et al. 1995; 
Koutsodontis, Tentes et al. 2001). 
In addition to p21, 14-3-3σ (sigma) is a p53-response gene, which regulates cellular 
activity by binding and sequestering phosphorylated proteins. Upon induction, 14-3-3σ 
inactivates Cdc25 and Cdc2 by sequestering them in the cytoplasm causing a pre-mitotic 
G2/M  cell cycle arrest upon DNA damage (Chan, Hermeking et al. 1999; Lopez-Girona, 
Furnari et al. 1999).  Further, 14-3-3σ has been shown to promote the translocation of 
Bax out of the cytoplasm, delaying apoptotic signaling resulting in a G2 arrest (Samuel, 
Weber et al. 2001).  
Apoptosis 
Initial observations on the role of p53-induced apoptosis came from studies of the 
temperature sensitive mutant of p53 which acquires wild-type p53 conformation at the 
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permissive temperature of 32°C. After shifting cells to 32°C, rapid cell death was 
observed (Yonish-Rouach, Resnitzky et al. 1991). The role of p53-dependent apoptosis 
was further eludicated using mouse models. Mice expressing SV40 Large T-antigen 
developed slow growing tumors due to suppression of p53-dependent growth arrest 
function. Mice cross-bred on a p53 null background developed more aggressive tumors 
(Symonds, Krall et al. 1994) suggesting p53 is needed to prevent tumor formation in vivo. 
In a study utilizing myc-driven lymphogenesis, blocking p53-mediated apoptosis 
prevented the selection of p53 mutations (Schmitt, Fridman et al. 2002). This suggests 
that p53 mutations are acquired as a means to overcome apoptosis. There are at least two 
broad pathways that lead to apoptosis, an "extrinsic" and an "intrinsic" pathway.  P53 
plays a role in both of these pathways. 
The Intrinsic Pathway 
The intrinsic apoptosis pathway begins when an injury occurs within the cell. It is 
governed by both pro- and anti-apoptotic members of the Bcl-2 family of proteins. The 
pro-survival (anti-apoptotic) family members are Bcl-2 and Bcl-XL. The pro-apoptotic 
family members include Bax, Bad, and Bid(Green and Evan 2002). There are also BH3 
domain only apoptotic family members such as Puma and Bim. These proteins are 
involved in mitochondrial membrane potential and maintenance and the release of 
cytochrome C. Several proteins in the Bcl-2 family are transactivated by p53. Bax was 
the first Bcl-2 family member recognized as a target of p53 activation following cellular 
stress (Miyashita and Reed 1995). Upon induction Bax undergoes a conformational 
change forming homodimers which translocate to the mitochondria and promote the 
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release of Cytochrome C (Adams and Cory 2001). Mice deficient for Bax have increased 
tumor growth and a decrease in  apoptosis (Yin, Knudson et al. 1997). 
In addition to Bax, Puma is also upregulated following a p53 response to cellular 
stress (Nakano and Vousden 2001). Puma functions by promoting the oligomerization of 
Bax. On the other hand, Bax deficient cells are resistant to PUMA-mediated apoptosis 
(Yu, Wang et al. 2003).  Other p53-inducible genes involved in the intrinisic apoptotic 
include Noxa, Bid, and APAF-1 (Oda, Ohki et al. 2000; Moroni, Hickman et al. 2001; 
Walensky, Pitter et al. 2006).  Bid links the extrinsic and intrinsic pathways. Caspase-8 
(involved in death receptor signaling) causes the cleavage of Bid. The truncated form of 
(tBid) induces Bax activation. Suprisingly, Bcl-2, an anti-apoptotic protein is also a 
transcriptional target of p53 but is repressed following p53 activation (Shen and Shenk 
1994). 
The Extrinsic Pathway 
The extrinsic pathway begins outside a cell, when conditions in the extracellular 
environment signal the cell to undergo programmed cell death. Binding of Fas ligand 
(FasL or CD95L) to the Fas receptor (CD95) results in clustering of receptors and 
initiates the extrinsic pathway. Fas is a p53 response gene which is upregulated following 
chemically induced DNA-damage (Muller, Wilder et al. 1998). Fas clustering recruits 
FADD and pro-caspase 8 to form a complex. Formation of the death-receptor-inducing-
signaling complex (DISC) results in activation of effector caspases.  In addition, the 
death-domain-containing receptor DR5/KILLER of the TRAIL family is also a target of 
p53 activation (Wu, Kim et al. 2000).   
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Cellular Senescence 
Following oxidative stress or telomere shortening, cells stop dividing and can 
undergo cellular senescence. Both p53 and Rb tumor suppressors are activated during 
senescence. Inactivation of p53 in mouse embryo fibroblast cells is sufficient to 
circumvent cellular senescence (Dirac and Bernards 2003).  The induction of p21 by p53 
is important for the activation of the RB pathway and for triggering senescence following 
DNA damage and telomere uncapping (Herbig, Jobling et al. 2004). Telomere shortening 
can be prevented by the overexpression of the human telomerase catalytic subunit, 
hTERT.  Interestingly, hTERT has been shown to be downregulated by p53 whereas 
overexpression of hTERT can overcome p53-induced apoptosis (Xu, Wang et al. 2000).   
DNA Repair 
P53 has been linked to both the base excision repair (BER) and nucleotide excision 
repair mechanisms (NER). P53 induces GADD45 (usually induced following gamma 
irradiation in p53 wild-type cells) which can enhance NER (Smith, Ford et al. 2000). On 
the other hand, p53’s interaction with DNA polymerase β and AP endonuclease (APE) 
substantiates its regulation of BER (Zhou, Ahn et al. 2001). Furthermore, following 
gamma irradiation, p53 induction is followed by an increase in 3-methyladenine (3-
MeAde), an enzyme necessary for BER (Zurer, Hofseth et al. 2004). 
Inhibition of Angiogenesis and Metastasis 
Angiogenesis is the formation of new blood vessels which are required to sustain a 
tumor.  It can be triggered by hypoxic conditions which activate the Hypoxia Inducible 
transcription factor (HIF-1). HIF-1 can induce the expression of VEGF, a potent 
endothelial mitogen necessary for vessel formation (Dachs and Tozer 2000). P53 can 
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inhibit this process in several ways. P53 can mediate the MDM2-dependent proteosomal 
degradation of the alpha subunit of HIF-1 (HIF-1α) (Ravi, Mookerjee et al. 2000).  
Moreover, p53 can down regulate the expression of VEGF and up regulate anti-agiogenic 
proteins such as Tsp-1 which has been shown to be suppressed in a variety of tumors 
(Bouvet, Ellis et al. 1998).  P53 has also been shown to enhance the expression of the 
metastasis suppressor Nm23-H1.  Further,  the matrix  metalloproteinases,  MMP-1 and 
MMP-13, which promote tissue invasion by causing extra cellular matrix degradation are 
repressed by activated p53 (Sun, Sun et al. 1999; Sun, Cheung et al. 2000). 
P53 Mediated Transcriptional Repression 
Although gene transactivation has been the most intensively studied tumor 
suppressive function of p53 to date, p53 also plays an important role in gene repression.     
For instance, p53 mediated cell cycle arrest occurs not only by the upregulation of p21 
and 14-3-3σ but by the transrepression of cyclin B and cdc2. Additionally, the putative 
caspase inhibitor Survivin is also downregulated by p53 (Hoffman, Biade et al. 2002). An 
elevated level of Survivin has been identified in numerous tumor types and is correlated 
with poor survival outcomes. The overexpression of Survivin has been shown to inhibit 
p53-inducible apoptosis.  Other genes which are negatively regulated by p53 include the 
following: MDR1, Map4, stathmin, VEGF, PTGFβ, WT-1, and hTERT. 
P53 has also been shown to repress transcription by competing for binding at target 
promoters. For example, repression of the alpha-fetoprotein gene (AFP) is the result of 
overlapping DNA binding sites for p53 and HNF-3 within the AFP promoter. 
Displacement of HNF-3 by activated p53 leads to a reduction in AFP transcription (Lee, 
Crowe et al. 1999).  Repression by p53 can also occur in the absence of a specific p53 
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consensus sequence. For example, downregulation of hTERT occurs by p53 interfering 
with the coactivator, sp1 binding at the promoter (Xu, Wang et al. 2000).  
P53 can also cause direct interference by interacting with basal transcriptional 
machinery.  For example, cyclin B promoter deletions or mutations do not affect its 
repression by p53 suggesting that p53 is acting through the basal transcriptional 
machinery to inhibit transcription.  Further, p53 has been shown to interact with TBP and 
certain TAFs which results in disruption of the pre-initiation complex assembly (Seto, 
Usheva et al. 1992).   
P53 has also been shown to alter the chromatin structure by recruiting histone 
deactylases (HDAC) and the corepressor mSin3a to p53 target promoters.  Moreover, in 
response to hypoxia the interaction between mSin3a and p53 is promoted resulting in 
downregulation of a subset of p53-repressed genes. HDAC inhibitors such as TSA has 
been shown to abrogate p53-mediated repression of MAP4. Further,  p53 expression has 
been shown to decrease histone acetylation at the Survivin promoter (Murphy, Ahn et al. 
1999).   
Both the N and C terminus of p53 have been shown to play a role in its ability to 
repress gene transcription. Mutation of p53 serine 25 prevents its ability to repress MAP4 
(Murphy, Ahn et al. 1999). On the other hand, mutating serine 386 C-terminal 
phosphorylation site of p53 attenuates p53-mediated repression of SV40 early promoters 
but not p53 activation (Hall, Campbell et al. 1996). Deletion of the PRD domain also 
impairs p53 transrepression function and is required for p53 and mSin3a interaction 
(Zilfou, Hoffman et al. 2001). This suggests that different regions are required to provide 
the specificity for p53-mediated transrepression under varying conditions.  
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P53 Regulation 
Following cellular insults, p53 must become rapidly activated in order to initiate 
cell cycle arrest or apoptosis. However, in normal undamaged cells p53 is maintained at 
low levels to prevent unwanted cell death and maintain cellular homeostasis. The ability 
of p53 to act rapidly based on its microenvironment involves a variety of 
posttranslational modifications including p53 ubiquitination, phosphorylation, 
acetylation, sumoylation and neddylation (Figure 2). Although increases in the rate of 
transcription or translation of p53 affect its cellular level, posttranslational modifications 
have been shown to be the most efficient way to elevate both the activity and stability of 
p53.  
 
 
Figure 2. Post-translational Modifications of Human p53 (Toledo and Wahl 2006). 
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P53 Ubiquitination 
The most well studied mechanism for the rapid turnover of p53 involves its 
negative regulator, MDM2.  MDM2, a p53 target protein, directs p53’s degradation via 
ubiquitin-dependent proteolysis. Thus, p53 directly activates expression of its own 
negative regulator, producing a potent negative feedback regulatory loop. Protein 
ubiquitination, including both mono- and polyubiquitination, is involved in many cellular 
processes. Polyubiquitination can target proteins for degradation by providing a 
recognition signal for the 26S proteasome. MDM2 acts as an E3 ligase, the final 
component of the enzyme cascade, conjugating ubiquitin to p53 to mark it for 
degradation via the proteosome (Haupt, Maya et al. 1997).  Furthermore, ubiquitination 
by MDM2 has been shown to differentially catalyze monoubiquitination and 
polyubiquitination of p53 in a dosage-dependent manner (Li, Brooks et al. 2003). More 
specifically, low levels of MDM2 activity induce monoubiquitination and nuclear export 
of p53, whereas high levels promote polyubiquitination and nuclear degradation of p53. It 
is possible that these distinct mechanisms are exploited under different physiological 
settings or simply that poly-ubiquitination follows mono-ubiquitination.  
Although, MDM2 is a major regulator of p53 protein stability, recent data suggests 
that MDM2-mediated ubiquitination, is not the only important factor for p53 regulation.  
In vitro, human p53 mutants in which all six highly conserved C-terminal lysine residues 
were mutated to arginine to prevent post-translational modifications including 
ubiquitylation and acetylation proved to be stable and more active than wild-type p53 
(Nakamura, Roth et al. 2000). Likewise, knock-in experiments in vivo show that a p53 
mutant protein, lacking the major ubiquitination sites for MDM2, has a normal half-life 
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and is stabilized and activated in response to stress (Feng, Lin et al. 2005; Krummel, Lee 
et al. 2005).   
In addition to MDM2, other E3 ligases have been shown to promote p53 
degradation. Pirh2, a RING-H2 domain-containing protein, interacts with p53 and 
promotes MDM2-independent p53 ubiquitination and degradation.  Similar to MDM2, 
Pirh2 is a p53 responsive gene and participates in a similar autoregulatory negative 
feedback loop (Leng, Lin et al. 2003).  COP1 is a direct ubiquitin ligase for p53 and is a 
p53-inducible target gene. Further, COP1 depletion by siRNA enhances p53-mediated G1 
arrest and can sensitize cells to ionizing radiation (Dornan, Wertz et al. 2004). ARF-BP1 
was recently identified as a HECT domain-containing E3 ligase that can ubiquitinate and 
degrade p53. ARF-BP1 was purified as a major ARF binding protein from p53-null cells. 
Interestingly, inactivation of ARF-BP1, in a manner reminiscent of ARF overexpression, 
induces tumor suppression in both p53 null and wild-type cells. This suggests that ARF-
BP1 is involved in both p53-dependent and p53-independent functions of ARF (Chen, 
Kon et al. 2005). Together, MDM2,  Pirh2, COP1 and ARF-BP1 represent an array of E3 
ligases that the cell utilizes to regulate p53 stability. Thus, p53 directly activates 
expression of its own negative regulator, producing a potent negative feedback regulatory 
loop. 
Recently, the discovery of deubiquitination enzymes (DUBs) added another layer 
of complexity to the ubiquitin-proteasome process. The herpesvirus-associated ubiquitin-
specific protease (HAUSP) was found to bind to and stabilize p53 adding an additional 
layer of p53 regulation through the ubiquitination pathway.  In the presence of HAUSP, 
p53 levels were sufficiently stabilized to induce growth arrest and apoptosis (Li, Chen et 
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al. 2002). On the other hand, siRNA-mediated reduction or knockout of  HAUSP in 
HCT116 cells resulted in p53 stability. This can be explained by the observation that 
HAUSP can interact with MDM2. HAUSP exhibits strong deubiquitinase activity and 
stabilization of MDM2. These data suggest that HAUSP-mediated deubiquitination of 
MDM2 is required to maintain a sufficient level of the protein to act as an E3 ligase for 
p53 (Li, Brooks et al. 2004).  
P53 Phosphorylation 
There have been 23 different phosphorylation and dephosphorylation sites 
identified for p53 (Figure 2). Most residues are phosphorylated by different kinases 
following cellular stress.  Upon DNA damage, one of the best characterized mechanisms 
of p53 stabilization and activation is its phosphorylation by activated checkpoint protein 
kinases. Upon activation by DNA damage, ATM, Chk1, and Chk2 phosphorylate p53 on 
several key serine residues. ATM phosphorylates p53 on serine 15 (Canman and Lim 
1998) which induces a cascade of p53 phosphorylation. Chk2 phosphorylates p53 on 
serine 20 (Hirao, Kong et al. 2000). Following DNA damage signaling, MDM2 
dissociates from p53 suggesting this is mediated through phosphorylation events. Indeed, 
tranfection studies indicate that phosphorylation of p53 by Chk2 is thought to disrupt 
MDM2-p53 binding (Unger, Juven-Gershon et al. 1999), but it has also been shown to be 
dispensable for efficient p53 induced G1 arrest (Jack, Woo et al. 2002). Further, in vitro 
studies with peptides from this region indicate that threonine 18 phosphorylation can 
significantly destabilize the MDM2-p53 association (Schon, Friedler et al. 2002).  By 
contrast, other studies have shown that p53 mutants, in which all serine residues in the 
entire protein were changed to Alanine, displayed wild-type stability and transactivation 
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(Wahl 2006). It is important to point out that mouse models with mutations of serine-15-
to-Alanine (human serine 18) or serine-23-to-Alanine (human serine 20) exhibited 
modest, tissue-specific deficiencies, but did not substantially destabilize or  inactivate 
p53 as would have been predicted if they were critical residues for reducing MDM2 
binding (Wu, Earle et al. 2002; MacPherson, Kim et al. 2004; Sluss, Armata et al. 2004). 
This suggests that post-translational modifications to MDM2 following DNA damage 
may also be required to attenuate MDM2-p53 interactions. For example, c-Abl kinase 
phosphorylation of MDM2 on Tyrosine 394  has been shown to destabilize the MDM2-
p53 interaction resulting in p53 stabilization and enhanced cell death (Goldberg, Vogt 
Sionov et al. 2002). 
DNA-PK has also been shown to induce phosphorylation on N-terminal residues of 
p53 including serine 37 which is necessary but not sufficient  for p53-DNA binding and 
transcriptional activity (Woo, McLure et al. 1998). C-terminal phosphorylation of p53 by 
CDKs, PKC, and CKII on serines 315, 378, 392 have been shown to mediate p53 
sequence specific binding in vitro (Bischoff, Friedman et al. 1990; Delphin and Baudier 
1994; Hall, Campbell et al. 1996).  Phosphorylation of p53 on serine 46 by the 
autophosphorylating kinase, DRK2 following severe DNA damage results in apoptosis 
by p53-mediated transactivation of the pro-apoptotic gene p53AIP (Oda, Arakawa et al. 
2000).  HIPK2 also phosphorylates p53 on serine 46 dissociating the MDM2-p53 
complex and inducing p53-mediated apoptosis (Di Stefano, Blandino et al. 2004). 
Conversely, the dephosphorylation of serine 215 by Aurora Kinase A reportedly inhibits 
the binding of p53 to DNA, overriding a DNA damage induced stress response (Liu, 
Kaneko et al. 2004). Likewise, the dephoshorylation of some residues of p53 have been 
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correlated with p53 activation. For example, serine 376 is phosphorylated in unstressed 
cells, but following DNA damage, it becomes dephosphorylated enhancing its interaction 
with 14-3-3 (Stavridi, Chehab et al. 2001). Dephosphorylation of p53 can also lead to its 
inhibition. For example the intracellular domain of NOTCH-1 can bind to p53 inhibiting 
its phosphorylation on serine 15, 37, and 46 resulting in reduced p53 activation (Kim, 
Chae et al. 2007).  The intricate control of p53 by a wide variety of kinases suggests a 
potential redundancy which would ensure that p53 is effectively activated under a 
multitude of stress conditions.    
P53 Acetylation 
Histone acetyltransferases such as p300/CBP and PCAF mediate acetylation of the 
C-terminal lysines of p53. DNA damage induced phosphorylation of the N-terminal of 
p53 increases its association with p300/CBP enhancing p53 acetylation and resulting in 
its activation (Barlev, Liu et al. 2001).  MDM2 has been shown to inhibit the interaction 
of p53 and p300 in the absence of stress (Ito, Kawaguchi et al. 2002). The DNA damage 
inducible gene p33ING2, a potential tumor suppressor has been shown to increase Lysine 
382 acetylation enhancing a G1/S specific checkpoint arrest (Garkavtsev, Grigorian et al. 
1998). Additionally, PML, a protein induced by various stimuli, localizes to nuclear 
bodies together with p53 and CBP where it triggers N-terminal phosphorylation and C-
terminal acetylation of p53 to facilitate its transcriptional activation (Guo, Salomoni et al. 
2000; Pearson, Carbone et al. 2000). 
P53 Neddylation and Sumoylation 
P53 C-terminal lysine residues can also be altered by neddylation or sumoylation. 
Sumoylation is similar to ubiquitylation in that an isopeptide bond is formed between the 
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C-terminal carboxy group of the small ubiquitin-like protein SUMO1 and the ε-amino 
group of a lysine residue in the target protein. The target for sumoylation in p53 is Lysine 
386 and sumoylation was reported to modulate p53 transcriptional activity (Gostissa, 
Hengstermann et al. 1999). Sumoylation of p53 seems to be regulated by MDM2- and 
ARF mediated nuclear targeting (Chen and Chen 2003). It has been shown to induce 
senescence in normal human fibroblasts and apoptosis is Rb-deficient cell lines (Bischof, 
Schwamborn et al. 2006). Whether p53 can be de-sumoylated is not yet known. 
Neddylation inhibits p53 transcriptional activation  in a process promoted by 
MDM2 (Xirodimas, Saville et al. 2004). In this modification, the C-terminal glycine 
residue of the ubiquitin-like protein NEDD8 can be covalently linked to Lysines 370, 
372, or 373 of p53. NEDD8 is conjugated to MDM2, which apparently promotes 
conjugation of NEDD8 to p53. Three of the neddylated lysine residues overlap with 
lysine residues that are ubiquitinated. Whether p53-specific de-neddylation pathways 
exist, or whether neddylation competes with acetylation or augments ubiquitylation is not 
yet clear.  Other modifications that regulate p53 activity include methylation mediated by 
methyltransferases such as Set9 on Lysine 372 which causes stabilization and activation 
of p53 when overexpressed (Chuikov, Kurash et al. 2004).  
P53 Cellular Localization 
Nuclear import and export of p53 is a tightly regulated process. Nuclear 
localization is required for p53-mediated transcriptional regulation. P53 contains three 
nuclear localization signals (NLS) that upon stimulation enable its nuclear import 
whereas nuclear export of p53 to the cytoplasm is mediated by two nuclear export signals 
(NES) (O'Brate and Giannakakou 2003). However, efficient nuclear export of p53 to the 
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cytoplasm requires the ubiquitin ligase function of MDM2 (Boyd, Tsai et al. 2000; 
Geyer, Yu et al. 2000). Mutations of the lysine residues in the C-terminus, where MDM2-
mediated ubiquitination occurs, abrogates MDM2-directed nuclear export (Nakamura, 
Roth et al. 2000; Rodriguez, Desterro et al. 2000).  This is thought to be due to the 
exposure or activation of a nuclear export sequence of p53 by MDM2. Nuclear export of 
p53 has been shown to be necessary for efficient p53 degradation.  
In some tumor types, such as neuroblastomas, expression of wildtype p53 is 
coupled with its failure to accumulate in the nucleus.  The observed nuclear exclusion 
may be an effect of hyperactive MDM2 or the activity of glucocorticoid receptors (GR) 
(Lu, Pochampally et al. 2000; Sengupta, Vonesch et al. 2000). The latter involves 
complex formation between p53 and GR, resulting in cytoplasmic sequestration of both 
p53 and GR. Dissociation of this complex by GR antagonists, results in accumulation of 
p53 in the nucleus, activation of p53-responsive genes, growth arrest and apoptosis. 
Other  proteins that directly or indirectly effect p53 nuclear import/export are importin-α, 
PI3/Akt, p14ARF, Pacr, actin, vimentin and mot2 (O'Brate and Giannakakou 2003). 
P53 mutations in Human Cancer 
P53 mutations have been identified in a broad range of tumors to date including 
cancers of the ovary (48%), colon (43%), esophagus (43%), lung (38%), stomach (32%) 
and breast (25%) (Figure 3) (Lim, Lim et al. 2007).  Increasing numbers of sequences 
obtained from human cancers add to a database of over 10,000 somatic tumorigenic p53 
mutations (Hainaut and Hollstein 2000). Point mutations have been identified in more 
than 250 codons of p53. About 95% of these lie in the core DNA-binding domain, 
revealing the key role that p53 has in transcriptional activation. Furthermore, 75% occur 
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as single missense mutations in one allele of p53 rather than deletions, insertions or 
frameshifts. So, the oncogenic form of p53 is predominantly a full-length protein with 
single amino-acid mutations. The result of these mutations is usually high expression of 
stable mutant p53. These mutations assert a dominant-negative effect over the remaining 
wild-type allele by generating a heterooligomer of wild-type p53 with mutant p53. The 
second wild-type allele of p53 is generally also lost by a process called loss-of-
heterozygosis (LOH) resulting in genetic instability.  Many of these mutations affect the 
structural integrity of p53 or its ability to interact with DNA at target promoters, leading 
to the partial or complete loss of protein function.  Other evidence suggests that some 
mutants of p53 possess oncogenic activity by a gain-of function mechanism (Dittmer, 
Pati et al. 1993; Harvey, Vogel et al. 1995).  Mutant p53 is capable of activating an 
alternate subset of promoters such as c-myc as well as MDR1 (multi-drug resistance) 
genes which facilitate cell proliferation even under unfavorable growth conditions 
(Frazier, He et al. 1998; Sampath, Sun et al. 2001). Mutant forms of p53 are still able to 
interact with cofactors such as p300 and CBP causing deregulated gene expression. Thus, 
human tumors favor selection for accumulation of p53 mutations to promote tumor 
progression. 
 Most of the p53 mutations (30%) are found at six specific codon 'hotspots': R175, 
R245, R248, R249, R273, R282 in the core domain. Overall the most prevalent mutation 
occurring in human cancer affects R248. Although the resulting protein maintains a wild-
type conformation, its DNA-binding capability is severely compromised (Ory, Legros et 
al. 1994). Mutations to codon R175 result in an altered conformation in p53 with a more 
severe phenotype in vitro (Soussi and Beroud 2001).  
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Figure 3. Prevalence of p53 mutation by site. from IARC TP53 Mutation Database 
November 2007 
 
Clinical Consequences of p53 Mutation 
There are severe clinical consequences for individuals when p53 mutations occur. 
According to several studies, specific p53 mutations can be associated with a poor 
prognosis or weak response to treatment. For example, colon cancer patients with p53 
mutations in codon 175 have a lower probability of survival compared to patients with 
other mutations (Goh, Yao et al. 1995). Likewise breast cancer patients harboring p53 
DNA-contact mutations also have poor prognosis compared to patients with p53 
mutations which affect structural integrity (Takahashi, Tonoki et al. 2000).  
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The specific amino acid substitution may also have prognostic significance. For 
example, polymorphisms in codon 72 can result in substitution of either an Arginine or 
Proline resulting in the expression of two different p53 proteins. The Arginine 72 form of 
p53 has been found to be more efficient at inducing apoptosis than the Proline 72 form. 
In contrast, the Proline 72 form appears to induce a higher level of G1 arrest. These 
results demonstrate significant differences in how the codon 72 polymorphism affects the 
biological activity of p53 (Pim and Banks 2004). Furthermore, the arginine form of p53 
was found to be significantly more susceptible than the proline form to E6 mediated 
degradation. Moreover, allelic analysis of patients with HPV-associated tumors revealed 
a striking overrepresentation of homozygous arginine-72 p53 compared with the normal 
population, indicating individuals homozygous for arginine 72 are about seven times 
more susceptible to HPV-associated tumorigenesis than heterozygotes (Storey, Thomas et 
al. 1998).  
Non-Mutated p53 in Human Cancer 
While half of human tumors acquire a mutation in the p53 gene, the remaining 50% 
of cancers suppress p53 by disrupting its activation. For example, overexpression of the 
negative regulator MDM2 by gene amplification occurs in many tumor types (Momand, 
Jung et al. 1998; Dworakowska, Jassem et al. 2004; Ragazzini, Gamberi et al. 2004; 
Muthusamy, Hobbs et al. 2006). Increased expression of MDM2 leads to continuous 
degradation of p53 and therefore suppresses its activity. MDMX, a MDM2 homologue, 
has been found to be overexpressed in several tumor types and this leads to a reduction in 
p53 transcriptional activity (Danovi, Meulmeester et al. 2004). 
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Alternatively, upstream modulators of p53 are often inactivated in some tumor types. 
For example, mutations to ATM in the human disease ataxia-telangiectasia (AT) renders 
p53 unphosphorylated at serines 15 and 20 which can attenuate DNA-damage induced 
p53 stabilization (Maya, Balass et al. 2001). The AT-patients show multiple 
abnormalities including increased risk for lymphomas. Likewise a Chk2 germline 
mutation has been indentified in Li-Fraumeni-like syndrome patients that lack mutations 
in p53 (Bell, Varley et al. 1999). Additionally, the tumor suppressor ARF binds directly 
to MDM2, preventing MDM2-mediated degradation of p53 following mitogenic stress or 
oncogene activation (Sherr 2001). Loss of the INK4a/ARF/INK4b locus on chromosome 
9p21 is among the most frequent cytogenetic events in human cancer (Kim and Sharpless 
2006). Tumors which express wild-type p53 but lack ARF are unable to signal to p53 
following oncogene activation (Ruas and Peters 1998). 
Cancer Therapies involving p53  
Current cancer treatments usually consist of heavy doses of chemo-or-radio 
therapies. These therapies primarily act to kill rapidly dividing cells but do not target 
specific aberrant pathways unique to tumor cells. As mentioned previously, to evade 
these therapies, about 50% of human tumors have mutated p53.  Theoretically, it is 
possible to restore functional activity to p53 mutants by using second site suppressor 
mutations. These second site suppressor mutations can restore the stability and result in 
additional DNA contacts, and therefore restore the normal function to p53 mutants. One 
example is that the suppressor mutant N239Y can restore the ‘hotspot’ mutation G245S, 
and result in an improvement in DNA binding (Nikolova, Wong et al. 2000).  
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Other strategies have been developed to eliminate cells bearing mutant p53. For 
example, targeting malignant cells with oncolytic viruses (ONYX-015) genetically 
engineered to proliferate in cells containing mutant p53 genes have been identified as 
therapeutic approaches in previous animal studies (McCormick 2000). Initial clinical 
trials have confirmed functional activity and expression of the transgene product in 
tumors injected with a replication-deficient adenoviral vector containing wild-type p53 
(Heise, Sampson-Johannes et al. 1997; Ries and Korn 2002; Crompton and Kirn 2007). 
Further, screening of a low-molecular-weight compound library yielded the identification 
of  PRIMA-1, a compounds that can restore wild-type function to mutant p53. It is 
capable of inducing apoptosis in human tumor cells by restoring sequence-specific DNA 
binding and the active conformation to mutant p53 proteins in vitro and in living cells 
(Bykov, Issaeva et al. 2002). Several other investigators have identified small synthetic 
molecules or peptides that allow mutant p53 to maintain an active conformation (Foster, 
Coffey et al. 1999; Friedler, Hansson et al. 2002).  With further work aimed at improving 
potency and deliverability, this class of compounds may be developed into anticancer 
drugs with broad utility. 
As mentioned above, in tumors lacking p53 mutations, the maintenance of wild 
type p53 accompanies deficiencies in alternate components of the p53 pathway, such as 
amplification of MDM2. The crystal structure of MDM2 in complex with an N-terminal 
peptide of p53 shows that the p53 peptide forms an amphipathic α-helix that interacts 
with a hydrophobic pocket on MDM2 (Kussie, Gorina et al. 1996), suggesting small 
molecules could compete with MDM2 binding and activate p53. High throughput 
screening resulted in the recent development of Nutlin-1 and RITA, which restore the 
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apoptosis-inducing function of p53 by disrupting p53-MDM2 complex formation in 
tumor cells and xenograft models (Issaeva, Bozko et al. 2004; Vassilev, Vu et al. 2004).  
To date, a compound which can effectively inhibit MDMX-p53 binding has not been 
identified. 
P53 Monitors Ribosomal Integrity  
In addition to the nucleolar  protein ARF, other components of the nucleolus 
interact with the p53 pathway resulting in p53 activation. The nucleolus serves as the 
processing center for rRNA synthesis and ribosomal assembly. Protein synthesis requires 
an available pool of rRNA causing cell growth and proliferation to be dependent on 
changes in ribosome production. rRNA synthesis requires three basal transcription 
factors: promoter-selectivity factor (SL1), upstream binding factor (UBF) and RNA 
Polymerase I (Pol I).  A large family of small nucleolar RNAs extensively modifies and 
processes the pre-rRNA producing several rRNA intermediates, and finally, mature 18S, 
5.8S and 28S rRNAs. The mature rRNA species associates with more than 70 ribosomal 
proteins to form the small (S, 40S) and the large (L, 60S) ribosomal subunits. After their 
assembly, the large and small subunits are transported to the cytoplasm to initiate protein 
synthesis (Nazar 2004). During G1, an increase in rRNA synthesis and ribosome 
assembly is necessary for protein synthesis during S phase. rRNA is maximal in S and G2 
phases, repressed in mitosis and increased in G1. This link between cell-cycle 
progression and protein synthesis exists to ensure accurate cell growth and proliferation 
under appropriate conditions. Disrupting the pool of rRNA could subject the cell to 
deregulated growth conditions. The ability of the cell to recognize ribosomal stress and 
induce cell cycle arrest may be a determinant of cell survival in suboptimal conditions. 
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This suggests that failure to recognize ribosomal stress could result in tumor initiation or 
oncogenic progression (Ruggero and Pandolfi 2003). In fact, nucleolar morphology has 
long been used a clinical marker for cell transformation. However, it remains to be 
determined whether this is a cause or a consequence of the transformation process.  
Several lines of evidence suggest that the ribosome can signal the cell to regulate 
proliferation. A screen for cell lines generated from zebra fish which have a high 
propensity towards cancer incidence showed that ribosomal proteins can function as 
haploid-insufficient tumor suppressors (Amsterdam, Sadler et al. 2004).  In addition, 
Germline mutation of DKC1, the gene altered in Dyskeratosis congenita, has a direct 
affect on ribosome assembly, and in humans has been associated with an increased risk of 
cancer (Ruggero, Grisendi et al. 2003; Ruggero and Pandolfi 2003). DKC1 mediates the 
posttranscriptional conversion of uridine to psuedouridine, which is required for proper 
rRNA folding and eventually ribosome biogenesis. In mouse models of Dyskeratosis 
congenita, over 50 percent of mutant mice develop tumors (Ruggero, Grisendi et al. 
2003; Ruggero and Pandolfi 2003). Additionally, the small ribosomal subunit protein S19 
has been shown to be mutated in Diamond-Blackfan anemia, a condition associated with 
an increased susceptibility to haematopoetic malignancies (Da Costa, Tchernia et al. 
2003; Choesmel, Bacqueville et al. 2006). The direct mechanism of S19-induced 
tumorigenesis is not known, but it provides evidence that ribosomal defects can promote 
cancer susceptibility (Draptchinskaia, Gustavsson et al. 1999).  
Ribosomal Stress and p53  
The nucleolus has previously been regarded as a static entity, directing over 50% of 
cellular transcription, rRNA transcription. So, how is ribosome biogenesis coupled to cell 
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cycle progression?  It has been demonstrated that serum-starvation of cycling cells results 
in both growth arrest and the inhibition of rDNA transcription. In addition, growth 
inhibitory stimuli represses RNA polymerase I transcription through pRB-UBF 
interactions (Hannan, Hannan et al. 2000; Ciarmatori, Scott et al. 2001). The Syrian 
hamster temperature cell line BHK21 is unable to produce a mature 28S RNA and 60S 
ribosome subunits and undergoes growth arrest at permissive temperatures (Toniolo and 
Basilico 1976; Mora, Darzynkiewicz et al. 1980). Inhibiting the nucleolar protein p120, a 
protein necessary for 60S ribosomal subunit formation, by siRNA induces G1 arrest of 
human lymphocytes (Fonagy, Swiderski et al. 1992). A conditional deletion of the S6 
ribosomal protein in mice leads to defective ribosome biogenesis and reduced cellular 
proliferation (Volarevic, Stewart et al. 2000). The results of these studies imply that 
aberrant ribosome biogenesis may induce a checkpoint that prevents cell cycle 
progression. Since p53 is a cell sensor with capabalitities to quickly respond to both 
intrinsic and extrinsic cellular assaults, it follows that p53 could also play a role in 
monitoring ribosomal integrity. 
Genetic Models of Ribosomal Stress and p53.  
Several recent genetic models show that p53 is responsible for responding to rRNA 
perturbations. Transcription intermediary factor (TIF) IA is an RNA polymerase-I-
specific transcription factor that is required for recruitment of polymerase I to the rRNA 
promoter.  A dominant negative mutant of TIF-IA can suppress cell-cycle progression in 
proliferating HEK293T tumor cells, presumably by restricting ribosome production and 
thereby halting growth (Zhao, Yuan et al. 2003).   The genetic inactivation of TIF-IA is 
embryonic lethal in mice.  Cre-mediated depletion of TIF-IA in MEFs leads to disruption 
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of nucleoli, cell cycle arrest, upregulation of p53, and induction of apoptosis. RNAi-
induced loss of p53 overcomes proliferation arrest and apoptosis in response to TIF-IA 
abrogation (Yuan, Zhou et al. 2005).  Additionally, nucleolar stress induced by 
inactivating BOP1, using a BOP1 dominant negative mutant (BOP1D) first identified in a 
cDNA screen designed to isolate growth suppressors (Pestov, Grzeszkiewicz et al. 1998) 
led to a p53-dependent cell cycle arrest (Pestov, Strezoska et al. 2001). BOP1 is cell cycle 
regulated with peak levels at mid G1 phase (Strezoska, Pestov et al. 2000), concomitant 
with increased nucleolar function. Expression of BOP1D leads to cell growth arrest in the 
G(1) phase and results in specific inhibition of the synthesis of the 28S and 5.8S rRNAs 
without affecting 18S rRNA formation. Importantly, inhibition of p53 function results in 
the attenuation of cell cycle arrest induced by BOP1D (Strezoska, Pestov et al. 2002).  
The correlation between perturbation of rRNA biogenesis with elevated levels of p53 and 
induction of cell death supports the notion that the nucleolus can signal to p53 and direct 
cellular fate. 
Actinomycin D induces Ribosomal Stress 
In order to study the effects of ribosomal stress on p53 activation many laboratories 
utilize actinomycin D (ActD) to inhibit ribosome biogenesis (Iapalucci-Espinoza and 
Franze-Fernandez 1979). ActD is an agent widely used in combination chemotherapy for 
the treatment of choriocarcinoma (Kendall, Gillmore et al. 2003; Newlands 2003), 
testicular cancer (Miyazaki, Kawai et al. 2003), and soft tissue sarcomas (Bernstein, 
Kovar et al. 2006). ActD can induce DNA damage and inhibits general transcription at 
high concentrations (430 nM), but at low concentrations (5 nM) selectively inhibits RNA 
polymerase I and induces ribosomal stress. Low concentrations of ActD cause a 
 32 
breakdown of nucleolar structure allowing release of L proteins (L5, L11, L23) from the 
nucleolus to the nucleoplasm where they become localized with and have increased 
binding affinity for MDM2.  The MDM2-L protein interaction results in stabilization and 
activation of p53 (see MDM2 and Ribosomal Stress).  
Nucleolin and Nucleophosmin/B23 signal to p53 
In addition to L proteins, other components of ribosomal RNA processing such as 
nucleolin (Saxena, Rorie et al. 2006) and nucleophosmin/B23 (Itahana, Bhat et al. 2003; 
Korgaonkar, Hagen et al. 2005) have been implicated in signaling to the p53-MDM2 
network. Nucleolin protein levels in unstressed cells correlate with levels of p53. 
Nucleolin directly binds to MDM2 and inhibits both p53 ubiquitination and MDM2 auto-
ubiquitination.  Increases in nucleolin levels in unstressed cells led to higher expression 
of p21, a reduced rate of cellular proliferation, and increased apoptosis (Saxena, Rorie et 
al. 2006).  NPM/B23 (nucleophosmin), an abundant protein associated with ribosomal 
protein assembly, can activate p53 when overexpressed in many primary cells (Colombo, 
Marine et al. 2002). Conversely, knocking down B23 inhibits the processing of pre-
ribosomal RNA and induces cell death (Itahana, Bhat et al. 2003).  NPM affects p53 
stability by interacting with ARF. NPM targets ARF to nucleoli and blocks ARF-
mediated p53 activation and growth suppression in a dose-dependent manner. When 
NPM expression levels are reduced, ARF is released from its nucleolar constraints 
allowing it to bind to and suppress MDM2 resulting in p53 activation and growth-
inhibition (Korgaonkar, Hagen et al. 2005). It is unclear why so many different proteins 
involved with ribosome biogenesis would interact with MDM2. Perhaps each protein 
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represents a signaling molecule, which is responsible for recognizing specific types of 
ribosomal stress.   
MDM2-independent Ribosomal Stress Signaling 
Although the mechanisms described thus far involve ribosomal signaling through 
the direct inhibition of MDM2, several MDM2-independent p53 signaling mechanisms 
exist.  For example, ribosomal protein L26 can bind to the 5′ untranslated region of p53 
mRNA enhancing p53 translation following DNA damage, increasing cell-cycle arrest 
and irradiation-induced apoptosis (Takagi, Absalon et al. 2005). Alternatively, the 
ribosomal protein S27L (S27-like protein) was identified as a p53 inducible gene in a 
genome-wide chip-profiling study. S27L harbors a concensus p53-binding site in the first 
intron.  Further investigation revealed a p53-dependent induction of RPS27L in multiple 
cancer cell lines. In addition, expression of RPS27L promotes etoposide-induced 
apoptosis (He and Sun 2006). Lastly, a mitochondrial ribosomal protein L41 can directly 
bind to p53 and enhance translocation of p53 to the mitochondria, thus contributing to 
p53-induced apoptosis (Yoo, Kim et al. 2005).  Overexpression of the mitochondrial 
ribosomal protein S36 also increases p53 expression and induces cell cycle arrest (Chen, 
Chang et al. 2006).  
MDM2 
The murine double minute (MDM2) oncogene, was originally cloned from the 
transformed mouse cell line 3T3-DM (Cahilly-Snyder, Yang-Feng et al. 1987; 
Fakharzadeh, Trusko et al. 1991). Three MDM genes were located on small, acentromeric 
extrachromosomal nuclear bodies, called double minutes, which were retained in cells 
only if they provided a growth advantage.  MDM2 protein overexpression proved to be 
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responsible for transformation of the 3T3-DM cell line. Additionally, the overexpression 
of MDM2 in mouse models showed a high risk of tumor formation, suggesting it may 
play a role in oncogenesis (Jones, Hancock et al. 1998). Later, MDM2 was co-purified 
with p53 and found to negatively regulate p53 stability and transcriptional activity (214).  
MDM2 overexpression, in cooperation with oncogenic Ras, promotes transformation of 
primary rodent fibroblasts, and leads to tumor formation in nude mice (Fakharzadeh, 
Trusko et al. 1991).  Further supporting the role of MDM2 as an oncogene, several 
human tumor types have been shown to have increased levels of MDM2, including soft 
tissue sarcomas and osteosarcomas as well as breast tumors (Momand, Jung et al. 1998).   
Structure and Function of MDM2 
The full-length transcript of the MDM2 gene encodes a protein of 491 amino acids 
with a predicted molecular weight of 56 kDa. MDM2 is a member of the RING finger 
domain family of E3 ubiquitin ligases. It contains at least four functionally independent 
domains, including an N-terminal domain (a.a. 19-102) that recognizes the N-terminal 
Box-I domain of p53, a central acidic domain (a.a. 223-274), a putative zinc finger (a.a. 
305-322), and a RING finger domain (a.a. 438-478) critical for its E3 ubiquitin ligase 
activity (Figure 4).   
The interaction between the N-terminal domains of MDM2 and p53 has been 
extensively studied and several compounds have been reported to inhibit this interaction.   
Binding between MDM2 and p53 has been shown inhibit p53’s transactivation function 
(Momand, Zambetti et al. 1992). However, recently studies using GST pull-down 
experiments have shown that MDM2 constructs without the N-terminal p53 binding 
domain still retain the ability to bind to p53 (Ma, Martin et al. 2006).  
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The nuclear export and import signals that are essential for proper nuclear-
cytoplasmic trafficking of MDM2 are located between the N-terminal domain and the 
acidic domain (Hay and Meek 2000).  The central acidic domain of MDM2 is required 
for its binding to a number of proteins, including p14ARF, p300, and YY1 (Bothner, Lewis 
et al. 2001; Sui, Affar el et al. 2004). The phosphorylation of residues within this domain 
appears to be important for regulation of MDM2 function. Another conserved domain 
within the MDM2 protein is a zinc finger domain, the MDM2 central zinc finger plays a 
critical role in mediating MDM2's interaction with ribosomal proteins and its ability to 
degrade p53 under ribosomal stress conditions (Lindstrom, Jin et al. 2007). 
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Figure 4. Structure of MDM2. 
 
 MDM2 also contains a C-terminal RING domain (amino acid residues 430-480) 
which is important for many functions of MDM2. First, it contains a Cis3-His2-Cis3 
consensus that coordinates zinc binding which is essential for proper folding of the RING 
domain (Boddy, Freemont et al. 1994). Second, the RING domain of MDM2 is necessary 
and sufficient for its E3 ligase activity towards p53 as well as itself (Fang, Jensen et al. 
2000). Third, the RING domain also binds specifically to 5S RNA, although the function 
of this is poorly understood (Elenbaas, Dobbelstein et al. 1996). Fourth, this region of 
MDM2 contains a cryptic nucleolar localization signal revealed upon protein interactions 
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with p14ARF (Lohrum, Ashcroft et al. 2000).  Last, an intact RING domain of MDM2 is 
required to interact with MDMX. Furthermore, the C-terminal 130 amino acids of MDM2 
containing the RING domain are sufficient to ubiquitinate MDMX whereas deletion of 
the MDMX C-terminal RING domain ( 394-490) can prevent polyubiquitination by 
MDM2 (Pan and Chen 2003).  
The MDM2 RING domain also binds nucleotides with a strong preference for ATP 
and although such binding does not contribute to its E3 ubiquitin ligase activity, it is 
important for sub-nuclear translocation of MDM2 from the nucleoplasm to the nucleolus 
(Poyurovsky, Jacq et al. 2003). Lastly, the lysine residues within the RING domain of 
MDM2 have been shown to be substrates for CBP/p300-mediated acetylation leading to 
inhibition of the ubiquitin ligase activity (Wang, Taplick et al. 2004).  
MDM2 Interacts with p53  
MDM2 controls p53 through two distinct mechanisms, by directly binding and 
masking the N-terminal transactivation domain of p53 (Momand, Zambetti et al. 1992) 
and by promoting proteasomal degradation of p53 (Haupt, Maya et al. 1997).  The direct 
interaction between the two proteins has been localized to a relatively small (aa 25–109) 
hydrophobic pocket domain at the N-terminus of MDM2 and a 15 amino acid 
amphipathic peptide  at the N-terminus of p53 (Chen, Marechal et al. 1993; Kussie, 
Gorina et al. 1996). The minimal MDM2-binding  site on the p53 protein was mapped 
within residues 18–26 (Chen, Marechal et al. 1993; Bottger, Bottger et al. 1997; Haupt, 
Maya et al. 1997). Site-directed mutagenesis has shown the importance of p53 residues 
Leu14, Phe19, Leu22, Trp23, and Leu26, of which Phe19, Trp23, and Leu26 are the most 
critical. Accordingly, the MDM2-binding site p53 mutants are resistant to degradation by 
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MDM2 (Haupt, Maya et al. 1997; Kubbutat, Jones et al. 1997). Similarly, mutations of 
MDM2 at residues Gly58, Glu68, Val75, or Cys77 result in a lack of p53 binding 
(Freedman, Epstein et al. 1997). The interacting domains show a tight key-lock 
configuration of the p53-MDM2 interface. The hydrophobic side of the amphipathic p53 
-helix, which is formed by amino acids 19–26 (with Phe19, Trp23, and Leu26 making 
contact),  fits deeply into the hydrophobic cleft of MDM2. The MDM2 cleft is formed by 
amino acids 26–108 and consists of two structurally similar  portions that fold up into a 
deep groove lined by 14 hydrophobic and aromatic residues (Kussie, Gorina et al. 1996).  
The interactions between p53 and MDM2 are tightly regulated and have been shown to 
be disrupted by post-translational modifications to either protein. 
MDM2 promotes p53 degradation 
MDM2 functions as an E3 ubiquitin ligase toward p53 promoting its degradation 
through a complex series of steps that involve  E1, E2, and E3 proteins. The E1 enzyme 
binds ubiquitin, a 76-amino acid protein, activating it for further processing. The E2 
conjugating enzyme accepts the activated ubiquitin from E1 and transfers it to the E3 
enzyme, a ligase that covalently bonds the ubiquitin to the substrate. However, mutants of 
MDM2 lacking the E3 ubiquitin ligase activity can efficiently bind wild-type p53 and 
inhibit p53-mediated transcriptional activation in transfection experiments (Leng, Brown 
et al. 1995).  MDM2 can also promotes its own degradation by autoubiquitination (Fang, 
Jensen et al. 2000; Honda and Yasuda 2000). This is a second mechanism of promoting 
p53 stabilization.  
Although MDM2 was believed to polyubiquitinate p53 for protein degradation, 
other evidence suggests that MDM2 mediates monomeric p53 ubiquitination on multiple 
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lysine residues rather than a polymeric ubiquitin chain (Lai, Ferry et al. 2001). This 
suggests other proteins must aid in polyubiquitination of p53 (Thrower, Hoffman et al. 
2000). Further research indicates that MDM2 requires p300 to catalyze p53 
polyubiquitination, whereas alone MDM2 can only catalyze p53 monoubiquitination 
(Grossman, Deato et al. 2003). MDM2 mutants lacking part of the acidic domain that 
overlaps the p300/CBP-binding domain failed to degrade p53 but accumulated 
monoubiquitinated p53 (Zhu, Yao et al. 2001). Interestingly, MDM2 can also bind to the 
p53-related proteins P63 and P73, yet it does not mediate their degradation (Zeng, Chen 
et al. 1999).  As mentioned earlier, the E3 activity of MDM2 is dependent on its RING 
finger domain and is abolished by mutations which delete the domain or substitute any of 
the amino acids required for the coordination of zinc (Honda and Yasuda 2000). 
Besides acting as an E3 ligase for p53,  MDM2 also stimulates the ubiquitination of 
additional proteins including MDMX (which will be discussed in more detail), b-arrestin, 
PCAF and insulin-like growth factor 1 receptor (IGF1R) (74, 93, 94, 136, 275).  
Furthermore, MDM2 promotes other forms of p53 posttranslational modifications such as 
sumoylation, acetylation, and neddylation. Sumo-1 is a 110 amino acid protein belonging 
to the ubiquitin-like family.  MDM2 mediates p53 sumoylation which moderately 
enhances p53 transcriptional activity (204). MDM2 suppresses p53 acetylation by 
binding to and inhibiting the function of CBP/P300, rendering p53 more susceptible to 
degradation (147). Furthermore, MDM2 promotes the conjugation of another ubiquitin-
like molecule, nedd8 to p53, leading to the transcriptional inhibition of p53 activity (79). 
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MDM2-p53 Negative Feedback Loop 
MDM2 is transcriptionally activated by p53 by binding to and transcriptional 
activating the MDM2 P2 promoter, a response element situated downstream of the first 
exon of the MDM2 (Figure 1) (Barak, Juven et al. 1993; Perry, Piette et al. 1993).  
Ionizing irradiation, UV-irradiation as well as other DNA damaging agents induce 
MDM2 expression in a p53-dependent manner (Perry, Piette et al. 1993; Price and Park 
1994; Bae, Smith et al. 1995). Because MDM2 inhibits p53 activity, this forms a negative 
feedback loop that tightly regulates p53 function. Likewise, decreasing p53 activity 
results in decreased MDM2 protein levels. In addition to transcriptional activation by 
p53, oncogenic Ras induces MDM2 through the Raf/MEK/MAP kinase pathway in a 
p53-independent manner (Ries, Biederer et al. 2000).  
MDM2 Regulation by DNA Damage 
Upon DNA damage, p53 is posttranslationally modified to inhibit its interactions 
with MDM2. Several kinases also phosphorylate MDM2 and modulate its interactions 
with p53 (Moll and Petrenko 2003).  For example, ATM phosphorylates MDM2 at serine 
395, disrupting the nuclear export signal that is needed for efficient p53 export into the 
cytoplasm (201). MDM2 can be phosphorylated by c-Abl on Tyr394 following DNA 
damage which contributes to apoptosis by blocking the ability of MDM2 to down-
regulate p53 function (96).  Other protein kinases that have been implicated in regulating 
MDM2 phosphorylation and function include AKT, p38 mitogen-activated kinase 
(MAPK), DNA-dependent protein kinase (DNA-PK),  cyclin A-dependent kinases 1 and 
2 (CDK1 and CDK2), and  protein kinase CK2 (Meek and Knippschild 2003).  
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Growing evidence suggests that dephosphorylation of MDM2 is also likely to be a 
critical event following stress and there are now two striking examples of mechanisms 
where MDM2 dephosphorylation plays a key role in the p53 response. The first of these 
involves the cyclin G1 protein, the product of one of the first p53 responsive genes to be 
identified (Okamoto and Beach 1994). The cyclin G1-PP2A complex dephosphorylates 
MDM2 residue Thr216 resulting in p53 induction by attenuating MDM2 regulation, 
leading to restoration of p53 levels and re-establishment of the MDM2-p53 feedback loop 
(Okamoto, Li et al. 2002). Dephosphorylation of the acidic domain of MDM2 is also 
thought to play a role in the network of events mediating p53 induction. Following 
ionizing radiation, key phospho-serine residues in the acidic domain of MDM2 (serine 
240, 242, 260, and 262) become rapidly dephosphorylated preceding p53 accumulation. 
Mutants of MDM2 with serine to Alanine substitutions at these phospho-serine residues 
alleviate degradation of p53 suggesting dephosphorylation of these residues results in a 
positive regulation of p53 (Blattner, Hay et al. 2002). 
MDM2 regulation by Oncogenic Stress 
Deregulated oncogenes, such as oncogenic Ras mutants, c-myc, or viral E1A, use 
yet another way of interfering with MDM2 regulation to stabilize and activate p53. 
Oncogenic stress stimulates an increase in the p14ARF protein (p19ARF in the mouse), the 
alternate product of the INK4A tumor suppressor locus. ARF binds to the RING finger 
domain of MDM2 and directly inhibits its E3 Ligase activity (Honda and Yasuda 1999). 
A model has been proposed in which ARF binds MDM2 and sequesters it into the 
nucleolus while p53 remains in the nucleoplasm resulting in enhanced p53 transcriptional 
activity (Tao and Levine 1999; Weber, Taylor et al. 1999). However, there is some 
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disagreement as to whether sequestration of MDM2 by ARF takes place in the nucleolus 
or in the nucleoplasm (Llanos, Clark et al. 2001). Whatever the actual mechanism of 
MDM2 inactivation by ARF, the major consequence is the stabilization of nuclear p53 
levels. The ARF-MDM2-p53 relationship appears to be an integrated part of several 
cellular networks involving complex mitogenic signaling pathways, such as Wnt (via ß-
catenin), Myc, and pRb-E2F (Sharpless and DePinho 1999; Sherr 2001).  
MDM2 regulation by Ribosomal Stress 
Ribosomal proteins such as L5 (Marechal, Elenbaas et al. 1997; Dai and Lu 2004), 
L11 (Lohrum, Ludwig et al. 2003; Zhang, Wolf et al. 2003; Bhat, Itahana et al. 2004; 
Dai, Shi et al. 2006), L23 (Dai, Zeng et al. 2004; Jin, Itahana et al. 2004) have also been 
implicated in p53 signaling (Figure 5). Ribosomal stress induced by inhibiting rRNA 
synthesis causes the release of L proteins from the nucleolus to the nucleoplasm. In the 
nucleoplasm,  L proteins bind to the central acidic domain/zinc finger of MDM2 and 
inhibit its E3 ubiquitin ligase activity towards p53. Each of the L proteins when 
overexpressed independently can inhibit MDM2’s repressive function toward p53 
causing an in increase in p53 target genes and cell cycle arrest (Bhat, Itahana et al. 2004; 
Dai and Lu 2004). Likewise, knockdown of any of the L proteins by siRNA can cause a 
decrease in p53 activation. On the other hand, all three ribosomal proteins can bind in a 
quaternary complex to MDM2 simultaneously without the need for p53 suggesting that 
each of these proteins is essential for p53 activation (Jin, Itahana et al. 2004).  Although 
previous studies report minor variations regarding the L protein-MDM2 binding region, 
an MDM2 zinc finger mutant (C305F) abrogates the interaction of MDM2 with L5 and 
L11 but not L23 (Lindstrom, Jin et al. 2006). The MDM2 mutant has decreased nuclear 
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export capabilities, retains the functional ability to promote p53 ubiquitination but 
delayed degradation, and escapes inhibition by L11.  Although some studies suggest that 
the MDM2-L protein interaction causes a steric hindrance preventing the transfer the 
ubiquitin moiety from E2 to p53 (Zhang, Wolf et al. 2003), the exact mechanism of p53 
protection has yet to be determined. 
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Figure 5. MDM2 Regulation by Ribosomal Stress. Under normal conditions the L 
proteins are associated with the large ribosomal subunit. Following ribosomal 
stress, the L proteins associate with MDM2 and attenuate its ability to degrade 
p53. 
MDM2 Mouse Models 
The importance of the MDM2/p53 interaction has been convincingly demonstrated 
in in vivo experiments. Mice lacking MDM2 are early embryonic lethal and die before 
implantation at 3.5 days post-coitum. This phenotype is completely rescued by 
concomitant deletion of p53, suggesting that the embryo lethality was due to overactive 
p53 (Jones, Roe et al. 1995; Leveillard, Gorry et al. 1998). Mice with a hypomorphic 
allele that expresses approximately 30% of the total MDM2 levels have a decreased body 
weight, defects in hematopoiesis, and are more radiosensitive than normal mice 
(Mendrysa, McElwee et al. 2003).  MDM2+/-  heterozygous mice are more resistant to the 
development of lymphoid tumors induced by expression of the Eu-Myc transgene (Alt, 
 43 
Greiner et al. 2003). These phenotypes are p53 dependent, emphasizing the importance of 
regulating MDM2 levels in many cell types.   
MDM2 Interacting Proteins 
Besides MDMX, ARF, and the ribosomal proteins described above, several other 
MDM2 interacting proteins have been identified in various systems.  Hypoxia-inducible 
factor 1a (HIF-1a) interacts with MDM2 and enhances p53 function by preventing the 
nuclear export of p53 (Chen, Li et al. 2003).  MDM2 was also identified as an RB 
binding protein.  MDM2 inhibits RB suppression of E2F1 function, causing cell cycle 
arrest (Xiao, Chen et al. 1995; Hsieh, Chan et al. 1999). MDM2 also interacts with the 
transcriptional activator Sp1 in vivo (Johnson-Pais, Degnin et al. 2001). MDM2/Sp1 
binding prevents Sp1-DNA interactions thereby blocking transcription. Rb has been 
shown to compete with Sp1 for binding to MDM2. However, there is no evidence that 
MDM2 plays a role in the degradation of either RB or Sp1. Furthermore, MDM2 can 
interact with the E2F1/DP1 complex to stimulate transcription (Martin, Trouche et al. 
1995). Additional reports indicate that MDM2 blocks the apoptotic activity of E2F1 
(Loughran and La Thangue 2000). Numb, a protein important for specifying cell fate 
during development, has also been identified as an MDM2 interacting protein that is 
degraded by MDM2 (Yogosawa, Miyauchi et al. 2003). The ability for MDM2 to 
promote cell proliferation by regulating components of the cell cycle underscores its 
importance. 
MDMX 
MDMX is emerging as a potent suppressor of p53 transcriptional activity following 
stresses imposed by DNA damage, loss of ribosomal integrity and aberrant mitogenic 
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signaling. MDMX was first identified as a p53 (Shvarts, Steegenga et al. 1996) and later 
as an MDM2 (Sharp, Kratowicz et al. 1999; Tanimura, Ohtsuka et al. 1999) binding 
protein. MDMX is structurally similar to MDM2 (Shvarts, Steegenga et al. 1996), but it 
does not have intrinsic E3 ligase activity nor does it promote p53 degradation (Stad, 
Little et al. 2001).  MDMX forms heterodimers with MDM2 through C-terminal RING 
domain interactions (Sharp, Kratowicz et al. 1999; Tanimura, Ohtsuka et al. 1999), and 
stimulates the ability of MDM2 to ubiquitinate and degrade p53 (Gu, Kawai et al. 2002; 
Linares, Hengstermann et al. 2003). Due to self-ubiquitination, MDM2 has a short half 
life; whereas MDMX is relatively stable in the absence of stress. Similar to its actions 
against p53, MDM2 can ubiquitinate and degrade MDMX (de Graaf, Little et al. 2003; 
Kawai, Wiederschain et al. 2003; Pan and Chen 2003) ultimately generating a steady 
state level of MDM2, MDMX, and p53 proteins.  
MDMX overexpression is found in a number of tumors or tumor cell lines with 
wild-type p53 (Ramos, Stad et al. 2001; Danovi, Meulmeester et al. 2004). A study of a 
large series of gliomas revealed that MDMX is amplified/overexpressed in 5/208 tumor 
samples (Riemenschneider, Buschges et al. 1999) and more recently it has been found to 
be severely amplified or overexpressed in retinoblastomas (65%) (Laurie, Donovan et al. 
2006). In approximately 30% of tumor cell lines tested,  MDMX  is either overexpressed 
or alternatively transcribed, and in general this correlates with the presence of wild-type 
p53 (Ramos, Stad et al. 2001). A recent analysis of a large series of tumors also revealed 
overexpression of MDMX  in 19% of  breast, colon , and lung cancers studied (Danovi, 
Meulmeester et al. 2004).  In all cases, amplification of MDMX correlated with wild-type 
p53 status and lack of MDM2 amplification.  In addition, MDMX overexpression can 
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prevent oncogenic Ras-induced premature senescence, and MDMX can cooperate with 
RasV12  to transform cells which are capable of forming tumors in nude mice (Danovi, 
Meulmeester et al. 2004). Taken together this evidence suggests that MDMX can 
suppress p53 and alleviate the need for its inactivation by mutation in order to promote 
tumor progression.  
Structure and Function of MDMX 
MDMX and MDM2 are structurally related proteins of 490 and 491 amino acids, 
respectively (Figure 6). The greatest similarity between the two proteins is at the N-
terminus, a region encompassing the p53-binding domain (53.6% homology). The 
residues required for interaction with p53 are conserved in MDM2 and MDMX (Shvarts, 
Steegenga et al. 1996), and the same residues in p53 are required for both MDMX-p53 
and MDM2-p53 interactions (Bottger, Bottger et al. 1999). Another well-conserved 
region common to MDMX and MDM2 is a RING-finger domain, located at the C-
terminus of each protein. The RING-finger domain is essential for MDMX-MDM2 
heterodimerization (Sharp, Kratowicz et al. 1999; Tanimura, Ohtsuka et al. 1999). Like 
MDM2, MDMX contains a zinc-finger domain which recent results suggest is necessary 
for interaction between MDMX and casein kinase 1 alpha (CK1α) (Chen, Li et al. 2005). 
The central regions of MDM2 and MDMX show no significant similarity, but both 
regions are rich in acidic residues. 
 
 
 46 
Zn (RING)Acidicp53 binding
MDMX 490
Zn RINGNLS Acidicp53 binding
MDM2
NES
491
 
            53.6%                                                       41.9%                     53.2% 
Figure 6. Comparison of the Structure of MDM2 versus MDMX. Both proteins 
contain a p53 binding domain, acidic region, zinc finger, and form 
heterodimers through their ring domains. 
At the genomic level, exons 4-12 are well conserved between MDMX and MDM2.  
However, the 5’ ends of the genes are quite distinct. Importantly, in contrast to MDM2, 
the MDMX promoter does not contain a p53-responsive element (Shvarts, Steegenga et 
al. 1996). One non-coding exon was found in the MDMX locus instead of two for 
MDM2. Also, the intron between exon 1 and 2 in MDMX is about 6 kb, while in MDM2 
the first three exons are within 1 kb. The MDM2 gene has two promoters, the second of 
which (P2) is responsive to p53.  Consistently, MDM2, but not MDMX is induced 
following p53 activation. This highlights the need to understand what makes these 
proteins so distinct.  
 MDMX Post Translational Modifications  
The post-translational modifications of MDMX that have been characterized to date 
include phosphorylation, ubiquitination and sumoylation. Ubiquitination of MDMX by 
MDM2 was the first described post translational modification of MDMX.  The RING 
domain of MDM2 is required both to interact with MDMX and to provide E3 ligase 
function (de Graaf, Little et al. 2003; Kawai, Wiederschain et al. 2003; Pan and Chen 
2003). This effect is stimulated by ARF and DNA damage and correlates with the ability 
of ARF to bind MDM2.  Interestingly, ARF inhibits MDM2 E3 ligase activity toward 
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p53 and MDM2, leading to stabilization of both proteins (139, 245). On the otherhand, 
ARF has been shown to promote MDM2-dependent degradation of MDMX (Pan and 
Chen 2003). This suggests that p53 activation by ARF occurs by both enhanced MDMX 
degradation as well as reduced p53 ubiquitination. 
Phosphorylation of MDMX has functional implications for p53 activation and 
MDMX degradation. Efficient degradation of MDMX following DNA damage requires 
ATM-dependent  phosphorylation on S342 and S367 by Chk2 and S403 by ATM (Chen, 
Gilkes et al. 2005; Okamoto, Kashima et al. 2005; Pereg, Shkedy et al. 2005; LeBron, 
Chen et al. 2006). Furthermore, Chk2-mediated phosphorylation of MDMX on S367 is 
important for stimulating 14-3-3 binding, MDMX nuclear import, and degradation by 
MDM2 (LeBron, Chen et al. 2006). Other studies suggest that ultra violet radiation 
results in Chk1-mediated phosphorylation of S367 (Jin, Dai et al. 2006). Phosphorylation 
of MDMX reduces its affinity for the deubiquitylating enzyme (DUB) HAUSP/USP7  
which has been shown to be essential in for maintenance of both MDM2, MDMX, and 
p53 protein levels (Cummins, Rago et al. 2004; Meulmeester, Pereg et al. 2005). Basal 
phosphorylation of MDMX can also occur on serines 96 and 289 by kinases CDK2 and 
CK1α, respectively. Phosphorylation of serine 96 is proposed to regulate MDM2 
localization, whereas CK1α mediated phosphorylation stimulates the MDMX-p53 
interaction (Chen, Li et al. 2005; Elias, Laine et al. 2005). 
Sumoylation of MDMX has been cited but its functional importance has yet to be 
described. MDMX is conjugated with SUMO-1 on K254 and K379, but conversion of 
K254 and K379 to arginine has no effect on MDMX function (Pan and Chen 2005). 
Further studies indicate that endogenous MDMX is modified by SUMO-2 on K254 and 
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K379. The role of post translational modifications of MDMX are continuing to be 
characterized. Mouse models involving these modifications may help to determine the 
physiological role of these modifications. 
Mouse Models of MDMX 
The physiological importance of MDMX’s functional affect on p53 was 
characterized by the embryonic lethality of MDMX null mice, which can be rescued by 
the concomitant knockout of p53 (Parant, Reinke et al. 2001; Finch, Donoviel et al. 2002; 
Migliorini, Lazzerini Denchi et al. 2002). Moreover, conditional alleles have recently 
been developed to offer further insight on MDMX regulation of p53. MDM2 and MDMX 
were conditionally inactivated in neuronal progenitors.  Mice lacking MDM2 expression 
in the central nervous system suffered from apoptosis, whereas MDMX deletion 
enhanced cell cycle arrest and apoptosis at a later stage of embryonic development. The 
deletion of both genes contributed to an even earlier and more severe CNS phenotype 
(Xiong, Van Pelt et al. 2006). Similar studies in which  p53 was conditionally expressed 
in neuronal progenitor cells or in post-mitotic cells of mice lacking MDMX or MDM2 
showed that MDM2 prevents p53 accumulation while MDMX contributes to the overall 
inhibition of p53 activity, independent of MDM2 (Francoz, Froment et al. 2006). 
Interestingly, the phenotypes disappear in the absence of p53. This suggests that both 
MDM2 and MDMX are required to inhibit p53 activity in the same cell type, and MDM2 
does not compensate for loss of MDMX in vivo. However, a recent paper suggests that 
overexpression of an MDM2 transgene rescues the embryonic lethality associated with 
MDMX-deficiency (Steinman, Hoover et al. 2005). MDMX has also been conditionally 
inactivated in cardiomyocytes and smooth muscle cells of the GI tract (Boesten, Zadelaar 
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et al. 2006; Grier, Xiong et al. 2006). In contrast to loss of MDM2, loss of MDMX leads 
to only minor defects in histogenesis and tissue homeostasis. Overall these studies 
suggest that the absence of MDMX enhances p53 transcriptional activity.  
The analysis of mice encoding a mutant p53 lacking the proline-rich domain (p53
P) also enabled evaluation of MDMX function (Toledo, Krummel et al. 2006). This 
hypomorphic p53 mutant is able to fully rescue MDMX deficiency. In the absence of 
MDMX, the transcription of MDM2 is stimulated to some extent, leading to slightly 
increased MDM2 levels. While MDMX loss did not alter MDM2 stability, it significantly 
increased p53 P partially restoring cell cycle control. In contrast, decreasing MDM2 
levels increased p53 P levels without altering p53 P transactivation. This suggests 
MDMX regulates p53 activity, while MDM2 controls p53 stability. 
The difference between the MDM2-null and MDMX-null phenotypes may be a 
result of the fact that loss of MDM2 leads to dramatic accumulation of the p53 protein, 
whereas  loss of MDMX does not significantly increase p53 levels in vivo. 
MDMX –MDM2-p53 Pathway 
The first reported activity of MDMX is the inhibition of p53-induced transcription 
following ectopic expression on both luciferase reporter genes and endogenous p53 
targets (Shvarts, Steegenga et al. 1996). This effect is dependent on the p53-binding 
domain of MDMX. The same amino acids in p53 are required for both MDMX/p53 and 
MDM2/p53 interactions, and these amino acids are located in the transcriptional 
activation domain of p53 (Bottger, Bottger et al. 1999). This suggests that MDMX may 
inhibit p53 transcriptional activity by interfering with the ability of p53 to interact with 
the basal transcription machinery or to recruit essential coactivator (s) or it could inhibit 
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p53 binding at target promoters.  MDMX abrogates p300/CBP-mediated acetylation of 
p53 even in MDM2-null cells and the same result is also observed with a mutant of 
MDMX defective for MDM2 binding (Sabbatini and McCormick 2002; Danovi, 
Meulmeester et al. 2004) resulting in  stimulation of p53 activation.  
MDMX binds to MDM2 through the MDM2 RING domain which could result in 
several different outcomes for p53 and MDM2 stability. One study suggests MDMX 
stabilizes MDM2 by interfering with its auto-ubiquitination (Stad, Little et al. 2001). 
Another study shows that knocking down MDMX expression with siRNA results in 
decreased MDM2 levels and an increase in p53 (Gu, Kawai et al. 2002). Alternatively, 
knocking down MDMX in U2OS and MCF-7 cells by siRNA increased both MDM2 and 
p53 levels (Linares, Hengstermann et al. 2003). Further studies demonstrate, that there is 
no significant effect on MDM2 or p53 levels after knocking down MDMX in MCF-7 
cells (Danovi, Meulmeester et al. 2004).  While still other studies have suggested that 
elevated levels of MDMX could stabilize p53 by inhibiting its degradation by MDM2, 
without interfering significantly with MDM2-dependent p53 ubiquitination (Jackson and 
Berberich 2000; Stad, Little et al. 2001; Migliorini, Lazzerini Denchi et al. 2002). This 
effect was proposed to be a consequence of reduced MDM2 induced p53 nuclear export, 
an event thought to be required for efficient p53 degradation (Boyd, Tsai et al. 2000; 
Geyer, Yu et al. 2000).  
The discrepancies in these findings suggest that the ratio of MDMX to MDM2 may 
be necessary to determine the overall affect on p53. If the MDMX:MDM2 ratio is about 
1:1, p53 undergoes MDM2-dependent proteasomal degradation. When MDMX is 
expressed at levels greater than MDM2, MDMX inhibits MDM2-mediated p53 
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degradation. Furthermore, in the presence of high MDMX levels, MDM2 and MDMX 
compete for p53 binding and MDM2 is likely to be displaced from p53. In these 
conditions, MDMX inhibits p53 transcriptional activity independent of MDM2 (Marine 
and Jochemsen 2005).  
Our lab has studied the effects of p53 activation in cells which either have an 
overexpression or knock down levels of MDMX following DNA damage or ribosomal 
stress (Chen, Gilkes et al. 2005; Gilkes, Chen et al. 2006). These studies show that while 
endogenous p53 levels show little change in response to altered MDMX levels, following 
cellular stress the level of p53 activation is inversely correlated to the amount of MDMX 
in these cells due to formation of inactive p53-MDMX complexes. In the presence of a 
high level of MDMX these complexes fail to bind the DNA of target promoters. In 
contrast,  knockdown of MDMX abrogates HCT116 tumor  xenograft formation in nude 
mice. MDMX overexpression does not accelerate tumor growth but increases resistance 
to 5-FU treatment in vivo. Our studies show that MDMX plays a negative role in p53 
transcriptional activation. 
MDMX Localization 
Exogenous MDMX is mainly localized in the cytoplasm as determined by cell 
fractionation and indirect immunofluorescence studies (Rallapalli, Strachan et al. 1999; 
Migliorini, Danovi et al. 2002). Co-expression of MDM2 stimulates the recruitment of 
MDMX into the nucleus (Gu, Kawai et al. 2002; Migliorini, Danovi et al. 2002). This 
effect is independent of p53 but requires intact RING finger domains on both MDMX 
and MDM2 proteins, and the NLS of MDM2. Other studies report that p53 can target 
MDMX to the nucleus independent of MDM2 (Li, Chen et al. 2002). However, it is 
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important to note that MDMX nuclear entry is also observed following DNA damage in 
p53/MDM2 double-null MEFs, suggesting a mechanism of  MDMX nuclear localization 
independent of both MDM2 and  p53 (Li, Chen et al. 2002).  Importantly, our lab 
recently showed that Chk2-mediated phosphorylation of MDMX on S367 and binding of 
14-3-3 was important for MDMX nuclear import by exposing a cryptic nuclear import 
signal. Mutation of MDMX S367 to Arginine prevents MDMX nuclear import (LeBron, 
Chen et al. 2006). These results suggest that phosphorylation of MDMX is important for 
its localization in response to DNA damage. 
MDMX Regulation by DNA Damage  
Following DNA damage, both p53 and MDM2 are phosphorylated by several 
kinases; most notably, ATM which functions as the primary signal transducer of DNA 
double-strand breaks (Shiloh 2003).  Until recently, little was known about the affects of 
DNA damage on MDMX. Although, it was recognized that DNA damage induces 
MDMX degradation in p53-deficient cells, without inducing MDM2 (Kawai, 
Wiederschain et al. 2003). Recently our laboratory and others showed that MDMX is 
phosphorylated at several key C terminal serine residues in an ATM-dependent manner 
following DNA damage. ATM modifies S403 (Pereg, Shkedy et al. 2005) and Chk2 
modifies S342 and S367 (Chen, Gilkes et al. 2005) on MDMX. Chk1 has also been 
shown to modify S367 under certain conditions (Jin, Dai et al. 2006). Phosphorylation of 
MDMX led to increased binding to MDM2 followed by ubiquitination and degradation of 
MDMX. When HCT116-Chk2-/- cells were compared to wild-type HCT116 cells after 
gamma irradiation (5 Gy), MDMX phosphorylation and degradation were impaired 
showing that DNA damage-induced phosphorylation of S342 and S367 strictly requires 
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Chk2. The addition of Chk2 to Chk2-null cells increased MDMX phosphorylation and 
ubiquitination. Functionally, the degradation of MDMX was necessary for p53 
activitation following DNA damage since cells overexpressing MDMX were unable to 
undergo a cell cycle arrest.  
p53 MDM2
MDMX
S403S367S342
S395
S20S15
DNA Damage
ATM Phosporylation
Chk2 Phosphorylation
 
Figure 7. MDMX-MDM2-p53 pathway following DNA damage.  
 
To further elucidate this mechanism, we showed that DNA-damage induced 
phosphorylation of S367 increased the affinity of MDMX/14-3-3 binding (LeBron, Chen 
et al. 2006). Mutating the MDMX S367 binding site abrogated the MDMX/14-3-3 
interaction increasing MDMX stability. Furthermore, phosphorylation of S367 was 
required for MDMX nuclear import after DNA damage. The results suggested that 14-3-3 
proteins regulated MDMX localization and abundance in response to DNA damage, and 
contribute to the efficient activation of p53. 
Additional means by which MDM2 and MDMX become destabilized following 
DNA damage have also been proposed (Meulmeester, Pereg et al. 2005). The 
deubiquitinating enzyme HAUSP can directly interact with both MDMX and MDM2. 
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HAUSP deubiquitinates MDMX counteracting MDM2-mediated degradation. However, 
DNA Damage can inhibit the interactions between HAUSP and both MDMX and 
MDM2. Notably, ectopic expression of HAUSP was not able to rescue DNA damage-
mediated degradation of MDMX. 
MDMX Regulation by induction of ARF 
Oncogenic insults can activate p53 by promoting the binding of ARF and MDM2. 
The interaction of ARF with MDM2 inhibits MDM2's E3 activity towards p53 (Honda 
and Yasuda 1999) and relocalizes MDM2 to the nucleolus (Weber, Taylor et al. 1999; 
Lohrum, Ashcroft et al. 2000; Rizos, Darmanian et al. 2000; Weber, Kuo et al. 2000). 
However,  relocalization of MDM2 is not essential for the inhibition of MDM2 function 
by ARF in all cells (Llanos, Clark et al. 2001; Korgaonkar, Zhao et al. 2002). Our lab has 
shown that ARF binding to MDM2 selectively blocks p53-ubiquitination but promotes 
ubiquitination of MDMX (Pan and Chen 2003). Our data shows MDMX overexpressing 
cells have reduced induction of p21 and cell cycle arrest following E2F activation of ARF 
whereas MDMX siRNA can sensitize cells to ARF-induced cell cycle arrest (unpublished 
observations). A recent paper by Laurie et al. shows that inactivation of the Rb pathway 
in the developing mouse or human retina leads to activation of the ARF–MDM2–p53 
tumor surveillance pathway. Genetic changes resulting in MDMX gene amplification can 
occur in the preneoplastic retinoblastoma cells causing the p53 pathway to be inactivated. 
Cells with amplified MDMX will have a growth advantage over those with an intact 
ARF–MDM2/MDMX–p53 pathway resulting in retinoblastoma development (Laurie, 
Donovan et al. 2006). This highlights the need to determine how MDMX is amplified as 
well as to identify specific inhibitors of the MDMX-p53 interaction.  
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MDMX Regulation by induction of Ribosomal Stress 
Recent studies revealed a connection between ribosomal stress and p53-dependent 
cell cycle arrest, suggesting that aberrant rRNA and ribosome biogenesis are sensed by 
p53 (Marechal, Elenbaas et al. 1994; Pestov, Strezoska et al. 2001; Lohrum, Ludwig et al. 
2003; Zhang, Wolf et al. 2003). Ribosomal stress induced by actinomycin D, serum 
starvation, or contact inhibition cause p53 stabilization and activation (Bhat, Itahana et al. 
2004). These studies suggest a mechanism involving the translocation of ribosomal 
proteins, L5, L11, and L23 from the nucleolus to the nucleoplasm where they bind to 
MDM2 and prevent p53 degradation (Bhat, Itahana et al. 2004; Dai, Zeng et al. 2004; Jin, 
Itahana et al. 2004). Each of these L proteins when overexpressed can inhibit MDM2 
degradation of p53. Results described in this dissertation suggest that activation of p53 by 
ribosomal stress requires down-regulation of MDMX. This process can be blocked by 
MDMX overexpression. As a result, tumor cells expressing high-level endogenous MDMX 
have less efficient p53 activation and growth arrest during ribosomal stress. Furthermore, we 
found that the widely used chemotherapy agent 5-FU activates p53 in part through inducing 
ribosomal stress. As such, MDMX overexpression can cause significant resistance to 5-FU 
in cell culture and tumor  xenograft models. These observations suggest that MDMX plays a 
unique and important role in regulating p53 response to perturbations in ribosome 
biogenesis.  
MDM2/MDMX Inhibitors 
MDM2 has been an attractive target for the development of novel anti-tumor agents 
(Bond, Hu et al. 2005).  Recently, high throughput screening was utilized to identify, 
Nutlins, a class of cis-imidazoline analogues, which can bind to MDM2 and inhibit the 
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p53-MDM2 interaction (Vassilev, Vu et al. 2004; Vassilev 2005).  MDMX and MDM2 
proteins share the highest degree of sequence homology at the N-terminal region within 
the p53-binding domain. Since previous studies using peptide inhibitors suggested that 
the p53-binding site on MDMX is similar to MDM2, it has been speculated that MDM2 
inhibitors may perform a dual function also blocking the MDMX-p53 interaction 
(Freedman, Epstein et al. 1997). However, three separate laboratories have shown that the 
MDM2 inhibitor Nutlin-3 is ineffective at targeting MDMX-p53 binding (Hu, Gilkes et 
al. 2006; Patton, Mayo et al. 2006; Wade, Wong et al. 2006).  Additionally, elevated 
MDM2 levels following Nutlin treatment are not able to degrade MDMX in several 
tumor cell lines. More importantly, overexpression of MDMX prevents p53 activation by 
Nutlin-3.  However, using a phage display library, we recently identified a peptide 
sequence, which blocks both MDM2 as well as MDMX binding. The peptide can activate 
p53 and induce growth arrest more effectively than blocking MDM2 alone (Hu, Gilkes et 
al. 2007). Since MDMX has been identified as an important negative regulator of p53 
function, it will be necessary to design specific MDMX/p53 binding inhibitors. A dual 
inhibitor of MDM2/MDMX-p53 binding would be even more effective. 
Ras/MAPK Signaling Pathway 
The MAP Kinase pathway participates in many diverse processes including cell 
proliferation, differentiation, transformation, and apoptosis. At the center of this signaling 
cascade is the small guanine nucleotide–binding protein, Ras. It is localized at the plasma 
membrane and can exist in two conformations: a guanosine triphosphate (GTP)–bound 
active state and the guanosine diphosphate (GDP)–bound inactive state. Receptors 
regulate Ras through nucleotide exchange factors, such as the murine Son of Sevenless 
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(SOS) protein, that can load Ras with GTP, and through GTPase-activating proteins 
(GAPs) that facilitate the hydrolysis of GTP to GDP to inactivate Ras. The GTP-bound 
form of Ras signals by its preferential binding to several effector molecules, most notably 
c-Raf-1, a serine-threonine kinase. Raf-1 activation initiates a kinase cascade through 
MEK (mitogen-activated protein kinase or ERK kinase), a dual-specificity protein kinase, 
which in turn phosphorylates ERK (extracellular signal–regulated kinase), another serine-
threonine kinase (Downward 1998).  ERK can phosphorylate other kinases, such as Rsk2, 
and transcription factors, such as c-Fos and Elk1 . Thus, the original signal is not only 
amplified in signal strength through a succession of kinases but is also diversified by the 
number of kinase substrates. This leads to the multiple effects seen by extracellular 
stimuli and growth factor stimulation (Garrington and Johnson 1999). 
The Ras-p53 connection 
Expression of constitutively active forms of Ras in primary mouse or human 
fibroblasts leads to elevated levels of p53 which in turn induce the expression of target 
genes that can cause growth arrest.  Although the precise mechanism by which Ras 
induces p53 is not fully elucidated, activated Ras and Raf have been shown to promote 
the expression of ARF. As mentioned previously,  ARF binds to MDM2,  allowing p53 to 
become stabilized and accumulate, leading to induction of p53 target genes that promote 
cell cycle arrest (Groth, Weber et al. 2000). In accordance with this model, ARF-null 
MEFs are also susceptible to Ras transformation since they do not undergo p53-induced 
senescence (Kamijo, Zindy et al. 1997). The mechanism by which Ras elicits ARF 
expression is unclear, but it is possible that the c-Myc, E2F, or DMP1 transcription 
factors may provide an important link.  
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It has been shown that MEK activity is important for expression of p53 at the 
transcriptional level and also for p53 activation by genotoxic agents (Persons, 
Yazlovitskaya et al. 2000; Agarwal, Ramana et al. 2001). For example, overexpression of 
ERK2 in AP14 cells (low levels of MAPK phosphorylation and p53 compared to parental 
cells) restored both MAP kinase activity and p53 expression. Furhermore, The levels of 
p53 mRNA increased significantly when activated Ras was introduced into wild-type 
cells. The levels of the p53 and p21 proteins decreased substantially in wild-type cells 
treated with the MEK inhibitor U0216 (Agarwal, Ramana et al. 2001).  Inhibition of 
ERK1/2 activation with the mitogen-activated protein kinase (MEK1) inhibitor PD98059 
resulted in decreased p53 protein half-life and diminished accumulation of p53 protein 
during exposure to cisplatin. P53 protein can also be co-immunoprecipitated with 
ERK1/2 protein and phosphorylated by activated recombinant murine ERK2 in vitro 
(Persons, Yazlovitskaya et al. 2000). 
The Ras-MDM2/MDMX connection 
Proper regulation of MDM2 and MDMX expression levels is critical for the tumor 
suppressive function of p53. MDM2 expression is often increased following mitogenic 
activation. For example, cells exposed to IGF-I have enhanced levels of MDM2 (Leri, 
Liu et al. 1999). Likewise, cells treated with basic FGF show increased levels of MDM2 
protein. Further, cells constitutively exposed to a basic FGF autocrine loop do not 
respond to cisplatin, which to a large extent occurs through p53-mediated apoptosis 
(Shaulian, Resnitzky et al. 1997). Interestingly, a screen for transcripts that accumulate in 
cells harboring a chimeric M-CSF/PDGF revealed MDM2 (Fambrough, McClure et al. 
1999). This data eventually led to the finding that the MDM2 gene is also regulated by 
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the Ras/Raf/MEK/MAP kinase pathway in a p53-independent mannerRas-activated Raf–
MEK–ERK pathway targets cis-acting AP-1 and Ets DNA elements in the first intron of 
the MDM2 gene. MDM2 induced by activated Raf degrades p53 and may account for the 
observation that cells transformed by oncogenic Ras are more resistant to p53-dependent 
apoptosis following exposure to DNA damage (Ries, Biederer et al. 2000). In normal 
MEFs, the ERK/MAP kinase pathway induces the expression of both MDM2 and ARF 
with no net consequence on the level of p53 expression. The biological significance of 
MDM2 regulation at the transcriptional level is exemplified by the effect of a single 
nucleotide polymorphism in the MDM2 promoter, which is associated with increased 
susceptibility to tumor development (Bond, Hu et al. 2004).  
In contrast, MDMX expression is not induced by p53 and the regulation of its 
promoter is still largely unknown. Furthermore, MDMX gene amplification only 
accounts for a subset of the cases of protein overexpression in cell lines and tumors, 
indicating that regulation of promoter activity is also a critical means of overexpression. 
The results section of this dissertation shows that MDMX expression level is closely 
correlated with MDMX mRNA levels and MDMX promoter activity in different tumor 
cell lines. However, unlike the MDM2 promoter, a survey of a large cell line panel did 
not reveal a sequence polymorphism in the MDMX promoter region. We also found that 
the Ras oncogene and IGF1 growth factor induces MDMX expression through activation 
of mRNA transcription.  Further, evaluation of the MDMX promoter showed that 
increased ERK phosphorylation led to increased levels of MDMX whereas inhibiting 
phosphorylation using a MEK inhibitor led to a decrease MDMX mRNA and protein. 
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Elk-1/c-Ets-1 
The Ets family consists of a large number of evolutionarily conserved transcription 
factors, many of which have been implicated in tumor progression. Ets proteins have a 
conserved DNA-binding domain (GGAA/T) and regulate transcriptional initiation from a 
variety of cellular and viral gene promoter and enhancer elements. Interestingly, Ets 
family members can act as both upstream and downstream effectors of signaling 
pathways. As downstream effectors their activities are directly controlled by specific 
phosphorylations, resulting in their ability to activate or repress specific target genes. As 
upstream effectors they are responsible for the spacial and temporal expression of 
numerous growth factor receptors.  Some members of the Ets family, Ets-1 and Ets-2, 
cooperate in transcription with the AP-1 transcription factor, the product of the proto-
oncogene families, fos and jun, while others, Elk-1 and SAP-1, form ternary complexes 
with the serum response factor (SRF) (Macleod, Leprince et al. 1992).  
Ets-1 is involved in both normal and pathological functions. It is expressed in a 
variety of cells, including endothelial cells, vascular smooth muscle cells and epithelial 
cells. Ets-1 regulates the expression of several angiogenic and extracellular matrix 
remodeling factors promoting an invasive phenotype. In fact, in many tumors such as 
breast cancer, expression of c-Ets-1 indicates a poor prognosis (Lincoln and Bove 2005).  
Many Ets family members including c-Ets-1 and Elk-1 have been identified as 
substrates for MAPK phosphorylation. In vitro, MAP kinase phosphorylates the Elk-1 C-
terminal region at multiple sites, which are also phosphorylated following growth factor 
stimulation in vivo (Marais, Wynne et al. 1993).  Ets-1 has a single MAPK 
phosphorylation site located near the Pointed domain (Brunner, Ducker et al. 1994). 
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Phosphorylation generally enhances their ability to activate transcription. 
Phosphorylation of Elk-1 by ERK both enhances its recruitment to DNA (Gille, 
Kortenjann et al. 1995; Sharrocks 1995) and potentiates its transcriptional activation 
activity (Hill, Marais et al. 1993; Marais, Wynne et al. 1993; Gille, Kortenjann et al. 
1995). In order to enhance DNA-binding of Elk-1, phosphorylation by ERK can induce a 
conformational change (Yang, Shore et al. 1999). Likewise, enhanced ERK1/2 
phosphorylation of Ets-1 has been shown to increase Ets-1 protein levels and induce 
target promoter activation (Liu, Liang et al. 2005). 
In the results section of this dissertation, analysis of the human MDMX proximal 
promoter revealed a cluster of potential transcription factor binding sites which included 
both Ets-1 and Elk-1. These sites appeared to be critical for elevated MDMX expression 
in tumor cell lines. Chip assays revealed enhanced promoter binding of both Ets-1 and 
Elk-1 under conditions of increased erk-phosphorylation by IGF-1 stimulation.  Taken 
together , our results suggest that both Ets-1 an Elk-1 may play a role in both endogenous 
and growth factor stimulated activation of MDMX. 
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Chapter Two 
Materials & Methods 
 
 
Cell Lines 
Tumor cell lines H1299 (lung, p53-null), A549 (lung), U2OS (bone), SJSA (bone, 
MDM2 amplification), MCF-7 (breast), JEG-3 (placenta, MDM2 overexpression) were 
maintained in DMEM medium with 10% fetal bovine serum. HCT116-p53+/+ and 
HCT116-p53-/- cells were kindly provided by Dr Bert Vogelstein. Normal human skin 
fibroblasts (HFF) were provided by Dr Jack Pledger. MDMX/p53 double null  (41.4), 
MDM2/p53 double null (174.1) and p53-null (35.8) MEFs were provided by Dr. Gigi 
Lozano. P53- null (35.8) and p53/ARF double  null (DKO) cells expressing activated K-
Ras were generated by infection with retrovirus pBabe-HA-K-Ras (12V). Infected cells 
were selected with 1 µg/ml puromycin and drug resistant colonies were pooled.  
To generate cells with expression of lentiviral MDMX vector a Lentivirus vector 
expressing MDMX was generated using the ViraPowerTM T-RExTM system following 
instructions from the manufacturer (Invitrogen). Overexpression of MDMX was achieved 
by infecting with the MDMX lentivirus and selection with Zeocin to obtain a pool of 
resistant colonies. Tetracycline inducible expression of MDMX in U2OS cells was 
achieved by first infecting with the T-REX regulator lentivirus and selection with 
Blasticidin, followed by infection with the MDMX lentivirus and selection with Zeocin. 
MDMX expression was subsequently induced with 0.1-1 µg/ml tetracycline. 
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 To inhibit MDMX in human cell lines by RNAi, double-stranded oligonucleotide 
(5’GATCCCGTGATGATACCGATGTAGATTCAAGAGATCTACATCGGTATCATC
ACTTTTTTGGAAA, MDMX sequence underlined) was cloned into the 
pSuperiorRetroPuro vector (OligoEngine) and the pSilencer. Cells expressing the 
pSuperiorRetroPuro were infected with the MDMX shRNA retrovirus and selected with 
0.5-1 µg/ml puromycin. Cells expressing pSilencer siMDMX were selected with G418. 
Drug-resistant colonies were pooled for analysis. A virus expressing a scrambled shRNA 
(5’GATCCCGCCGTCGTCGATAAGCAATATTTGATATCCGATATTGCTTATCGA
CGACGGCTTTTTTA) was used as control.  
To transiently inhibit MDMX expression, U2OS or MCF-7 cells were transfected 
with 200 nM control siRNA (AATTCTCCGAACGTGTCACGT) or MDMX siRNA 
(AGATTCAGCTGGTTATTAA) using Oligofectamine (Invitrogen) as described below. 
L11 siRNA pool was purchased from Dharmacon. 
Transfections 
Calcium Phosphate 
Calcium phosphate transfection was usually performed in H1299 cells because of 
their high transfection efficiency. In transient transfection assays, > 2 x 106 cells were 
seeded into 10 cm tissue culture dishes for 24 hrs. For each transfection, a total amount of 
40 µg of plasmid DNA was mixed with 450 µl of H2O and 125 mM calcium chloride.  A 
mixture of 500 µl of HEPES (0.28 M NaCl, 0.05 M HEPES, 1.5mM CaCl2) was bubbled 
with air and the water/DNA mixture was added dropwise. Immediately after bubbling, 
the mixture was added to the cells and incubated for 16 hours. After incubation, 
transfected cells were washed 2 times with PBS, refed with complete medium and 
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incubated for another 24 hours before harvest. To generate a stable cell line, 48 hours 
after transfection, the cells were drug selected by complete medium containing 750 µg/ml 
G418 or 0.5-1.0 µg/ml puromycin for two weeks. Drug-resistant colonies were either 
pooled or cloned. 
Lipofectamine Transfection 
For Lipofectamine™ transfection experiments,  2 x 105 cells were seeded into 6 cm 
tissue culture dishes for 24 hrs, washed with 3 ml of serum free media and refed with 2 
ml of serum free medium. For each transfection, a total amount of 4 µg of plasmid DNA 
was mixed with 250 µl of serum-free medium and 10 µl of lipofectamine plus reagent 
and incubated for 15 min at room temperature. A pre-mix 10 µl of lipofectamine reagent 
was mixed with 250 µl serum-free medium and then with the previously described DNA 
solution. The mixture was incubated for another 15 min before being added to the cells. 
The reaction mixtures were scaled according to the number of cells plated (i.e. 24-well, 
6-well, 60-mm, or 100-mm plates) After 4 hrs incubation, the cells were refed with 
complete medium and harvested 24-72 hours later. 
Oligofectamine Transfection 
For transfection of RNAi oligonucleotides Oligofectamine™ transfection reagent 
was utilized. Approximately,  2 x 105 cells were seeded into a 6-cm tissue culture dishes 
for 24 hrs, washed with 3 ml of serum free media and refed with 2 ml of serum free Opti-
MEM reduced serum medium. For each transfection, 10 µl of a 20 µM stock 
oligonucleotide was mixed with 175 µl medium to give a 200 nM final oligonucleotide 
concentration. In a separate tube, 4 µl of Oligofectamine™ Reagent was mixed into 
medium without serum for a final volume of 15 µl and incubated for 10 min at room 
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temperature. The diluted Oligofectamine™ reagent  was mixed with the diluted 
oligonucleotide and incubated at room temperature for 15  before being added to the 
cells. After 4 hrs incubation, the cells were refed with complete medium and harvested 72 
hours later. 
 
Protein Analysis 
Western Blot 
To detect proteins by Western blot, cells were lysed in lysis buffer (50mM Tris–
HCl (pH 8.0), 5mM EDTA, 150mM NaCl, 0.5% NP40, 1mM PMSF, and protease 
inhibitors), centrifuged for 10 min at 10,000 g at 4ºC and the insoluble debris were 
discarded. Cell lysate (10–50 ug protein) was fractionated by SDS–PAGE and transferred 
to Immobilon P PVDF filters (Millipore). The filter was blocked for 1 hr with washing 
buffer containing phosphate buffered saline (PBS), 5% non-fat dry milk and 0.1 % 
Tween-20. The filter was then incubated for two hours to overnight with primary 
antibodies diluted in blocking buffer. The filter was washed three times (10 min each) 
with PBS containing 0.1 % Tween-20. Next, bound primary antibodies were conjugated 
with secondary antibody HRP IgG goat-anti-mouse or HRP IgG goat-anti-rabbit by 
incubating the filter with the secondary antibody diluted in blocking buffer for two hours. 
After the filter was washed three times (10 min each), they were developed using either 
ECL-plus reagent (Amersham) or Supersignal (Pierce). The following antibodies were 
utilized for experiments: 
• Human MDMX was detected using monoclonal 8C6 with a 1:40 dilution 
• Mouse MDMX was detected using monoclonal 7A8 or 10C2 with a 1:40 dilution 
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• Human MDM2 was detected using monoclonal 3G9  with a 1:30 dilution 
• p53 was detected by DO-1 (mouse, Pharmigen) with 1:10,000 dilution or  FL393 
(rabbit, Santa Cruz) with a 1:5,000 dilution   
• ARF was detected by 14PO2 (Neomarkers) with a 1:500 dilution 
• p21 was detected using  anti-WAF1 at 1:1000 dilution 
• Flag tagged proteins were detected with an  α-Flag monoclonal antibody with  a 
1:5000 dilution 
• Ets-1 was detected using c-Ets-1 (N-276) (Santa Cruz Biotechnology) at a 1:2000 
dilution 
• Ets-1 was detected using Elk-1 (H-160) (Santa Cruz Biotechnology) at a 1:5000 
dilution 
• Total ERK was detected using ERK-2 (Santa Cruz Biotechnology) at a 1:5000 
dilution  
• Phosphorylated ERK was detected using ERKp42/p44  (Cell Signaling Technology) 
at a 1:1000 dilution 
• Total ERK was detected using ERK2 (Santa Cruz Biotechnology) at a 1:5000 
dilution 
• HA-tagged K-Ras was detected using  HA.11 (Covance Research Products) at a 
1:2000 dilution 
• L11 was detected using a rabbit polyclonal antibody provided by Dr. Yanping 
Zhang.  
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Affinity purification of MDMX and MDM2    
Purification of MDMX complex was performed using HeLa cells stably transfected 
with FLAG-tagged MDMX ( 2 108 cells). Cells were lysed in 10 ml lysis buffer (50 
mM Tris–HCl (pH 8.0), 5 mM EDTA, 150 mM NaCl, 0.5% NP40, 1 mM PMSF, 200 nM 
Okadaic acid). The lysate was precleared with 100 µl bed volume of protein A sepharose 
beads for 30 min, and then incubated with 50 µl bed volume of M2-agarose bead (Sigma) 
for 4 h at 4°C. The beads were washed and MDMX was eluted with 70 µl of 20 mM Tris 
pH 8.0, 2% SDS, 200 µg/ml FLAG epitope peptide for 15 min. The eluted proteins were 
fractionated on SDS–PAGE and stained with Coomassie Blue. 
To purify MDM2 complexes, human MDM2 cDNA expression plasmid was 
transiently transfected into 293T cells. Two days after transfection, cells (~2x108) were 
treated with 30 µM MG132 for 4 hours, lysed in a total of 10 ml lysis buffer and 
centrifuged for 5 minutes at 10,000 g. The lysate was precleared with protein A 
Sepharose beads for 30 minutes, and then incubated with 40 µl protein A Sepharose 
beads and 0.5 ml 2A9 hybridoma supernatant for 4 hours at 4˚C. The beads were washed 
with lysis buffer and boiled in SDS sample buffer. The eluted proteins were fractionated 
on SDS-PAGE and stained with Coomassie Blue. Proteins co-purified with MDMX and 
MDM2 were cut out from the SDS-Page gel and identified by mass spectrometry.  
Immunoprecipitation Assay 
For immunoprecipitation assays, cells were lysed in lysis buffer (50mM Tris–HCl 
(pH 8.0), 5mM EDTA, 150mM NaCl, 0.5% NP40, 1mM PMSF, and protease inhibitors), 
centrifuged for 10 min at 10,000 g at 4ºC and the insoluble debris were discarded.  Cell 
lysate (500–1000 ug protein) was immunoprecipitated using 100 µl Pab1801, 100 µl 
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3G9, or 100 µl 8C6 hydridoma antibody and 40 µL protein A Sepharose bead slurry at 
4ºC overnight with rotation.  The beads were washed 5 times with lysis buffer, boiled in 
SDS sample buffer, fractionated by SDS–PAGE, and analyzed by Western blot.  
In vivo Ubiquitination 
H1299 and U2OS cells in 10-cm plates were transfected with combinations of 1 µg 
GFP expression plasmid, 5 µg His6-ubiquitin expression plasmid, 1-5 µg human MDMX, 
5 µg MDM2 and 5 µg ARF or L11, L5 or L23 expression plasmids using calcium 
phosphate precipitation method (see above). Thirty-two hours after transfection, cells 
from each plate were collected into two aliquots. One aliquot (10%) was used for 
conventional western blot to confirm expression and degradation of transfected proteins. 
The remaining cells (90%) were used for purification of His6-tagged proteins by Ni2+-
NTA beads. The cell pellet was lysed in buffer A (6 M guanidinium-HCl, 0.1 M 
Na2HPO4/NaH2PO4, 0.01 M Tris-Cl pH8.0, 5 mM imidazole, 10 mM β-mercaptoethanol) 
and incubated with Ni2+-NTA beads (Qiagen) overnight at room temperature. The beads 
were washed one time each with buffer A, B (8 M urea, 0.1 M Na2PO4/NaH2PO4, 0.01 M 
Tris-Cl pH8.0, 10 mM β-mercaptoethanol), C (8 M urea, 0.1 M Na2PO4/NaH2PO4, 0.01 
M Tris-Cl pH6.3, 10 mM β-mercaptoethanol), and C + 10% triton-X and bound proteins 
were eluted with buffer D (200 mM imidazole, 0.15 M Tris-Cl pH6.7, 30% glycerol, 
0.72M β-mercaptoethanol, 5% SDS). The eluted proteins were analyzed by western blot 
for the presence of conjugated MDMX by 8C6 antibody,  MDM2 by 3G9 antibody, or 
p53 by DO-1 antibody . 
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Acid Extraction of DNA bound proteins 
To detect chromatin bound proteins such as gamma-H2A.X acid extraction of 
proteins is necessary. After treated cells were washed and collected by scraping, they 
were resuspended in 300-500 µL of lysis buffer (50 mM Tris-Cl pH7.4, 10% Glycerol, 
10mM KCl, 0.2% NP-40, 1mM EDTA, protease inhibitors). After spinning for 5 minutes 
at 14,000 rpm and removing the cytoplasmic fraction, the nuclear fraction was 
resuspended in 100 µL of nuclear lysis buffer (50 mM Tris-Cl pH7.4, 20% Glycerol, 
10mM KCl, 0.4M NaCl, 0.2% NP-40, 1mM EDTA, protease inhibitors) and kept on ice 
for 30 minutes. The samples were spun at 14,000 rpm for 5 min at 4ºC. The nuclear 
extract was removed and the insoluble chromatin bound proteins was then acid extracted 
in 20-50 µL of  acid extraction buffer  (0.25 M HCl, 10% Glycerol, 100mM β-
mercaptoethanol). The supernatant was spun down and neutralized to pH = 7.0 before 
loading onto an SDS page gel.  
Cell Viability and Growth Assays 
Cell Cycle Analysis by Flow Cytometry 
  After treatment, cells were harvested by trypsinizing and washed once in PBS. 
The cells were resuspended in 1 ml of PBS and fixed by adding 4 mL of ethanol while 
slowly vortexing. Fixed cells were placed at -20ºC overnight, but may be stored for 
several months in fixative. Cells were washed once in PBS and then resuspended in 1 mL 
of staining solution (50 µg/ml RNase A treatment and 50 µg/ml propidium iodide in 
PBS) and incubated for at least one hour at 4ºC. Flow cytometry was performed on an 
argon laser-equipped Becton Dickinson (Sunnyvale, CA) FACScan instrument to 
determine the number of cells in sub Go, G1/M, S, or G2 phase of the cell cycle. 
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BRDU Assay 
In order to compare the number of cells which are capable of DNA synthesis, we 
utilized the 5-Bromo-2´-deoxy-uridine Labeling and Detection Kit III by Roche. Briefly, 
after experimental treatment, cells were incubated with 10 mmoles of BrdU for 2 to 4 
hours. Then the samples were fixed with ethanol/HCl. Following fixation of cells cellular 
DNA is partially digested by nuclease treatment. Next a peroxidase labeled antibody to 
BrdU (anti-BrdU POD, Fab fragments) was added and binds to the BrdU label.  In the 
final step, the peroxidase substrate is added. The peroxidase enzyme catalyses the 
cleavage of the substrate yielding a colored reaction product.  The absorbance of the 
sample was determined using a microplate reader and is directly correlated to the level of 
BrdU incorporated into cellular DNA. 
MTS Assays 
U2OS, MCF-7 or HCT-116+/+ cells were plated in 24-well plates with 
approximately 10,000-30,000 cells plated per well. Fresh media (250 µL) containing 10 
µL of MTT reagent was added to each well. The plates were kept in the 37ºC incubator 
for 15-30 min. The reactions were stopped by putting the plates on ice. From each well, 
200 µL was transferred into a 96 well plate. The plate was measure using an OD of 490. 
The absorbance reading correlates with the number of live cells per well. 
Colony Formation Assays 
U2OS or HCT116 cells were plated with 100 cells per well in a 6-well plate. After 
treatment (24 hrs), cells were refed with complete media and allowed to grow for ~ 1 
week. The media was removed and cells were washed in PBS. Each well was incubated 
with crystal violet (0.5% crystal in 50% Ethanol). After 15 minutes, each well was 
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carefully washed with distilled water and allowed to air dry. Visible colonies were 
counted for comparison. 
RNA Analysis 
RNA Isolation  
Total RNA was extracted from 10 cm plates of cells using the RNeasy Mini Kit by 
Qiagen following the manufacturer’s protocol. Briefly, samples were lysed and 
homogenized in the presence of a highly denaturing guanidine-thiocyanate–containing 
buffer.  Ethanol was added and then the sample was applied to an RNeasy Mini spin 
column. The total RNA was bound to the membrane and contaminants were washed 
away. The RNA was eluted from the column using 50 µl of water. 
Real-time PCR  
Reverse transcription of total RNA was performed using the SuperScript III kit 
(Invitrogen). The following PCR primers were used for qPCR analysis: p21F (5' 
CAGACCAGCATGACAGATTTC) and p21R (5' TTAGGGCTTCCTCTTGGAGA); 
MDM2FW (5’ CCCTTAATGCCATTGAACCT) and MDM2REV (5’ 
CATACTGGGCAGGGCTTATT); p53FW (5’ GGCAGCTGGTTAGGTAGAGG) and 
p53REV (5’ AGGTCGACCAAGAGGTTGTC); 18SFW 
(5’GATTAAGTCCCTGCCCTTTGTACA) and 18SREV (5’ 
GATCCGAGGGCCTCACTAAAC). Samples were analyzed in triplicate. 
Promoter Analysis Assays 
Genomic DNA isolation 
Adherent cells were removed from plates by trypsinization followed by washing 
with PBS. Cells were resuspended in 1 volume of digestion buffer (25 mM EDTA, 10 
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mM Tris-HCl, pH 8.0, 100 mM NaCl, 0.5% SDS and 100 µg/ml proteinase-K) and 
incubated overnight at 50ºC. Each sample was extracted with an equal volume of 
phenol/chloroform/isoamyl alcohol and centrifuged at 1700 x g for 10 minutes. The 
aqueous top layer was transferred to a new tube.  NaCl was added to a 0.1 M final 
concentration  and two volumes of ethanol were added. DNA was recovered by 
centrifuging at 1700 x g for two minutes. The pellet was rinsed in 70% ethanol and air 
dried before being reconstituted in TE. 
Construction of the MDMX promoter reporter plasmids.  
To isolate the 5' upstream region of MDMX, PCR was performed using an 
antisense primer in exon 1 of the MDMX gene (5’AAGAGCCACACCTTACGGCA) and 
a sense primer in a 5' genomic sequence (5’CTATCTCGGCTCACTGCAAC) with 
genomic DNA isolated from MCF-7 cells as a template. The resulting 1100-bp fragment 
was cloned into pDrive vector (Qiagen) and then transferred to the luciferase reporter 
plasmid pGL2-Basic (pGL2-FL MDMX) and was confirmed by sequencing. The mutant 
promoter constructs were generated using the QuickChange Site-Directed Mutagenesis 
kit (Stratagene) in the context of the pGL2-FL MDMX according to the manufacturer's 
instructions.  
Reporter Transfections 
Cell lines were cultures in 24-well plates and transfected with a mixture containing 
50 ng luciferase reporter plasmid (BP-100 or MDMX promoter fragments), 10 ng CMV–
lacZ plasmid, 200ng of ssDNA and 5ng of GFP. Transfection was achieved using 
Lipofectamine PLUS reagents (Invitrogen) as described above. Forty eight hours after 
transfection, cells were analyzed for luciferase and Beta-galactosidase expression. 
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Chromatin immunoprecipitation 
Two confluent 15 cm plates per cell line (approximately 2 x 107 - 2 x 108 cells) 
were used per sample.  Formaldehyde was added directly to tissue culture media to a final 
concentration of 1% and incubated on a shaking platform for 10 minutes at room 
temperature.  The crosslinking reaction was stopped by adding glycine to a final 
concentration of 0.125 M and mixing for 5 minutes.  The plates were rinsed twice with 
cold 1X PBS plus protease inhibitors and PMSF, scraped and centrifuged to collect. The 
pellet was resuspended in 7 mL of cell lysis buffer (5 mM PIPES pH 8.0, 85 mM KCL, 
0.5% NP40  plus the protease inhibitors PMSF (10 ul per ml), aprotinin (1 ul per ml) 
leupeptin (1 ul per ml)),  incubated on ice for 10 minutes, and centrifuged at 4,000 rpm 
for 7 minutes at 4ºC to pellet the nuclei.  The nuclear pellet was resuspended in 500-900 
µL of nuclei lysis buffer (50 mM Tris-Cl pH 8.1, 10 mM EDTA, 1% SDS, protease 
inhibitors) and incubated on ice for 10 minutes. Next, samples were sonicated to an 
average chromatin length of about 500-1000 bp and then centrifuged at 14,000 rpm for 
10 minutes at 4ºC.  The supernatant was transfered to a new tube, precleared by adding 
40 µL of protein A/DNA slurry (Upstate Biotechnology) and incubated on a rotating 
platform at 4ºC for 30 minutes.  Samples were centrifuged at 14,000 rpm for 5 minutes 
and divided into 100-200 µL aliquots for immunoprecipitation.  
The following antibodies have been added and utilized for chromatin 
immunoprecipitation: 
MDM2: 100µL of 2A9, 5B10, and 4B11 
MDMX: 100µL of 8C6 and 10C2 
P53: 100µL of 1801 and 10 µL DO-1 (BD Pharmigen) 
c-Ets: 5 µg of c-Ets-1 (N-276) (Santa Cruz Biotechnology) 
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Elk-1: 5 µg of Elk-1 (H-160) (Santa Cruz Biotechnology) 
YY-1: 5 µg of YY-1 (c-20)  (Santa Cruz Biotechnology) 
 
The final volume of each sample was adjusted to 800 µL using IP dilution buffer 
(0.01% SDS, 1.1% Trition X 100, 1.2 mM EDTA, 16.7 mM Tris-Cl pH 8.1, 167 mM 
NaCl). Control samples that were used for experiments include a "no antibody" sample as 
well as "mock" samples which contain 1X dialysis buffer instead of chromatin. Samples 
were incubated on a rotating platform at 4ºC overnight.  
The following day 60 µL of protein A beads/DNA slurry (Upstate Biotechnology) 
was added and incubated on a rotating platform at 4ºC for 2 hours. Samples were 
centrifuged and supernatant from the "no antibody" sample was saved as "total input 
chromatin". Beads were washed one time in low salt buffer, one time in high salt buffer, 
two times in LiCl buffer (100 mM Tris-Cl pH 8.0, 500 mM LiCl, 1% NP40, 1% 
deoxycholic acid) and 2 times in TE. For each wash, samples were rotated for 3 minutes 
then centrifuged at 14,000 rpm for 3 minutes at room temp. Chromatin was eluted two 
times by adding 250 µL of IP elution buffer (50 mM NaHCO3, 1% SDS) while shaking 
for at least 15 minutes.  The eluates were combined and then centrifuged  at 14,000 rpm 
for 5 minutes to remove any traces of Protein A beads and transferred to a clean tube.  
RNase A (2µL of  10 mg/ ml) and 5M NaCl was added to a final concentration of 0.3 M.  
Samples were incubated at 67ºC for 4 hours to overnight to reverse formaldehyde 
crosslinks.  Next, 20µL of 1.0M Tris, pH 6.5, 10 µL 0.5M EDTA, pH 8.0 and 5 µL of 10 
mg/ml proteinase K were added per 500 µL sample and incubated at 45ºC for 2 hours. 
The DNA was purified using the Qiagen PCR purification kit or by phenol/chloroform 
extraction and reconstituted in 50 µL of water. For each PCR reaction, 1-3 µL was 
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utilized. For p53 promoter binding, samples were subjected to SYBR Green real-time 
PCR analysis using forward and reverse primers for the p53 binding sites in the MDM2 
promoter (5’-CGGGAGTTCAGGGTAAAGGT and 5’-CCTTTTACTGCAGTTTCG) 
and p21 promoter (5’-TGGCTCTGATTGGCTTTCTG and 5’-
TCCAGAGTAACAGGCTAAGG). For MDMX promoter studies, co-precipitated 
chromatin was analyzed by standard PCR (30-32 cycles) using primers (5’ 
ACTCTCTCCCCGGACTAGGA and 5’ CGAGTAATGAAGCCGCAACT) to amplify 
the human basal MDMX promoter containing the c-Ets-1 and Elk-1 binding sites. 
Primers located 3 kb upstream of the basal promoter (5’ 
TAAACGATCCTCCCACCTTG and 5’ CCTGGAGCCTTGGAATATGA) were used as 
negative PCR controls. 
Immunohistochemistry Staining 
Tissue microarrays were de-parrafinized in three changes of xylene, rehydrated 
using a decreasing gradient of ethanol, followed by incubation in sodium citrate buffer 
(10mM sodium citrate, 0.05% Tween-20, pH 6.0) at 95ºC for 20 min. Slides were cooled 
at room temperature for 20 minutes, washed in two changes of PBS and incubated in 1% 
H2O2 for 10 min to quench endogenous peroxidase activity. The ABC Staining system 
(Santa Cruz Biotechnology) was used for staining. Briefly, slides were blocked in 1.5% 
serum in PBS.  A polyclonal MDMX antibody was affinity purified by the procedure 
described below and incubated at a 1:500 dilution overnight at 4ºC. After washing, slides 
were incubated with biotinylated secondary, then with AB enzyme reagent followed by 
incubation with DAB chromogen. 
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  The polyclonal MDMX antibody was validated for its specificity using cell lines 
expressing different levels of endogenous and transfected MDMX. The tumor array was 
scored according to MDMX staining intensity (1 as low intensity, 2 intermediate, and 3 
as intense staining). A phospho-ERKp42/p44 antibody (1:100; Cell Signaling Technology) 
was used for the same array and scored as percent-positive tumor cells (0 as negative, 1 
as 1–30%, 2 as 30–70% and 3 as 70–100% positive).   
Affinity Purification of MDMX antibody 
This protocol was used to purify MDMX polyclonal antibody in order to stain the 
colon tumor array. Recombinant MDMX protein (5 ug) diluted in 5mL of western blot 
transfer buffer was spotted onto a nitrocellulose filter. The filter was blocked in 3% BSA 
in 10mM TrisHCl (pH= 8.0), 150 mM NaCl, 0.2% Tween-20 (TBS-T) for 30 min at 
room temperature.  Next, the nitrocellulose filter was incubated with 1 ml of  MDMX 
rabbit anti-MDMX serum in 10 ml total volume of TBS-T. The filter was washed 4 times 
for 5 minutes with TBS-T.  Antibody was eluted from the filter using 10 mM glycine-
HCl (pH = 2.7), and neutralized by adding 1.5 M Tris.HCl (pH 8.8). The filter was 
washed two times and the procedure was repeated. The elutes were combined and 
dialyzed in PBS overnight, then concentrated to a 500 µL volume. For storage purposes, 
10% normal goat serum was added to the concentrated antibody and stored at -20ºC. 
Xenograft Studies 
Athymic-NCr-nu female mice between 7 and 8 weeks were inoculated s.c. on both 
flanks with 5 × 106 of HCT116-p53+/+ control, MDMX, or MDMX siRNA cells. For 5-
FU treatment response, control and Lenti-MDMX expressing tumors were grown for 10 
days to ~0.1 cm3 on both flanks. Mice were treated with 5-FU at 50 mg/kg/day for 4 days 
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by tail vain injection. Tumor size was measured every other day using a digital caliper, 
and tumor volume was calculated with the formula: (Average (Rmax, Rmin)^3)*0.5236, 
where Rmax and Rmin are the maximum and minimum tumor radii, respectively. Data 
were analyzed using the student paired t-test to assess differences in tumor growth rates. 
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Chapter Three 
Mdmx Regulation of P53 Response to Ribosomal Stress 
 
 
Abstract 
Ribosomal stress such as disruption of rRNA biogenesis activates p53 by release of 
ribosomal proteins from the nucleoli, which bind to MDM2 and inhibit p53 degradation. 
We found that p53 activation by ribosomal stress requires degradation of MDMX in an 
MDM2-dependent fashion. Tumor cells overexpressing MDMX are less sensitive to 
actinomycin D-induced growth arrest due to formation of inactive p53-MDMX 
complexes. Knockdown of MDMX increases sensitivity to actinomycin D, whereas 
MDMX overexpression abrogates p53 activation and prevents growth arrest. 
Furthermore, MDMX expression promotes resistance to the chemotherapeutic agent 5-
FU, which at low concentrations activates p53 by inducing ribosomal stress without 
significant DNA damage signaling. Knockdown of MDMX abrogates HCT116 tumor 
xenograft formation in nude mice. MDMX overexpression does not accelerate tumor 
growth but increases resistance to 5-FU treatment in vivo. Therefore, MDMX is an 
important regulator of p53 response to ribosomal stress and RNA-targeting chemotherapy 
agents.  
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Results 
Ribosomal proteins selectively bind MDM2 but not MDMX 
In experiments aimed at identifying MDM2 and MDMX binding proteins, we 
performed affinity purification of MDM2 and MDMX from stable or transiently 
transfected cells followed my mass spectrometry to indentify the coprecipitating bands. 
As reported by others, MDM2 co-purified with several ribosomal proteins, the most 
prominent being L5, L11 and L23. This binding pattern was observed with transfected 
MDM2 (Figure 8a), or endogenous MDM2 from SJSA cells (not shown). In contrast, flag 
tagged MDMX co-purified with casein kinase 1 alpha and 14-3-3 under the same 
washing conditions (Figure 8b) (Chen, Li et al. 2005). Reproducibly absent from the 
MDMX immunoprecipitation (IP) was the binding of ribosomal proteins. These results 
indicated that ribosomal proteins directly target MDM2 but not MDMX. 
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Figure 8. Differential binding of ribosomal proteins to MDM2 and MDMX. (a) 
MDM2 expression plasmid was transfected into 293T cells for 2 days. MDM2 
complex was immunoprecipitated using 2A9 antibody and stained with 
Coomassie Blue. (b) FLAG-tagged MDMX stably expressed in Hela cells was 
purified using M2-agarose beads and eluted with FLAG epitope peptide. 
 80 
 
To further confirm the results from the mass spectometry analysis, U2OS cells 
stably expressing tetracycline-regulated MDMX and MDM2 were immunoprecipitated 
using MDMX and MDM2 antibodies, followed by western blot for L11. MDMX and 
MDM2 expression were induced to ~10-fold above endogenous levels using tetracycline. 
Coprecipitation between MDM2 and L11 was detected when MDM2 was induced, 
whereas MDMX-L11 interaction was not detectable (Figure 9). This result suggested that 
MDMX-L11 interaction was negligible even in overexpression conditions. The dramatic 
difference in ribosomal protein binding suggested that MDMX is regulated differently by 
ribosomal stress compared to MDM2. 
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Figure 9. L11 binds to MDM2 not MDMX. U2OS cell lines expressing Tet-on MDMX 
or Tet-off MDM2 were treated with tetracycline for 16 hours to modulate 
expression levels, followed by MDMX or MDM2 IP and L11 western blot. 
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Ribosomal stress induces MDMX degradation 
To determine the effect of ribosomal stress on MDMX, we used actinomycin D 
(ActD) to inhibit ribosome biogenesis. ActD is a chemotherapeutic agent that can induce 
DNA damage and inhibit general transcription at high concentrations (>30 nM), but at 
low concentrations (5 nM) it selectively inhibits RNA polymerase I and induces 
ribosomal stress (Lohrum, Ludwig et al. 2003; Zhang, Wolf et al. 2003). 
When HCT116 and U2OS cells were treated with 5 nM ActD for 8-20 hours, 
significant activation of p53 was observed, resulting in the induction of p21 and MDM2. 
In contrast, MDMX level decreased significantly after ActD treatment (Figure 10). 
MDMX was also down-regulated to the same degree in HCT116-p53-/- cells despite 
much weaker induction of MDM2 (Figure 10), suggesting that additional mechanisms 
contributed to reduction in MDMX level.  
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Figure 10. Down regulation of MDMX by ribosomal stress. Cells were treated with 5 
nM ActD for 16 hours and analyzed by western blot. 
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HCT116-p53-/- cells were treated with ActD and MG132 to block proteosomal 
degradation, MDMX down regulation was partially inhibited (Figure 11). Gamma 
irradiation has previously been shown to induce protein degradation of MDMX and was 
utilized as a control to show MDMX degradation can be prevented with the addition of 
MG132.  These results suggested that ActD promotes degradation of MDMX.   
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Figure 11. MDMX is degraded by ribosomal stress. HCT116-p53-/- cells were treated 
with 5 nM ActD for 8 hours, with or without 30 µM MG132 for the last 4 
hours and analyzed by western blot. 
 
Recent studies showed that phosphorylation of MDMX C terminus by ATM and 
Chk2 promote MDMX degradation by MDM2 (Chen, Gilkes et al. 2005; Pereg, Shkedy 
et al. 2005). We found that ActD (5 nM) and 5-FU (50 µM) did not induce significant 
phosphorylation of histone gamma H2A.X which is a well accepted marker for DNA 
damage (Figure 12). Cells treated with the DNA damaging agents CPT, and Gamma 
Irradiation (10 Gy) were used as a positive control for phosphorylation of histone gamma 
H2A.X. 
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Figure 12. Actinomycin D and 5-FU do not induce DNA Damage. U2OS cells treated 
with indicated agents for 18 hours or irradiated for 4 hours were analyzed by 
western blot using antibody against phosphorylated H2A.X, followed by 
reprobing for total H2A.X. 
 
DNA damage induces ATM-dependent phosphorylation and degradation of 
MDMX. Phosphorylation of MDMX by CHK2 on S367 has been confirmed by 
phosphopeptide-specific antibodies and is enhanced followed by DNA damage ultimately 
leading to MDMX ubiquitination and degradation by MDM2 (Chen, Gilkes et al. 2005). 
To determine whether MDMX degradation following ribosomal stress enhances MDMX 
(S367) phosphorylation we compared phosphorylation levels following treatment with 
ActD, 5-FU, CPT, or Gamma Irradiation (Figure 13). Cells treated with ActD or 5-FU 
did not have enhanced MDMX phosphorylation suggesting an alternate mechanism for 
MDMX degradation under these conditions. 
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Figure 13. Ribosomal Stress does not Induce MDMX S367 phosphorylation. 
HCT116 overexpressing MDMX was treated with indicated drugs and 
analyzed by MDMX IP and western blot for phosphorylated S367, a target 
site for Chk2 kinase. The membrane was reprobed for total MDMX level. 
 
As an additional method to show that MDMX degradation following ribosomal 
stress is independent of CHK2 we tested HCT116-Chk2 deficient cells for their ability to 
prevent MDMX degradation following ribosomal stress. We found that while gamma 
irradiation of MDMX requires CHK2, it had no effect on ActD or 5-FU induced MDMX 
degradation (Figure 14). These results suggested that ribosomal stress induces MDMX 
degradation without causing DNA damage.  
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Figure 14. Ribosomal Stress induced MDMX degradation does not require CHK2.  
HCT116 cells wild type or null for Chk2 were treated with indicated agents 
for 16 hours and analyzed for MDMX degradation. 
 
L11 promotes MDMX degradation by binding MDM2 
Release of L11 from the nucleolus during ribosomal stress and binding to MDM2 
was implicated in p53 activation. Therefore, we tested whether L11 stimulates MDMX 
ubiquitination by MDM2. The results showed that in HCT116-p53-/- cells, exogenous 
L11 stimulated MDMX poly-ubiquitination by MDM2 (Figure 15). L11 expression did 
not increase MDM2 level, suggesting that the E3 ligase function of MDM2 was 
stimulated by L11. These results suggested that L11-MDM2 interaction is unique in its 
ability to promote MDMX degradation during ribosomal stress. 
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Figure 15.  L11 promotes MDMX ubiquitination. HCT116-p53-/- cells were 
transiently transfected with His6-ubiquitin, MDMX, MDM2 and L11 
plasmids. MDMX ubiquitination was detected by Ni-NTA purification 
followed by MDMX western blot. 
 
Next, the role of MDM2 was tested using MDM2-null mouse embryonic 
fibroblasts (174.1 cells) (McMasters, Montes de Oca Luna et al. 1996). ActD induced 
significant proteasome-dependent degradation of MDMX in MDM2+/+ MEFs compared 
to MDM2-/- control, suggesting that degradation of MDMX required MDM2 (Figure 16). 
The MDMX-/- cells were utilized as a control to show the specificity of the MDMX 
antibody. Further, knockdown of MDM2 in HCT116-p53-/- using a siRNA retrovirus 
against MDM2 also blocked MDMX degradation after ActD and 5-FU treatment (Figure 
17). Taken together these experiments exemplify the role of MDM2 in MDMX 
degradation following ribosomal stress. 
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Figure 16. MDMX degradation by ribosomal stress requires MDM2. Mouse embryo 
fibroblasts with indicated genotypes were treated with ActD for 9 hours with 
MG132 for the last 6 hours and analyzed by western blot with the 7A8 
antibody.  
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Figure 17. MDMX degradation by ribosomal stress requires MDM2. Knockdown of 
MDM2 prevents MDMX down regulation by ribosomal stress. HCT116-p53-
/- cells stably transduced with retrovirus expressing MDM2 shRNA were 
treated with 2 nM ActD or 50 µM 5-FU for 16 hours, followed by analysis of 
MDM2 and MDMX levels. 
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To assess the specificity of L11 in degrading MDMX, MDMX was cotransfected 
with either L11 or L23. First, MDMX degradation was induced by L11 in MDM2+/+ 
cells (Figure 18b), but not in MDM2-/- cells unless MDM2 was restored by transfection 
(Figure 18a).  Further, the addition of L23 or L5 (not shown) did not promote MDMX 
degradation suggesting that L11 is specific in its ability to degrade MDMX.  
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Figure 18. MDM2 and L11 mediate MDMX down regulation by ribosomal stress. (a, 
b) MEFs with and without MDM2 were transfected with 0.5 µg MDMX, 0.1 
µg MDM2 and indicated amounts of L11 plasmids and analyzed by western 
blot.  
 
To test the role of L11 in human cell lines, L11 was partially knocked down using a 
transient siRNA oligonucleotide in HCT116 cells. Cells were then treated with ActD 
overnight to assess the role of L11 in MDMX downregulation (Figure 19). MDMX was 
degraded in cells which maintained L11 expression.  
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Figure 19. L11 is required for MDMX degradation in the presence of ActD. HCT116 
were transfected with 100 nM L11 siRNA for 48 hours and treated with 5 nM 
ActD for 18 hours, followed by western blot analysis. 
 
To further test the specificity of L11 regulation of MDM2 and MDMX, we 
generated the MDM2-C305S mutant with a mutated zinc finger in the L11 binding 
region. A similar mutation on MDMX (C306S) completely abrogated binding to casein 
kinase 1, revealing the structural importance of the zinc finger (Chen, Li et al. 2005). As 
expected, in transient transfection assays MDM2-C305S did not bind L11 but retained 
binding to L5, L23, and ARF (Figure 20). The ability of MDM2-C305S to ubiquitinate 
and degrade MDMX was no longer stimulated by L11, but remained responsive to ARF 
as expected (Figure 21). This result indicated that L11 stimulates MDMX degradation by 
binding to MDM2 and activating its ability to ubiquitinate MDMX. 
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Figure 20. MDM2-305S mutant does not bind to L11. H1299 cells co-transfected with 
MDM2-C305S and FLAG-tagged L11, L5, and L23 were analyzed by MDM2 
IP followed by FLAG western blot for coprecipitation of L proteins. 
Expression was verified by MDM2 and FLAG western blot of whole cell 
extract. 
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Figure 21. L11 does not enhance the ability of the MDM2-305S mutant to 
ubiquitinate MDMX. HCT116-p53-/- cells transfected with indicated 
plasmids were analyzed for MDMX ubiquitination, showing the loss of 
MDM2-C305S regulation by L11. 
 
 91 
Since the lack of MDM2 did not completely prevent MDMX down regulation by 
ActD (Figure 16), additional mechanisms for MDMX regulation were investigated. For 
example, quantitative RT-PCR analysis of MDMX showed that ActD causes a 20% 
reduction in MDMX mRNA level (Figure 22). The activity of a 1 kb human MDMX 
promoter-luciferase construct was also inhibited 30% by ribosomal stress but not by 
DNA damage (Figure 23). Therefore, although the mRNA level of MDMX seems to be 
slightly reduced in the presence of ribosomal stress, MDM2-mediated degradation played 
the major role in the rapid down-regulation of MDMX. mRNA levels for p53 target 
genes, p21 and MDM2 are also included in Figure 22. Following ribosomal stress, p53 
target genes are induced to similar levels as seen in DNA damage treated cells. 
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Figure 22. MDMX mRNA transcripts are reduced following ribosomal stress.  
U2OS and MCF-7 cells were treated with 5 nM actinomycin D, 50 µM 5-FU, 
0.5 µM CPT for 16 hours or irradiated with 10 Gy for 4 hours. The mRNA 
levels of indicated genes were analyzed by SYBR Green quantitative RT-
PCR. 
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Figure 23. MDMX promoter activity is reduced following ribosomal stress. U2OS 
cells were transiently transfected with luciferase reporters driven by a 1 kb 
MDMX promoter or the p53-responsive MDM2 P2 promoter for 24 hours. 
Cells were treated with drugs for 16 hours and analyzed for the expression of 
luciferase and cotransfected CMV-lacZ. Luciferase levels are shown after 
normalization to beta galactosidase activity. 
 
MDMX overexpression reduces p53 response to ribosomal stress 
Since MDM2 and MDMX showed different expression and binding to ribosomal 
proteins, they likely have distinct effects on p53 response to ribosomal stress. To test this 
hypothesis, we compared tumor cell lines with different levels of MDMX and MDM2. In 
this panel, MDMX level can be ranked from highest to lowest in the order of JEG-3, 
MCF-7, U2OS, HCT116, A549, H1299, and SJSA. JEG-3 and SJSA have the highest 
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MDM2 levels due to gene amplification or increased translation (Leach, Tokino et al. 
1993; Landers, Cassel et al. 1997). H1299 is p53-null and served as a control. After 
treatment with ActD, all cell lines showed p53 stabilization irrespective of MDM2 level. 
However, induction of p21 correlated inversely with the level of MDMX, but not MDM2 
(Figure 24), suggesting that high MDMX levels kept the stabilized p53 in an inactive 
state. 
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Figure 24. MDMX overexpression correlates with actinomycin D resistance. Cell 
lines were treated with 5 nM ActD for 18 hours and analyzed by western blot. 
 
The same cell lines were also analyzed for cell cycle arrest after ActD treatment. 
Cell lines with high levels of MDMX (JEG-3, MCF-7) were unable to undergo cell cycle 
arrest. On the otherhand, cell lines with lower levels of  MDMX (SJSA, A549, U2OS, 
HCT116) showed a more significant reduction in the number of cells in S-phase (MCF-7, 
JEG-3) (Figure 25-26).  Interestingly, SJSA cells showed a strong response to ActD 
despite expressing the highest level of MDM2. As expected, p53-null H1299 did not 
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respond to ActD. Therefore, cell cycle sensitivity to ActD also correlated with MDMX 
level, but not MDM2 level. These results suggested that MDMX overexpression has a 
significant impact on p53 activation by ribosomal stress. 
 
Figure 25. MDMX overexpression correlates with cell cycle arrest after 
Actinomycin D treatment. Cells were treated with ActD for 18 hours and 
analyzed for cell cycle distribution by FACS. The degree of growth arrest was 
shown as the decrease of S phase population compared to untreated controls. 
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Figure 26. Representative FACS histograms of cell cycle profile following ActD 
treatment. FACS profile of cell lines expressing high (JEG-3), and low 
(A549) levels of MDMX. H1299 cells do not have p53 and are used as a 
negative control. 
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Modulation of MDMX expression affects p53 activation by ribosomal stress 
To further confirm that MDMX overexpression at a physiological level inhibits p53 
activation and cell cycle arrest after ribosomal stress, HCT116 cells were infected with 
MDMX cDNA lentivirus and siRNA retrovirus. Polyclonal cell lines expressing MDMX, 
scrambled siRNA, or MDMX siRNA were analyzed. MDMX lentivirus provided ~5-fold 
increase in  MDMX levels in the HCT116 cell line. To show that this is a physiological 
level of MDMX expression we compared it to the levels of MDMX in MCF-7 cells 
(Figure 27).  
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Figure 27. MDMX is expressed to physiological levels in HCT116-LentiMX cells.  
Expression level of MDMX by lentivirus-mediated stable transduction 
compared to endogenous levels in MCF-7 and U2OS. Identical amounts of 
total protein were loaded in each lane. 
 
Next we tested p53 activation status in each cell line following treatment with 
ActD. MDMX overexpression reduced the sensitivity, whereas MDMX knockdown 
sensitized cells to ActD induction of p21 (Figure 28a). Furthermore, ActD did not induce 
p21 in HCT116-p53-/- cells, and MDMX overexpression or knockdown had no effect on 
p21 expression (Figure 28b). Manipulation of MDMX level did not affect p53 
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stabilization by ActD. These results showed that MDMX overexpression blocked p53 
activation, whereas MDMX knockdown increased sensitivity to ribosomal stress.  
Next, the effect of MDMX on cell cycle arrest was analyzed. Treatment with 1-2 
nM ActD for 18 hours caused significant reduction of S phase population in FACS 
analysis. HCT116 cells with MDMX overexpression were efficiently protected from cell 
cycle arrest by ActD, and knockdown of MDMX caused more efficient arrest (Figure 
29). 
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Figure 28. MDMX overexpression correlates with actinomycin D resistance in HCT 
p53 wild-type cells. (a) HCT116 p53-wildtype or (b) p53-null cells were 
infected with MDMX lentivirus, scrambled siRNA, and MDMX siRNA 
retrovirus. Pooled colonies were treated with either 1 or 2 nM of ActD for 18 
hours and analyzed by western blot. 
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Figure 29. MDMX prevents cell cycle arrest following ActD treatment. (a) HCT116 
cell lines expressing different levels of MDMX were treated with ActD for 18 
hours and analyzed for cell cycle distribution by FACS. The percent of cells in 
S phase population is shown. (b) FACS histograms from data summarized in 
(a) showing cell cycle profiles from HCT116-p53+/+ cells before and after 
actinomycin D treatment. 
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We also used U2OS cells to knockdown or overexpress MDMX and examine p53 
activation. Similar to HCT116 cells, MDMX overexpression reduced the sensitivity to 
ActD, whereas MDMX knockdown sensitized cells to ActD induction as measured by 
p53 target genes p21 and MDM2 (Figure 30). These results demonstrated that MDMX 
expression level has significant impact on p53 response to ribosomal stress. To confirm 
these results, we generate a stable pool of MCF-7 cells with MDMX knockdown. After 
treating with ActD, MCF-7 cells with a reduced dosage of MDMX were able to more 
readily undergo cell cycle arrest (Figure 31). 
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Figure 30.  MDMX overexpression in U2OS cells prevents p53 activation. U2OS 
cells stably transfected with MDMX cDNA or siRNA plasmids were treated 
with 5 nM ActD for 16 hours and analyzed by western blot. 
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Figure 31.  MDMX knockdown in MCF-7 cells enhances p53 activation. MCF-7 cells 
stably infected with an MDMX siRNA virus were treated with 2 nM ActD for 
16 hours and analyzed by (a) Western Blot and (b) FACS analysis  
 
MDMX overexpression sustains cell proliferation after ribosomal stress 
Cells contain a stockpile of ribosomes that can sustain normal protein synthesis for 
at least 24 hours after inhibition of rRNA processing (Pestov, Strezoska et al. 2001). 
Therefore, overcoming p53-mediated arrest should permit cell proliferation until 
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depletion of the ribosomes. To determine the maximum potential of MDMX in 
maintaining cell proliferation during ribosomal stress, we generated a U2OS cell line 
expressing MDMX at ~30-fold above endogenous level (Figure 30). BrdU labeling after 
18 hours of ActD treatment showed that cells overexpressing MDMX continued to 
synthesize DNA (Figure 32).  Conversely, MDMX knockdown caused more efficient 
shutdown of DNA synthesis even when treated with the lowest concentration (1 nM) of 
ActD.  
 
0.0
1.0
2.0
3.0
4.0
5.0
6.0
7.0
0 1 2 5 0 1 2 5 0 1 2 5
U2OS-MDMX U2OS-cDNA3 U2OS-MXSi
B
rd
U
 in
co
rp
or
at
io
n
ActD (nM)
 
Figure 32. MDMX overexpression prevents cell cycle arrest. U2OS expressing 
different levels of MDMX were treated with ActD for 18 hours and analyzed 
for DNA synthesis by BrdU incorporation. 
 
Next, we tested the effect of MDMX overexpression on cell proliferation during 
ribosomal stress. Starting at ~10% confluence, cells cultured in the continuous presence 
of ActD were analyzed by MTT assay over 4 days. After 1 day of treatment with ActD, 
U2OS cells expressing MDMX siRNA stopped proliferating, indicating activation of cell 
cycle checkpoints. Conversely, U2OS cells overexpressing MDMX continued to 
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proliferate at a significant rate, ultimately reaching confluency in the presence of ActD 
(Figure 33).  
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Figure 33. MDMX overexpression prevents growth arrest. Growth curve of U2OS 
cell lines in the presence of actinomycin D. Cells were plated at 10% 
confluency and cultured in the continuous presence of 1-2 nM ActD for 4 
days. Cell proliferation was measured by MTT assay. 
 
As expected, cell proliferation sustained by MDMX overexpression would 
eventually reach a limit as ribosomes were depleted. When cells were given unlimited 
space to proliferate by plating at a low density, MDMX-overexpressing cells were only 
able to give rise to micro colonies before cell proliferation stopped completely in 2 nM 
ActD (Figure 34). However, the growth arrest was reversible, as removal of ActD after 7 
days of treatment allowed MDMX overexpressing cells to form large colonies (Figure 
35). MDMX siRNA significantly reduced long-term viability after ActD treatment (data 
not shown). These results suggested that MDMX overexpression abrogated p53-mediated 
growth arrest and allowed cells to proliferate through multiple cycles after inhibition of 
ribosome biogenesis.  
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Figure 34. MDMX overexpression allows cells to form microcolonies in the presence 
of ActD. Colony size of U2OS cell lines after continuous 2 nM actinomycin D 
treatment for 7 days. 
 
 
 
 
 
 
                     
Figure 35. Cells overexpressing MDMX can recover after removal of ActD. U2OS 
cell lines after continuous 2 nM actinomycin D treatment for 7 days and then 
refed without drugs for 4 more days. 
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To test the growth advantage from having moderate MDMX overexpression, 
HCT116 and HCT116-Lenti-MDMX cells were mixed at 20:1 ratio. Cells were treated 
with 3 nM ActD for 4 days followed by normal medium for 4 days. After the treatment 
cycle was repeated for a total of 30 days, the ActD-resistant colonies were pooled and 
MDMX expression was determined. The results showed that the surviving cells were 
predominantly HCT116-Lenti-MDMX cells (Figure 36). This suggests that cells 
overexpressing MDMX have a clear survival advantage under conditions of ribosomal 
stress.  
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Figure 36. HCT 116+/+ Lenti-MX have a growth advantage when cycled with 
treatments of  of ActD.  10,000 HCT116 positive cells and 200 HCT116-
Lenti-MDMX cells were mixed and maintained on and off in ActD for 30 
days then analyzed for their ability to respond to ActD. 
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MDMX sequesters p53 into inactive complexes  
Since MDMX does not significantly affect p53 stability, we investigated the 
mechanism by which p53 is inactivated by MDMX overexpression. The fractions of free 
p53 and p53-MDMX complex were analyzed by MDMX immuno-depletion followed by 
p53 IP.  The results showed that overexpression of MDMX in U2OS sequestered the 
majority of p53 into MDMX-p53 complexes. After treatment with ActD or 5-FU, the 
majority of p53 remained bound to MDMX. In contrast, DNA damage by CPT released 
~50% of p53 into a free form (Figure 37). This assay also revealed that >50% of p53 in 
MCF-7 can be co-precipitated with endogenous MDMX after ActD treatment (Figure 
38), confirming that physiological MDMX overexpression is sufficient to quantitatively 
sequester p53.  
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Figure 37. MDMX sequesters  p53 into MDMX-p53 complexes.  Lysate of U2OS-
MDMX, U2OS or U2OS-MxSi cells treated with the indicated drugs for 16 
hours were immuno-depleted with MDMX antibody to detect MDMX-p53 
complex, followed by IP with p53 antibody to detect free p53. The 
precipitates were analyzed by p53 western blot.  
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Figure 38. Endogenous MDMX sequesters p53 into MDMX-p53 complexes. MCF-7 
cells treated with the indicated drugs  for 16 hours followed by immuno-
depletion with MDMX antibody to detect the MDMX-p53 complex, followed 
by IP with p53 antibody to detect free p53.  
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To further test whether MDMX interferes with p53 binding to DNA, U2OS cells 
expressing different levels of MDMX were analyzed by ChIP assay using p53 antibodies 
and PCR primers for MDM2 and p21 promoters. The results of p53 ChIP showed that 
MDMX overexpression reduced p53 DNA binding to both MDM2 and p21 target 
promoters after ActD treatment compared to control cells, whereas MDMX knockdown 
increased p53 DNA binding in both untreated and ActD-treated cells (Figure 39). These 
results suggested that MDMX inhibits the DNA binding activity of p53. However, the 
difference in p53 binding to the p21 promoter appeared insufficient to account for the 
large difference in p21 expression level (Figure 30). This suggests that MDMX may also 
function by blocking p53 interaction with basal transcription factors at the promoter. We 
currently cannot confirm or rule out the presence of MDMX-p53 complex on DNA 
because ChIP assay using MDMX antibodies was inconclusive. 
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Figure 39. MDMX prevents p53 binding to target promoters. U2OS cells expressing 
different levels of MDMX were treated with 5 nM ActD for 16 hours and 
analyzed by ChIP to detect p53 binding to the MDM2 and p21 promoters. 
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MDMX prevents p53 activation by serum starvation and contact inhibition 
To test the role of MDMX in p53 response to other types of ribosomal stress, we 
expressed MDMX in primary human foreskin fibroblasts (HFF) using lentivirus vector. 
Infection of HFF with MDMX lentivirus increased expression to a level similar to that of 
U2OS (data not shown). Therefore, this represents a physiologically achievable level of 
MDMX up-regulation. Normal human fibroblasts undergo p53 activation and G1 arrest 
during serum starvation or contact inhibition. A recent study showed that inhibition of 
rRNA expression and release of L11 was responsible for p53 activation during serum 
starvation (Bhat, Itahana et al. 2004). Other studies have shown that contact inhibition of 
normal fibroblasts causes a decrease in rRNA synthesis by inhibiting the recruitment of 
UBF to the rDNA promoter (Hannan, Hannan et al. 2000; Hannan, Kennedy et al. 2000).  
HFF and HFF-Lenti-MDMX were compared for p53 activation after culturing in 
0.5% serum for 18 hours (serum starvation), maintained at 100% density for 3 days 
(contact inhibition), or treated with 2 nM ActD for 18 hours. Western blot showed that all 
three treatments resulted in an increase in p53 and p21 levels in control HFFs. However, 
p21 induction was significantly weaker in HFF-lenti-MDMX cells (Figure 40), indicating 
ineffective p53 activation. Cell cycle analysis by FACS shows that HFF-Lenti-MDMX 
cells were desensitized to all three growth inhibitory conditions resulting in inefficient 
cell cycle arrest (Figure 41).  
 111 
Human skin fibroblasts
p53--
p21--
Actin--
MDMX--
MDM2--
Untreated
0.5% 
serum
Contact
Inhibition
2 nM
Act D
C
on
tro
l
C
on
tro
l
C
on
tro
l
C
on
tro
l
 
Figure 40. Effects of MDMX overexpression on p53 activation in normal human 
fibroblasts.  Control HFF or Lenti-MDMX infected HFF were cultured in 
0.5% serum for 24 hours, contact inhibited for 3 days, or treated with 2 nM of 
actinomycin D for 18 hours and analyzed by western blot. 
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Figure 41. Effects of MDMX overexpression on cell cycle arrest in normal human 
fibroblasts.  The fraction of cells in S phase measured by FACS analysis of 
serum starved, contact inhibited and actinomycin D treated HFF and HFF-
lenti-MDMX cells. 
 
Furthermore, an MTT assay was utilized to quantify the cell growth of  HFF or 
HFF-Lenti-MX cells serum starved over a three-day period. This experiment revealed 
that MDMX promotes cell proliferation in normal cells under growth inhibitory 
conditions. Interestingly, under non-stress conditions MDMX overexpression provides 
minimal growth advantage. These results demonstrated that a tumor-equivalent level of 
MDMX overexpression in normal cells was sufficient to interfere with p53 response to 
abnormal ribosomal biogenesis. 
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Figure 42. MDMX overexpression promotes cell proliferation during serum 
starvation. Growth of HFF and HFF-lenti-MDMX in 0.5% serum for 3 days. 
Cell number was quantified by MTT assay. 
 
MDMX overexpression confers resistance to 5-fluorouracil 
To investigate the relevance of MDMX overexpression in cancer chemotherapy, we 
tested its effect on sensitivity to 5-fluorouracil (5-FU). Inhibition of thymidylate synthase 
and DNA metabolism was thought to be responsible for the cytotoxicity of 5-FU (Parker 
and Cheng 1990). However, recent studies suggested that inhibition of RNA metabolism 
is responsible for its pro-apoptotic activity (Ghoshal and Jacob 1994; Longley, Boyer et 
al. 2002). Cell death by 5-FU can be prevented by uridine but not thymidine (Pritchard, 
Watson et al. 1997). Numerous reports showed that 5-FU at 100-500 µM induce p53 
phosphorylation at serine 15, possibly through DNA damage and ATM activation. 
However, it has also been suggested that lower concentrations of 5-FU (10-100 µM) 
activates p53 through mechanisms independent of DNA damage or ATM activation 
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(Longley, Boyer et al. 2002; Kurz and Lees-Miller 2004). We hypothesized that 5-FU 
may activate p53 by inhibiting rRNA synthesis and inducing ribosomal stress.  
 Tests using unmodified tumor cell lines showed that high endogenous MDMX 
levels were associated with reduced p21 induction after p53 activation following 5-FU 
treatment (Figure 43). This pattern was similar to ActD, and different from the DNA-
damaging drug camptothecin which was sufficiently able to induce p21 in a variety of 
cell lines. 5-FU also induced proteasome-dependent degradation of MDMX which is 
partially rescued by treating with the proteosome inhibitor MG132 (data not shown).  
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Figure 43. MDMX expression in tumor cell lines correlates with response to 5-FU 
not CPT Tumor cell lines were treated with 5 nM ActD, 50 µM 5-FU, and 0.5 
µM CPT for 18 hours and analyzed by western blot. 
 
Using a U2OS cell line expressing tetracycline-inducible Lenti-MDMX, we found 
that expression of MDMX 5-fold above endogenous levels resulted in significant 
inhibition of p21 induction by 5-FU and ActD, but had less of an effect on response to 
several DNA damaging agents (Figure 44). MDMX overexpression also sustained DNA 
replication in the presence of 5-FU, while MDMX knockdown increased sensitivity (data 
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not shown).  Compared to DNA damaging agents, 50 µM 5-FU induced very little p53 
serine 15 phosphorylation, gamma H2A.X phosphorylation, and MDMX S367 
phosphorylation (Figure 44, Figures 12-13), confirming the absence of significant DNA 
damage.  
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Figure 44. MDMX overexpression affects p53 response to ribosomal stress more 
than DNA damage. U2OS expressing tetracycline-inducible MDMX was 
treated with 1.0 µg/ml tetracycline and 5 nM ActD, 50 µM 5-FU, 1 µM 
doxorubicin or 0.5 µM CPT for 18 hours, or 10 Gy IR for 4 hours and 
analyzed by western blot. 
 
The effects of MDMX overexpression on 5-FU and ActD responses suggested that 
low concentrations of 5-FU mainly act by inducing ribosomal stress. To confirm that 5-
FU activates p53 by inhibiting RNA metabolism, HCT116 cells were treated with 5-FU 
in the presence of uridine, which bypassed inhibition of uridine synthesis by 5-FU 
(Longley, Harkin et al. 2003). Addition of uridine but not thymidine prevented p53 
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stabilization and p21 induction by 5-FU in a dose-dependent fashion (Figure 45), 
suggesting that inhibition of RNA metabolism and ribosomal biogenesis was responsible 
for p53 activation. Treatment with 5-FU also increased the amount of endogenous 
binding between MDM2 and L11 (Figure 46), and induced release of nucleolin from the 
nucleolus similar to ActD (Figure 47), consistent with nucleolar stress. These results 
suggested that low concentrations of 5-FU activate p53 by inducing ribosomal stress. 
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Figure 45. Uridine, but not Thymidine can reverse the actions of 5-FU. U2OS cells 
were treated with 5-FU and uridine or thymidine for 8 hours and analyzed for 
activation of p53. 
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Figure 46. 5-FU enhances the binding between MDM2 and L11. U2OS cells were 
treated with 5-FU and uridine for 8 hours or irradiated with 10 Gy for 4 hours 
and analyzed for MDM2-L11 binding by MDM2 IP and L11 western blot. 
MG132 was added for 4 hours to obtain similar levels of MDM2. 
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Figure 47. Release of nucleolin into nucleoplasm after 5-FU treatment. U2OS cells 
were treated with 2 nM actinomycin D and 100 µM 5-FU for 18 hours and 
stained using an antibody against the nucleolar protein nucleolin 
 
5-FU is a major chemotherapy agent for colorectal cancer. When HCT116 cells 
with overexpression and knockdown of MDMX were treated with 50 µM 5-FU, MDMX 
was degraded and p21 expression was induced in a p53-dependent fashion. Similar to 
ActD response, MDMX expression level showed an inverse correlation with p21 
induction (Figure 48). As expected, HCT116 cells null for p53 still had reduced MDMX 
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levels following treatment but were unable to respond to treatment through activation of  
p21 and MDM2. 
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Figure 48. MDMX expression levels showed an inverse correlation with p21 
induction following 5-FU treatment. HCT116 cell lines expressing different 
levels of MDMX were treated with 50 µM 5-FU for 18 hours and analyzed by 
western blot. 
 
HCT116 cells undergo apoptosis after 5-FU treatment. Knockdown of MDMX 
resulted in enhanced cell death, whereas MDMX overexpression blocked apoptosis in the 
presence of 5-FU (Figure 49a). MDMX overexpression also increased resistance against 
the DNA-damaging drug doxorubicin in short-term MTT assay (Figure 49b). However, 
the impact of MDMX on 5-FU sensitivity was more significant, particularly at low drug 
concentrations (compare Figure 49a and 49b). In colony formation assays, MDMX 
overexpression improved long-term survival after treatment with 5-FU, but not 
doxorubicin (Figure 50). These results suggested that MDMX is an important 
determinant of sensitivity to 5-FU. 
 119 
 
0 .2 0
0 .4 0
0 .6 0
0 .8 0
1 .0 0
0 .0 0 .2 0 .4 0 .6 0 .8 1 .0
C
el
l v
ia
bi
lit
y
HCT-MDMX
HCT116
HCT-MXSi
HCT p53-/-
Doxorubicin (µM)
0 .2 0
0 .3 5
0 .5 0
0 .6 5
0 .8 0
0 .9 5
0 2 5 5 0 7 5 1 0 0
HCT-MDMX
HCT116
HCT-MXSi
HCT p53-/-
5-FU (µM)
C
el
l v
ia
bi
lit
y
a b
 
Figure 49. MDMX prevents apoptosis in HCT116 following 5-FU or Doxorubicin 
treatment. HCT116 cell lines were treated with (a) 5-FU or (b) doxorubicin 
for 48 hours and analyzed for cell viability by MTT assay.  
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Figure 50. MDMX overexpression allows colony formation in the presence of 5-FU. 
Control and MDMX overexpressing HCT116 were plated at 5,000/well for 24 
hours, treated with drugs for 24 hours, incubated in drug-free medium for 7 
days, and stained for colony formation efficiency. 
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MDMX regulates tumor formation and drug resistance in vivo 
 To test the role of MDMX in tumor formation in vivo, HCT116 cells expressing 
scrambled or MDMX siRNA (Figure 48) were inoculated subcutaneously on the dorsal 
flanks of athymic nude mice. Each animal received both control and test cell lines. The 
scrambled siRNA had no effect on tumor formation compared to the unmodified HCT116 
cells (data not shown). In contrast, MDMX siRNA expressing cells showed significantly 
reduced tumorigenic potential (n=13, p=0.0005, Figure 51a, 51b). A second repeat of the 
experiment also generated similar results (not shown).  Very few MDMX siRNA tumors 
were capable of reaching a dissectable size.  However, dissectible tumors which form did 
form from the MDMX siRNA expressing cells were analyzed by Western blot. 
Interestingly, they showed an MDMX expression level similar to control HCT116 tumors 
(Figure 52). Since the MDMX siRNA cell line was a polyclonal pool of retrovirus 
infected colonies, it is likely that some of the cells regained normal MDMX expression 
and tumorigenic potential. These results demonstrated that partial knockdown of MDMX 
effectively blocked tumor formation in vivo. The results also suggested that the tumor 
environment caused unknown physiological stress that required suppression of p53 by 
MDMX. 
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Figure 51. MDMX expression is required for tumor formation. (a) HCT116 cells 
expressing control and MDMX siRNA were inoculated into athymic nude 
mice (5x106/site). Tumor growth was measured after 14 days. Tumors marked 
with A-to-H were analyzed for MDMX expression. (b) Representative 
pictures of tumor bearing animals. Left side: HCT116-control siRNA. Right 
side: HCT116-MDMX siRNA. 
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Figure 52. Tumors dissected 14 days after inoculation. Tumor samples recovered 14 
days after inoculation were analyzed by western blot for MDMX and 
indicated markers. 
 
To further test the effects of MDMX overexpression on tumor growth and 
treatment response in vivo, mice were inoculated with HCT116-vector and HCT116-
Lenti-MDMX cells. The mice were treated with 5-FU by i.v. injection for four 
consecutive days when all tumors had reached an average of  ~0.1 cm3 in size. In 
untreated animals, HCT116-Lenti-MDMX cells did not show increased tumor growth 
compared to HCT116-vector control (Figure 53), suggesting that the level of endogenous 
MDMX was sufficient for growth in vivo. However, MDMX overexpression resulted in 
statistically significant tumor resistance (p-value = 0.01) to 5-FU treatment (Figure 53). 
These results further demonstrated that MDMX inhibits tumor response to RNA-targeting 
chemotherapy drugs in vivo. 
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Figure 53. MDMX overexpression promotes tumor growth in the presence of 5-FU. 
HCT116 cells stably infected with lentivirus vector or lenti-MDMX were 
inoculated into nude mice. Mice with ~0.1 cm3 size tumors were treated with 
5-FU at 50 mg/kg/day for 4 days and tumor growth were measured during the 
indicated time frame.  
 
Discussion 
 Results described above show that MDMX is an important regulator of p53 
activation by ribosomal stress. MDMX overexpression at physiologically relevant levels 
significantly desensitizes cells to ribosomal stress-inducing agents. In contrast, 
physiological level of MDM2 overexpression (from gene amplification) does not confer 
resistance to ActD. Our results also demonstrated that endogenous MDMX expression in 
HCT116 cells is necessary for tumor formation, suggesting that MDMX is a useful drug 
target. 
 Differences in structure and function of MDM2 and MDMX may be responsible 
for their distinct effects on ribosomal stress response. MDM2 is an ubiquitin ligase that 
functions mainly by promoting p53 degradation. This mechanism may be highly sensitive 
to inhibition by ribosomal proteins. Therefore, physiological levels of MDM2 
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overexpression are effectively neutralized during ribosomal stress, resulting in p53 
stabilization. In contrast, MDMX is a stable protein that regulates p53 mainly by 
sequestering p53 into complexes (Francoz, Froment et al. 2006; Toledo, Krummel et al. 
2006). Because ribosomal stress does not induce p53 phosphorylation or block p53-
MDMX binding, MDMX overexpression will trap p53 in inactive complexes and prevent 
p21 induction, sustaining cell proliferation. We should note that our results do not rule 
out p53-independent effects of MDMX on p21 expression, such as by targeting it for 
degradation. 
 The biological significance of ribosomal stress in regulating cell proliferation in 
vivo is still not clearly defined. The ability of MDMX to attenuate p53 activation and cell 
cycle arrest during growth factor deprivation and other ribosomal stress conditions may 
provide an advantage in a tumor environment. It is possible that different regions of a 
tumor undergo cycles of proliferation, growth arrest, and cell death due to imbalance in 
the supply of growth factors and nutrients. MDMX overexpression would suppress p53 
activation by ribosomal stress, allowing additional rounds of cell division. The 
cumulative effect of such limited growth would be significant after repeated cycles of 
stress selection, as suggested by our mixing experiment. 
 MDMX overexpression may also interfere with p53 activation by other growth 
regulators. It has been shown that the retinoblastoma protein pRb inhibits RNA 
polymerase I-mediated transcription by binding to the UBF factor, thus inhibiting rRNA 
expression (Voit, Schafer et al. 1997). This function should lead to ribosomal stress and 
contribute to growth arrest by pRb during contact inhibition (Hannan, Kennedy et al. 
2000). In addition, p53 itself has been shown to inhibit rRNA transcription (Budde and 
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Grummt 1999), which would have a positive feedback effect through release of 
ribosomal proteins. Abnormal expression of MDMX may block p53 activation and 
weaken the effects of multiple tumor suppressor pathways.  
The ability of MDMX to abrogate p53 activation by 5-FU may have significant 
clinical relevance. This drug is a mainstay compound in the chemotherapy of colon 
cancer. 5-FU cytotoxicity depends on conversion to 5-fluoroUTP, 5-fluoro-dUMP, and 5-
fluoro-dUTP. Binding of 5-fluoro-dUMP to the enzyme thymidylate synthase inhibits the 
synthesis of thymidine nucleotides, giving rise to DNA strand breaks (Parker and Cheng 
1990), this was believed to be the major mechanism of cytotoxicity. However, 5-FU also 
inhibits rRNA processing (Ghoshal and Jacob 1994). In vitro studies have shown that 5-
FU incorporation into RNA but not DNA was associated with cell death (Geoffroy, 
Allegra et al. 1994). Incorporation into RNA is responsible for the gastrointestinal 
toxicity of 5-FU in mice (Houghton, Houghton et al. 1979). A study using p53-null mice 
showed that intestinal epithelial apoptosis induced by 5-FU is p53-dependent, and 
involves interference of RNA metabolism (Pritchard, Watson et al. 1997). Experiments 
using HCT116 cells also suggested a p53-dependent cytotoxicity of 5-FU through 
inhibition of RNA metabolism (Bunz, Hwang et al. 1999). Here we show that 5-FU 
activation of p53 is abrogated by uridine but not thymidine, and is highly sensitive to 
MDMX overexpression. These results suggest that induction of ribosomal stress and p53 
activation is an important mechanism of 5-FU cytotoxicity, although DNA damage may 
also be a contributing factor at high drug doses.  
 In light of the findings described above, it will be important to investigate whether 
there is a correlation between MDMX expression level and tumor response to 5-FU or 
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other RNA-directed drugs in the clinic. MDMX overexpression has been observed in 
both tumor cell lines and primary tumor biopsies (Ramos, Stad et al. 2001; Danovi, 
Meulmeester et al. 2004). MDMX gene amplification does not appear to be the major 
mechanism of overexpression (~5% in breast tumors) (Danovi, Meulmeester et al. 2004). 
Analyses of MDMX promoter suggested that MDMX expression level in tumor cell lines 
correlates with promoter activity (unpublished observations). The drug sensitization and 
anti-tumor effects of MDMX siRNA suggest that targeting MDMX-p53 interaction with 
small molecules may have therapeutic value. To this end, it is noteworthy that the MDM2 
inhibitor Nutlin 3 does not target MDMX-p53 binding (Vassilev 2004; Patton, Mayo et 
al. 2006), suggesting a need to develop novel MDMX inhibitors.  
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Chapter Four 
Regulation of Mdmx Expression by Mitogenic Signaling 
 
 
Abstract 
 MDMX is an important regulator of p53 transcriptional activity and stress 
response. MDMX overexpression and gene amplification are implicated in p53 
inactivation and tumor development. Unlike MDM2, MDMX is not inducible by p53 and 
little is known about its regulation at the transcriptional level. We found that MDMX 
levels in tumor cell lines closely correlate with promoter activity and mRNA level. 
Activated K-Ras and growth factor IGF-1 induce MDMX expression at the 
transcriptional level through mechanisms that involve the MAPK kinase and c-Ets-1 
transcription factors. Pharmacological inhibition of MEK results in down-regulation of 
MDMX in tumor cell lines. MDMX overexpression is detected in ~50% of human colon 
tumors and showed strong correlation with increased ERK phosphorylation. Therefore, 
MDMX expression is regulated by mitogenic signaling pathways. This mechanism may 
protect normal proliferating cells from p53 but also hamper p53 response during tumor 
development.  
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Results 
MDMX level in tumor cell lines correlates with promoter activity 
Recent studies demonstrated that MDMX expression is needed for the proliferation 
of tumor cell lines with wild type p53 in culture (Danovi, Meulmeester et al. 2004), and 
formation of tumor xenografts in nude mice (Gilkes, Chen et al. 2006). MDMX protein 
overexpression has been found in 40% of tumor cell lines (Ramos, Stad et al. 2001). 
MDMX mRNA overexpression has also been observed in 18.5% of breast, colon, and 
lung tumor samples as determined by in situ hybridization (Danovi, Meulmeester et al. 
2004).  However, MDMX gene amplification only occurs in 5% of breast tumors 
(Danovi, Meulmeester et al. 2004), suggesting that in most cases activated transcription is 
responsible for its overexpression. Therefore, we decided to investigate the pathways that 
regulate MDMX transcription.  
A survey of a panel of cell lines that express high (JEG-3, MCF-7), moderate 
(U2OS, HCT116), and low (A549, SJSA, H1299) levels of MDMX revealed that MDMX 
protein level correlated with its mRNA levels but showed no correlation with MDM2 
(Figure 54).  The mRNA level was measured using Real-Time PCR with SYBR green 
chemistry and normalized to the expression of 18S ribosomal protein mRNA.  
 129 
m
R
N
A 
M
D
M
X
 / 
18
S
MDM2--
MDMX--
Actin--
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
JEG-3 MCF7 HCT U2OS A549 SJSA H1299
 
Figure 54. MDMX overexpression occurs at the transcriptional level. Total RNA and 
protein from tumor cell lines were analyzed by quantitative PCR and western 
blot. MDMX mRNA level was normalized to 18S rRNA (n=3).   
 
To determine the stability of existing MDMX protein, we prevented cells from 
generating new MDMX protein by treating them with the protein synthesis inhibitor 
cyclohexamide. MDMX protein stability appeared much greater than MDM2 after 
treatment with cycloheximide (half life 4-8 hours), and is unrelated to cellular MDM2 
levels (Figure 55). Furthermore, blocking protein degradation with the proteasome 
inhibitor MG132 for 4 hours dramatically increased the level of MDM2 but not MDMX 
(Figure 56), indicating that MDM2 but not MDMX undergoes rapid turn over in 
unstressed cells. Therefore, the rate of MDMX turn over is inherently slow in unstressed 
cells and its overexpression in a subset of cell lines is not due to higher stability. These 
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results suggest that mRNA expression is an important determinant of MDMX level in 
unstressed cells.  
MDMX--
MDM2--
Actin--
JEG-3 MCF-7 HCT116
0 2 5 8CHX (hr) 0 2 5 8 0 2 5 8
 
Figure 55. MDMX turnover is slower than MDM2. JEG-3, MCF-7, and HCT116 cells 
were treated with cycloheximide (CHX; 50 µg/ml) for 0, 2, 5 or 8 hours and 
analyzed by western blot. 
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Figure 56. MDMX stability is greater than MDM2. JEG-3, MCF-7, and HCT116 cells 
were treated with MG132 (25 µM) for 4 hours and analyzed by western blot.  
 
To test whether the activity of the MDMX promoter is responsible for its 
expression level, a 1.1 kb genomic DNA fragment upstream of the MDMX mRNA 
coding region was cloned by PCR and inserted into the pGL2 promoter-less luciferase 
reporter. Transient transfection of the MDMX promoter construct into different tumor 
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cell lines showed activity levels (normalized to cotransfected CMV and RSV promoters) 
that generally correlated with their endogenous MDMX protein and mRNA levels 
(Figure 57). For example, the promoter is highly active in cells overexpressing MDMX. 
Therefore, MDMX promoter activity is responsible for or contributes to the variations in 
protein levels in the tumor cell lines. It is noteworthy that MCF-7 cells in which the 
MDMX promoter is highly active also have abnormal MDMX gene copy number (5 
copies instead of 2) (Danovi, Meulmeester et al. 2004), which may contribute to 
overexpression. Cotransfection of the MDMX promoter with several genes commonly 
involved in transformation (E2F1, c-myc, Stat3, Src, Akt,) did not show activation (data 
not shown), ruling out a direct role for these factors in MDMX overexpression. 
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Figure 57. MDMX promoter analysis. Cell lines were transfected with the 1.1 kb 
MDMX promoter-luciferase construct and CMV-LacZ. The luciferase/lacZ 
activity ratio is shown (n=3). 
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Identification of key transcription factor binding sites in the MDMX promoter 
To identify MDMX promoter elements necessary for promoter activity in the cell 
lines expressing high levels of MDMX, a series of 5’ deletion mutants were generated 
and transiently transfected into MCF-7 and H1299 cells (Figure 58). The full-length 
reporter fragment showed strong luciferase activity in MCF-7 cells, which have a high 
level of MDMX. Conversely, H1299 cells with low level MDMX expressed weak 
luciferase activity. Serial deletion from –990 bp to -120 bp (0 bp being the putative 
transcription start site based on promoter prediction analysis and the 5’ end of two 
longest cDNA sequences in Genbank: NM_002393 and BC067299) showed little effect 
on promoter activity in MCF-7 and H1299 cells. However, deleting the region from -120 
bp to 0 bp resulted in a greater than 90% loss of promoter activity in both cell lines. 
These results suggest that transcription factors binding between the -120 bp to 0 bp 
region are critical for regulating both basal and cell line-specific hyperactivation of the 
MDMX promoter.  
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Figure 58. Luciferase expression of promoter deletion constructs in MCF-7 and 
H1299 cells.  MCF-7 (high endogenous MDMX expression) and H1299 (low 
endogenous MDMX expression) cells were transfected with MDMX promoter 
deletion constructs and normalized by CMV-LacZ expression (n=3). 
 
A database search for putative transcription factors which potentially bind to the -
120 to 0 bp region revealed Aml-1, Cdxa, c-Ets-1, and Elk-1 consensus sequences. These 
sites are largely conserved in the putative mouse MDMX promoter (Figure 59), 
suggesting that they are important for regulation of MDMX expression. c-Ets-1 and Elk-1 
are downstream targets of Ras, regulated via ERK-mediated phosphorylation (Gille, 
Kortenjann et al. 1995; Liu, Liang et al. 2005). To confirm the function of these sites, 
point mutations at each of the potential transcription factor binding sites were introduced 
into the 1.1 kb promoter construct as bolded in Figure 59.  
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CATTGCTCCATCTATGGTTTCCGGAGGCCT
CACCGGAAGCCCTCGTGTGAGGCCGTGTGG
CCCCGGACTAGGATCTACTCTATGGTAGTG
AGCTCAGCCTTTCTAGCTCTCTAGTCCTCC
CCCCGGACTAGTGTGTACTCAATGGTAGAT
TCT TCAGCCTTTCTAGCTCTCTAGTCCTCC
AML-1
-120
-90
CDXA
_AG_GGTCCGTCTATGGTTTCCCCCGGCCT
CCCCGGAAGCTCTTGCGA _ACGCTGTTTGA
-60
-30
c-Ets-1 / Elk-1 (EE1)
c-Ets-1 / Elk-1 (EE2)
Human
Mouse
Human
Mouse
Human
Mouse
Human
Mouse
 
Figure 59. Sequence (–120 to 0 bp) of the human and mouse MDMX basal 
promoter. The positions of putative transcription factor binding sites 
underlined and mutated nucleotides are bolded. 
 
The mutated promoter constructs were expressed in JEG-3, MCF-7, and H1299 
cells along with the unmutated full length promoter and deletion mutants. Mutation of the 
Cdxa or Aml-1 sites resulted in a 2-3-fold decrease in promoter activity, whereas c-Ets-
1/Elk-1 individual site mutants had 4-fold reduced activity in JEG-3 and MCF-7 cells 
(Figure 60). Furthermore, 20 bp serial deletions of the –120 bp to 0 bp region caused a 
step-wise decrease in promoter activity (data not shown), suggesting that multiple 
transcription factor binding sites are necessary for MDMX promoter activity. Compound 
mutations of the Aml-1 and c-Ets-1/Elk-1 sites resulted in greater than 90% reduction in 
promoter activity, similar to the activity of the 0 bp construct or full-length reporter with 
mutations in all four transcription factor binding sites (quad mutant) (Figure 60). The 
activity of mutant luciferase reporter constructs also changed in a similar pattern in 
H1299 cells but at a reduced magnitude (Figure 61), presumably because the same set of 
factors are functioning at a reduced level.  
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Figure 60. MDMX promoter mutation analysis. Full-length, deletion, as well as single, 
double, and quadruple point mutations in the full-length MDMX luciferase 
reporter construct were tested for activity in  JEG-3 (a) and MCF-7 (b) cells 
(n=3).  
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Figure 61. MDMX promoter mutation analysis in H1299 cells. Full-length, deletion, 
as well as single, double, and quadruple point mutations in the full-length 
MDMX luciferase reporter construct were tested for activity in  H1299 cells 
(n=3).  
 
Next we considered whether c-Ets-1 was sufficient to induce MDMX promoter 
activity in cells with endogenously low levels of MDMX. MDMX reporter constructs 
were cotransfected with a c-Ets-1 expression plasmid in H1299 cells (Figure 62). c-Ets-1 
induced the 1.1 kb promoter activity but was not able to activate the c-Ets-1/Elk-1 mutant 
promoter construct. To test the roles of endogenous c-Ets-1 and Elk-1 in regulating 
MDMX expression and p53 activity, MCF7 cells were treated with siRNA. The results 
showed that transient knockdown of c-Ets-1 and Elk-1 expression reduced MDMX 
expression in MCF7 cells (Figure 63). This was associated with increased expression of 
p53 target genes p21 and MDM2 without changes in p53 level. Low concentration of 
actinomycin D induces MDMX degradation and p53 activation by causing ribosomal 
stress (Gilkes, Chen et al. 2006). Ets-1 and Elk-1 knockdown cooperated with 
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actinomycin D in further reducing MDMX level and increasing p53 activity similar to the 
effect of MDMX knockdown (Figure 63). Therefore, c-Ets-1 and Elk-1 control MDMX 
transcription and contribute to the suppression of p53 activity. 
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Figure 62. c-Ets-1 enhances MDMX basal promoter activity. H1299 cells were 
transfected with the full-length MDMX promoter and 50 ng of c-Ets-1 
plasmid to induce MDMX promoter activity. MDMX promoter mutants were 
also transfected with 50 ng c-Ets-1 to determine the response of each binding 
site mutant to c-Ets-1 expression. 
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Figure 63. MDMX suppression of p53 requires c-Ets-1 and Elk-1.  Synthetic RNAi 
oligonucleotides targeted to Elk-1, c-Ets-1, and MDMX mRNA were 
transfected into MCF7 cells using Oligofectamine reagent. After 48 hrs, cells 
were treated with actinomycin D for 20 hrs and analyzed for the expression 
level of indicated markers by Western blot. 
 
Activation of MAP kinase pathway induces MDMX expression  
MDM2 expression is induced by oncogenic H-Ras through activation of MAPK and c-
Ets-1 (Ries, Biederer et al. 2000). Because c-Ets-1 also appeared to be critical for 
MDMX promoter activity, we tested the role of the Ras-MAPK pathway in MDMX 
induction. P53-null (35.8) and p53/ARF double-null (DKO) mouse embryo fibroblasts 
were stably infected with retrovirus expressing HA-tagged mutant K-Ras oncogene 
(12V), which is more frequently involved in human cancer than H-Ras (Sebolt-Leopold 
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and Herrera 2004). K-Ras expression resulted in significant induction of MDMX in both 
35.8 and DKO cells. Additionally, phosphorylated ERK and downstream targets c-Ets-1 
and Elk-1 levels were elevated in K-Ras expressing cells (Figure 64a). Half-life 
comparison by cycloheximide treatment did not indicate a change in MDMX stability 
after K-Ras expression (data not shown). RT-PCR analysis showed that MDMX mRNA 
was increased by over 2-fold in K-Ras overexpressing cells when compared to vector-
infected control (Figure 64b), suggesting that the induction occurred at the transcriptional 
level. 
 
       
Figure 64. K-Ras induces MDMX protein and mRNA expression. (a) 35.8 (p53-null) 
and DKO (p53/ARF–double null) MEFs stably infected with pBabe-HA-K-
Ras (12V) virus were analyzed by western blot for indicated markers. (b) 
Total RNA from 35.8 and DKO cells expressing activated K-Ras were 
analyzed for MDMX mRNA level by qPCR (n=6). 
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 To further test whether downstream factors of the Ras signaling pathway have the same 
effect as activated Ras, H1299 cells with low endogenous MDMX were transiently 
transfected with constitutively active mutants of B-Raf (V600E) and MEK1. The results 
showed that expression of active B-Raf and MEK1 led to ERK phosphorylation and 
significant induction of MDMX protein level as expected (Figure 65a). Furthermore, the 
MDMX promoter construct was stimulated by cotransfection with activated Ras, MEK1, 
and B-Raf, whereas a promoter with mutated Ets-1 binding sites was not responsive 
(Figure 65b). These results suggest that activation of the Ras-Raf-MAPK pathway is 
sufficient to activate the MDMX promoter.  
      
Figure 65.  The Ras Pathway induces endogenous MDMX. (a) H1299 cells were 
transiently transfected with HA-K-Ras, HA-Mek1, B-RafV600E, or c-Ets-1. 
Endogenous expression of MDMX, phospho-ERK, ERK1/2, and actin were 
analyzed by Western blot. (b)  H1299 cells were transfected with full-length 
or EE1/EE2 mutant MDMX reporter constructs and expression vectors for 
HA-K-Ras, HA-Mek1, B-RafV600E, or c-Ets-1. The luciferase reporter 
activity for each of the transfection conditions is shown (n=3). 
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Inhibitors of the MAP kinase pathway down regulate MDMX expression 
To confirm that K-Ras induction of ERK phosphorylation mediated the increase in 
MDMX level, 35.8-K-Ras cells were treated with the MEK inhibitor U0126 for 8 hours. 
Inhibition of MEK/ERK pathway by U0126 has been shown to prevent the effects of 
oncogenic H-Ras and K-Ras (Zhang and Lodish 2004). U0126 treatment caused a 
reduction of MDMX in 35.8-K-Ras expressing cells to levels equivalent to 35.8 control 
cells (Figure 66). Additionally, treatment of MCF-7 cells (high MDMX) with the MEK 
inhibitor PD98059 led to a time-dependent decrease in MDMX protein expression 
(Figure 67). Therefore, the results of the inhibitors were as predicted from the activation 
experiments. 
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Figure 66. Oncogenic K-Ras induces MDMX expression in an ERK-dependent 
manner.  35.8 cells stably transfected with HA-K-Ras were treated with 
U0126 for 8 hours and analyzed for expression of MDMX and phospho-ERK. 
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Figure 67. Mek inhibition results in downregulation of MDMX. MCF-7 cells were 
treated with 37.5 µM PD98059 for the indicated time points followed by 
western blot analysis. 
 
To test whether there is a correlation between MAPK activation and MDMX 
overexpression, cell lines were compared for their p-ERK level, MDMX level, and 
response to UO126. The results from this small cell panel suggested a general association 
between high-level p-ERK and MDMX expression (Figure 68). Furthermore, UO126 
inhibited MDMX expression in most cell lines. As expected, MDM2 levels were also 
decreased in the presence of U0126 (Ries, Biederer et al. 2000). Therefore, strong 
activation signaling from the Ras/Raf/MEK/MAP kinase pathway may be responsible for 
MDMX overexpression in a majority of tumor cell lines. However, JEG-3 is an exception 
with low p-ERK, high MDMX, and insensitivity to UO126 (Figure 68), suggesting 
additional mechanism of MDMX overexpression independent of hyperactive MAPK 
pathway. The activity of MDMX promoter in JEG-3 cells still requires the Ets-1 and Elk-
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1 binding sites (Figure 60a), suggesting that these transcription factors are activated by 
MAPK-independent mechanisms in JEG-3 cells. 
+- +- +- +- +- +- +-
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Figure 68. Mek inhibition downregulates MDMX in panel of cancer cell lines. A 
panel of cell lines expressing different endogenous levels of MDMX were 
treated with 30 µM U0126 for 18 hrs and compared for expression of the 
indicated proteins and MDMX mRNA. 
 
Although MAPK inhibitors suppressed MDMX expression, they did not lead to 
reproducible increase in p53 activity and p21 expression (Figure 68). U0126 treatment 
also failed to induce several other p53 target genes (PUMA, 14-3-3 sigma, cyclin G, PIG-
3) when tested by RT-PCR, and did not activate p53-response promoter in reporter gene 
assay (data not shown). In contrast, direct knock down of MDMX by siRNA consistently 
induced p21 expression in the same panel of cell lines (Figure 69). These results suggest 
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that although MAPK pathway regulates MDMX expression, targeting this pathway by 
MAPK inhibitors does not provide a net activation of p53. This may be due to the 
complex biological effects or lack of specificity by the kinase inhibitors.  
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Figure 69. MDMX knockdown induces p21 and MDM2 expression. Cells were 
transfected with MDMX siRNA for 72 hrs and analyzed for expression of 
indicated markers by western blot. 
 
MDMX promoter activation correlates with increased Ets-1 and Elk-1 binding 
 Knockdown of Ets-1 and Elk-1 by siRNA resulted in reduced MDMX expression 
and p53 activation, suggesting that Ets-1 and Elk-1 are important factors in mediating 
MDMX induction by mitogenic signals. To determine whether promoter occupancy of 
Ets-1 and Elk-1 correlates with MDMX promoter activity and expression level, cell lines 
with high and low levels of MDMX were analyzed by ChIP using Ets-1 and Elk-1 
antibodies. The results confirmed that high-level MDMX expression was associated with 
increased promoter binding by Ets-1 and Elk-1, whereas YY1 binding was similar 
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(Figure 70). The binding difference was specific for the basal promoter region and was 
not observed using PCR primers 3 kb upstream from the basal promoter.  
 
-120 MDMX 
promoter --
-3kb MDMX 
promoter --
C-Ets-1 Elk-1 YY1 1/100  INPUTIP:  
Figure 70.  c-Ets-1 and Elk-1 bind to the MDMX promoter. JEG-3 (high MDMX 
expression), U2OS, and H1299 (low MDMX expression) cells were analyzed 
by ChIP to detect binding of endogenous c-Ets-1 and Elk-1 to the basal 
MDMX promoter. YY1 was used as a negative control. PCR of a promoter 
element 3 kb upstream of the basal MDMX promoter was performed as a 
specificity control. 
 
When MCF-7 cells were treated with UO126 (MEK inhibitor) and SB203580 (p38 
inhibitor), Ets-1 and Elk-1 binding to MDMX promoter was specifically reduced by 
UO126 but not by SB203580 (Figure 71). These results were also consistent with the 
effects of the inhibitors on MDMX expression level and promoter activity (Figure 72). 
These results provide additional evidence that MAP kinase signaling stimulates Ets-1 and 
Elk-1 binding to the MDMX basal promoter, inducing MDMX expression. 
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Figure 71. c-Ets-1 and Elk-1 binding is phosphor-erk dependent. MCF-7 cells treated 
with 30 µM of MAPK (U0126) or p38 stress kinase inhibitor (SB203580) 
were compared to H1299 cells by ChIP analysis for c-Ets-1 and Elk-1 binding 
to the MDMX promoter. 
 
IGF-1 increases expression of MDMX in a MAPK-dependent manner 
The involvement of Ras-MAPK pathway in stimulating MDMX expression 
suggests that extracellular growth factors may also influence MDMX expression. 
Mitogenic stimulation by FGF, IGF-1 or activated PDGF receptor has been shown to 
inhibit the p53 pathway by inducing MDM2 transcription (Shaulian, Resnitzky et al. 
1997; Fambrough, McClure et al. 1999). Additionally, IGF-1-induced cell division 
correlates with nuclear exclusion of p53 and enhanced p53 degradation (Jackson, Patt et 
al. 2006). MCF-7 cells have been shown to have up-regulated IGF receptor (IGFR-I) 
mRNA and protein (Clarke, Howell et al. 1997). To address the role of MDMX in 
mitogenic signaling to p53, serum starved MCF-7 cells were treated with IGF-1. This led 
to a marked increase of MDMX expression after 8 hours (Figure 72a). Additionally, IGF-
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1 stimulation of MCF-7 also led to an increase in activity of the transfected MDMX 
promoter (Figure 72b). These results indicate that MDMX expression can be regulated by 
extracellular growth factors.  
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Figure 72. IGF-1 induces MDMX expression (a) MCF-7 cells were starved in DMEM 
with 0% serum for 24 hrs. IGF-1 (10-100 ng/ml) was added and cells were 
analyzed 8 hrs later by western blot. (b) MCF-7 cells were transfected with 
MDMX promoter constructs for 24 hrs, serum starved for 24 hrs, and treated 
with 100 ng/ml IGF-1 for 8 hrs. Promoter activity was compared to MCF-7 
cells in 10% serum (n=3). 
 
The biological effects of IGF-1 are mediated by the activation of the IGF-1 
receptor, a transmembrane tyrosine kinase linked to the Akt and Ras-Raf-MAPK 
cascades (Datta, Brunet et al. 1999). To evaluate which signaling pathway is involved in 
IGF-1-mediated MDMX induction, serum starved MCF-7 cells were stimulated with 
IGF-1 in the presence of PI3K inhibitor (LY294002), MEK inhibitor (PD98059), or p38 
stress kinase inhibitor (SB203580). IGF-1 induction of MDMX was completely blocked 
by the MEK inhibitor PD98059 but not by the PI3K or p38 inhibitors (Figure 73). The 
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level of phosphorylated ERK, which decreased following serum starvation, was increased 
upon the addition of IGF-1, confirming that IGF-1 was activating the MAPK pathway. 
As expected, PD98059 completely abrogated ERK phosphorylation whereas LY294002 
and SB203580 had no effect (Figure 73). Quantitative RT-PCR analysis showed that 
IGF-1 induced MDMX mRNA expression by 3-fold over unstimulated MCF-7 cells 
(Figure 74). Additionally, the MAPK inhibitor PD98059 completely abrogated the 
induction of MDMX mRNA, while the p38 inhibitor had no effect. The PI3K inhibitor 
LY294002 was able to partially suppress MDMX mRNA expression. This is likely due to 
the cooperation between the PI3K and Ras activation pathways, which may act 
synergistically to increase ERK phosphorylation. 
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Figure 73. IGF-1 induces MDMX in serum starved cells. MCF-7 cells were serum 
starved for 24 hrs, and treated with IGF-1 and inhibitors against PI3K (30 µM 
LY294002), MAPK (37.5 µM PD98059), or p38 kinase (30 µM SB203580) 
for 8 hrs. Cell lysate was analyzed by western blot.  
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Figure 74. IGF-1 induces erk-dependent MDMX expression. Total RNA from serum 
starved MCF-7 treated with IGF-1, 30 µM LY294002, 37.5 µM PD98059, 
and 30 µM SB203580 were analyzed for MDMX mRNA levels by qPCR 
(n=3). 
 
MDMX overexpression correlates with ERK phosphorylation in colorectal tumors 
 MDMX mRNA overexpression has been observed in 18.5% of breast, colon, and 
lung tumor samples as determined by in situ hybridization (Danovi, Meulmeester et al. 
2004). MDMX protein expression was also observed in ~80% of adult pre-B acute 
lymphoblastic leukemia by immunohistochemical staining (Han, Garcia-Manero et al. 
2007), suggesting that its expression is associated with common changes in signaling 
pathways in tumor cells.  
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To verify the observation of MDMX overexpression in human tumors and test the 
association with hyperactive MAPK signaling, we performed immunohistochemical 
staining of a panel of colon tumors and normal colon mucosa controls. The results 
showed that normal mucosa expressed low levels of MDMX, whereas ~49% (49/99) of 
colon tumors expressed high-level MDMX as a diffused stain in both nucleus and 
cytoplasm (Figure 75a). MDMX overexpression was more frequently observed in high-
grade tumors (Figure 75b). The tumor array was also analyzed for p53 overexpression, 
which serves as an indicator of p53 mutation. The results revealed that p53 and MDMX 
overexpression were independently associated with high-grade tumors (data not shown). 
These results suggest that MDMX expression is elevated in aggressive tumors and occurs 
independent of p53 mutation status. 
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Figure 75. MDMX expression increases with tumor stage. (a) Representative MDMX 
immunohistochemical staining of normal colon mucosa and stage I-III tumors 
from a colon cancer tissue microarray (brown). An increased staining intensity 
as a function of tumor stage was observed.  (b) Each tumor in the array was 
manually scored according to MDMX staining intensity from 1 to 3, and 
displayed according to the stage of colon cancer progression. The correlation 
between intensity of MDMX staining and the stage of colon cancer was 
calculated using Spearman’s correlation analysis (n=117; r2 =0.36; p < 
0.0001). Staining of MDMX intensity in each stage was compared to normal 
colon mucosa and the p-value is indicated. 
 
Staining of the same tumor array using a phospho-ERK monoclonal antibody 
revealed a mosaic pattern of staining (20-40% cells positive) in a subset of tumors 
(Figure 76a). Tumors stained positive for phospho-ERK are 2-fold more likely to also 
have MDMX overexpression (Figure 76b). Unlike phospho-erk, the intensity of phospho-
AKT staining could not be correlated with MDMX staining (data not shown). These 
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results are consistent with cell culture analysis and suggest that hyperactive MAPK 
signaling may stimulate MDMX overexpression and compromise the p53 pathway.   
 
 
Figure 76. MDMX expression correlates with phospho-ERK level in colon cancer. 
(a) Representative pictures of colon tumors stained for MDMX (left) or 
phospho-ERK (right). Each pair of pictures is from consecutive sections of the 
same tumor at the same position. (b) Intensity of MDMX staining in the 
phospho-ERK -positive and negative colon carcinomas. The correlation 
between intensity of MDMX staining and phospho-ERK  was calculated using 
Spearman’s correlation analysis (n=117; r2 = 0.24; p=0.008). 
 
Absence of sequence polymorphism in the MDMX basal promoter  
The MDM2 P2 promoter (p53-responsive) contains a single nucleotide 
polymorphism (SNP309) which is heterozygous in 40% and homozygous in 12% of the 
MDMX and Phospho-Erk correlation p=0.008 
a
MDMX Phospho-ERK MDMX Phospho-ERK
MDMX Phospho-ERK MDMX Phospho-ERK
1
2
3
MDMX 
Staining 
Intensity
Positive Phospho-ErkNegative Phospho-Erk
b
15 16
22
34
19
11
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sample population which results in increased binding by the Sp1 transcription factor and 
increased MDM2 expression (Bond, Hu et al. 2004). Importantly, the SNP309 allele is 
associated with higher risk for cancer, presumably due to attenuated p53 function. 
Therefore, we asked whether promoter sequence polymorphism contributes to different 
levels of MDMX expression in tumor cell lines. A 0.7 kb region of the MDMX promoter 
(0 to -700 bp) was amplified from the genomic DNA of 30 human cell lines (27 tumor 
cell lines, 3 skin fibroblasts) and analyzed by DNA sequencing. The analysis identified 
only one cell line (K562) with a SNP, which is located outside of the -120 bp to 0 bp 
region (data not shown). Sequencing results further upstream of the basal promoter were 
uninformative due to artifacts caused by multiple poly-T tracks. Therefore, the MDMX 
basal promoter does not contain significant sequence polymorphism.  
Discussion 
A significant difference between MDM2 and MDMX regulation is that MDMX 
transcription is not activated by p53. However, results described above identified 
important similarities in the induction of both MDM2 and MDMX by the Ras-MAPK 
and growth factor pathways (Leri, Liu et al. 1999; Ries, Biederer et al. 2000; Heron-
Milhavet and LeRoith 2002). This finding provides an explanation for the frequent 
overexpression of MDMX in tumors, often in the absence of gene amplification. 
Induction of MDM2 and MDMX expression by the mitogenic pathways may serve to 
prevent unwanted p53 activation during normal cell proliferation in development and 
homeostasis. However, when inappropriately activated, this pathway also has oncogenic 
potential by blocking the tumor suppression functions of p53 during abnormal cell 
proliferation. Recent studies show that increased circulating IGF-1 levels put individuals 
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at a higher risk for developing numerous types of cancers (Larsson, Girnita et al. 2005).  
Induction of MDM2 and MDMX may play a role in this process. 
Following an initial oncogenic insult such as Ras mutation, MDMX and MDM2 
induction by MAPK pathway may suppress p53 activity and facilitate initial tumor 
progression. MDMX induction may also attenuate ARF activation of p53 (Li, Chen et al. 
2002). However, the lack of association between MDMX overexpression and p53 
mutation in colon tumors suggests that MDMX is not sufficient to bypass the selection 
for p53 mutations. Previous study also showed that MDM2 gene amplification does not 
obviate the need for silencing ARF expression (Lu, Lin et al. 2002). It is possible that in 
advanced stage tumors, strong ARF induction by multiple activated oncogenes is 
dominant over the MAPK-MDM2/MDMX pathway, creating selection pressure for p53 
mutation or ARF silencing. Consistent with this notion, ARF overexpression stimulates 
MDMX ubiquitination and degradation by MDM2 (unpublished results) (Pan and Chen 
2003). Therefore, loss of ARF by epigenetic silencing or deletion is a key event that 
unleashes the oncogenic potential of the MAPK-MDM2/MDMX pathway, giving tumor 
cells with hyperactive MAPK an advantage in terms of resistance to p53.  
MDM2 promoter polymorphism is prevalent among the human population, 
probably due to a certain level of evolutionary advantage it confers to the carriers at the 
expense of increased cancer risk. It is unclear whether MDMX expression level is 
affected by promoter polymorphism. Our sequence analysis of 30 human cell lines did 
not reveal significant variation in a 1.4 kb region including the proximal promoter and 
transcription factor binding sites necessary for basal and Ras-induced expression. 
Therefore, it is possible that sequence variations in this region that lead to increased or 
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decreased MDMX expression do not confer selection advantage and failed to accumulate 
in the population. However, these results do not rule out the presence of sequence 
polymorphism in other parts of the MDMX gene that may affect its transcription, 
splicing, and ability to regulate p53.  
Recent studies have demonstrated the therapeutic potential of MDMX as a drug 
target in cancer. Knockout experiments suggest that elimination of MDMX leads to 
significant activation of p53. Reduction of MDMX gene dosage delays myc-induced 
lymphoma in mice (Terzian, Wang et al. 2007). Furthermore, shRNA knockdown of 
MDMX expression activates p53 in cell culture and abrogates tumor xenograft formation 
by HCT116 cells (Gilkes, Chen et al. 2006). Therefore, down regulation of MDMX 
expression is a useful therapeutic strategy. However, our results in this report suggest that 
although MAPK pathway regulates MDMX expression, targeting this pathway by kinase 
inhibitors may not provide a net activation of p53. This may be due to the complexity of 
the MAPK pathway, involvement of Ets-1 in regulating p21 expression (Zhang, Kavurma 
et al. 2003), and toxicity of the kinase inhibitors. It has been shown that MEK activity is 
required for expression of p53 at the transcriptional level and also for p53 activation by 
genotoxic agents (Persons, Yazlovitskaya et al. 2000; Agarwal, Ramana et al. 2001). 
Therefore, more specific approaches that directly target MDMX expression or activity are 
necessary for effective p53 activation. 
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Scientific Significance 
 
P53 is a transcription factor that can be activated by a variety of stress signals. 
Upon activation, it induces a group of genes necessary to inhibit cell proliferation or 
induce cell death. The tumor suppressor p53 is mutated in a wide variety of human 
cancers at a frequency of about 50 percent. In tumors which retain wild-type p53, p53’s 
functional activity can potentially be attenuated by upregulation, overexpression, or 
amplification of either of its two major negative regulators, MDM2 and/or MDMX. In 
support of this notion, we found that overexpressing MDMX in cells maintaining 
functionally active non-mutated p53 inhibits p53-induced cell cycle arrest following 
ribosomal stress. Likewise, reducing the gene dosage of MDMX by siRNA stimulates 
p53 activity following ribosomal stress.  Additionally, staining MDMX in a colon tissue 
tumor array revealed a positive correlation between MDMX staining intensity and 
increased tumor grade. Taken together, our data shows that MDMX has the potential to 
suppress p53 in favor of tumor progression. 
Under “normal” conditions, a well accepted hypothesis for p53 maintenance posits 
that MDM2 acts as an E3 ligase towards p53 directing its degradation by the proteosome.  
While MDMX does not degrade p53 on its own, it can bind to p53’s transactivation 
domain blocking the induction of p53 target genes. It is not fully clear whether MDMX 
and MDM2 function independently or in a synergistic manner to prevent p53 activation. 
 157 
Several labs have suggested that the relative abundance of MDMX versus MDM2 may be 
critical for the outcome of p53 protein levels. When they are expressed at equivalent 
ratios, p53 undergoes MDM2-dependent proteasomal degradation. In the presence of 
high MDMX levels, it is reasonable to suggest that MDM2 and MDMX may compete for 
p53 binding resulting in more MDMX-p53 interactions. Indeed, our experiments showed 
that overexpressing MDMX leads to an increase in MDMX-p53 complex formation. If 
MDMX outcompeted MDM2 for p53 binding, one may expect p53 protein levels to 
remain the same or even increase. However, we actually found the opposite to be true. 
Overexpressing MDMX does not appear to modulate p53 protein levels whereas 
knocking down MDMX causes a modest increase in p53 levels. Futhermore, in a small 
panel of cell lines tested for MDMX and MDM2 expression, the ratio of MDM2-to-
MDMX does not correlate with p53 levels. This suggests that rather than competing for 
binding, MDMX and MDM2 may form complexes that bind to p53 and promote its 
degradation. Several studies show MDM2 forms hetero- and homodimers through ring 
domain interactions contributing to MDM2-mediated degradation of p53(Tanimura, 
Ohtsuka et al. 1999; Dang, Kuo et al. 2002; Linares, Hengstermann et al. 2003).  
Interestingly, two recent studies showed that heterodimers of a C-terminal point mutant 
of MDM2 (no E3 ligase activity) and MDMX are capable of targeting p53 for 
degradation, suggesting that the C-terminus of MDMX can substitute for MDM2 
(Poyurovsky, Priest et al. 2007; Uldrijan, Pannekoek et al. 2007).  Although we do not 
know the optimum ratio of MDMX-to-MDM2 which can prevent p53 induction under 
normal conditions but allow it to become be quickly activated following stress, we do 
know that these proteins do not play redundant roles in regulation of p53.  This was well 
 158 
demonstrated in mouse models showing the abrogation of either MDM2 or MDMX leads 
to embryonic lethality, but after crossing into p53 null background mice are viable. 
Following cellular stress, it is important for p53 to quickly become activated and 
induce cell cycle arrest or apoptosis. This should require inhibition of both MDM2 and 
MDMX.  MDM2 can stimulate the polyubiquitination and degradation of MDMX 
through the proteasome pathway. It is well recognized that p53 binding to MDM2 is 
weakened after DNA damage due to phosphorylation of both p53 and MDM2.  Recently, 
our lab showed that following DNA damage, ATM- dependent phosphorylation of 
MDMX enhances the degradation of MDMX by MDM2 an effect related to 14-3-3 
binding and increased binding to the deubiquitinating enzyme HAUSP. On the other 
hand, the regulation of MDM2 and MDMX and activation of p53 following ribosomal 
stress has not been as intensely studied. Several studies have shown that ribosomal stress 
causes enhanced binding of MDM2 to several ribosomal proteins. The interaction of 
MDM2 with ribosomal proteins reduces its E3 ligase activity towards p53.  Interestingly, 
we show that ribosomal stress-induced p53 induction is associated with rapid down-
regulation of the MDMX protein. We found that the interaction of MDM2 with ribosomal 
protein L11 is enhanced following ribosomal stress and promotes the ubiquitination of 
MDMX. Further, inducing ribosomal stress with the addition of either actinomycin D or 
5-FU does not lead to p53 or MDMX phosphorylation suggesting that DNA damage and 
ribosomal stress are completely unique in their ability to regulate MDM2, MDMX, and 
p53. Our data suggests that physiological levels of MDM2 overexpression can be 
effectively neutralized during ribosomal stress, resulting in p53 stabilization. In contrast, 
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MDMX is a stable protein that regulates p53 mainly by sequestering p53 into complexes 
which are not disrupted by ribosomal stress. 
The level of MDM2 and MDMX in a cell is clearly paramount to p53 activation.  
The level of MDM2 in cells is determined by the following main mechanisms: (1) P53-
dependent transactivation of the MDM2 gene (2) mitogen-dependent activation of factors 
such as Erk that also transactivate MDM2 (3) mitogen-dependent post-translational 
modifications that modulate MDM2 stability (4) self-ubiquitination and (5) interaction 
with HAUSP. The factors that influence MDMX abundance have not been widely 
studied. As mentioned previously, MDMX is targeted for degradation by MDM2. This is 
further stimulated following DNA damage and ribosomal stress. Furthermore, HAUSP, 
first identified as a P53-associated protein, appears to contribute to stabilization of both 
MDM2 and MDMX. Data from our current study show that like MDM2, MDMX can 
also be transactivated by components of the mitogen-activated protein kinase pathway 
such as Ras, Raf, and Erk and involves the transcription factors Ets and Elk. In addition, 
unlike MDM2, MDMX is a very stable protein with a long half-life (>2hrs). This can be 
partially explained by the fact that it does not have self-ubiquitination activity. Taken 
together, the data suggests that while MDM2 has dynamic control of p53, MDMX may 
have a more stable and long term affect on p53 activation. 
One of the interesting discoveries which came out of our current research was the 
ability of MDMX to be degraded by MDM2 without its stabilization or upregulation by 
p53 induction. For example,  MDMX is degraded to similar levels in both HCT p53 wild-
type and p53-null cells following actinomycin D treatment even though MDM2 levels 
remain low in HCT p53-null cells. Studies addressing MDMX degradation following 
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DNA damage induced by gamma irradiation have shown similar results. Interestingly, the 
degradation of MDMX is strongly attenuated in MEF cells lacking both p53 and MDM2.  
Furthermore, MDMX ubiquitination is increased following ribosomal stress due to an 
enhanced interaction of MDM2 with L11. This shows that the cellular level of MDM2 
may not be directly coupled to its potential E3 ligase activity for MDMX.  In support of 
this notion, we find after treatment with the MDM2-p53 inhibitor Nutlin-3, MDM2 levels 
are increased upon p53 activation but this does not lead to MDMX degradation in tumor 
cells. Interestingly, MDMX degradation appears to occur in non-tumor derived cell lines 
following Nutlin-3 treatment.  The complexity of MDM2’s E3 Ligase activity is not 
surprising. For example, studies have shown that the ring domain of MDM2 is necessary 
but not sufficient for p53 degradation while it is sufficient for degradation of MDMX. 
Therefore, further investigation of MDM2 E3 ligase activity is not only warranted but 
necessary to discern how it is potentiated under different stress conditions as well as its 
specificity for MDMX versus p53.   
Another important finding from our studies was the importance of MDMX on 
tumor xenograft formation. To test the role of MDMX in tumor formation in vivo, 
HCT116 cells expressing scrambled or MDMX siRNA were inoculated subcutaneously 
on the dorsal flanks of athymic nude mice. While tumors derived from the scrambled 
siRNA cell lines formed readily, MDMX siRNA expressing cells showed significantly 
reduced tumorigenic potential.  Likewise, a study by an independent group utilized MEF 
cells expressing a homozygous deleted PRD (proline rich domain) of p53 to introduce 
E1A and RAS and assess MDMX expression in a tumor xenograft model (Toledo, 
Krummel et al. 2006).  E1A and Ras transformed p53∆P/∆P cells showed no suppression of 
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oncogene-induced tumors when compared to E1A and Ras transformed p53+/+ cells. 
However, the number and size of tumors generated from E1A and Ras transformed 
p53∆P/∆P MDMX−/− MEFs were similar to those formed from E1A and Ras p53+/+ MEFs. 
These studies highlight the importance of MDMX suppression of p53 during tumor 
progression. Interestingly, in cell culture, HCT116 cells expressing an MDMX siRNA 
grow at rates comparable to scrambled siRNA cells. This suggests that the tumor 
environment causes a physiological stress that required suppression of p53 by MDMX. It 
is possible that tumors are constantly under ribosomal stress. A tumor cell has an 
increased demand for protein synthesis as they continue to undergo cycles of 
proliferation. This may lead to an increase in ribosome and therefore ribosomal protein 
synthesis. In this scenario, decreasing MDMX levels will be an important mechanism for 
stimulating p53 activation. This suggests that agents which decrease the MDMX-p53 
interaction may be important for future cancer therapies. While inhibitors such as Nutlin-
3 have been designed to target the MDM2-p53 interaction, it is important to note that 
they do not effectively inhibit MDMX-p53 binding (Vassilev 2004; Patton, Mayo et al. 
2006). This highlights the need for the development of novel dual inhibitors which block 
both MDMX and MDM2 interactions with p53.  
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